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SUMMARY
In recent years there has been a tendency to move away 
from a standardised stepped care regimen for treating 
patients with hypertension and to adopt instead a more 
flexible approach in which antihypertensive treatment is 
tailored to the needs of individual patients* A wider 
choice of drugs is now available and some of the newer 
agents such as calcium antagonists, ACE inhibitors and 
alpha.) adrenoceptor antagonists represent reasonable 
alternatives to a diuretic or beta blocker as first-line 
treatments. An individualised approach to treatment is a 
laudable goal but factors which determine the response to 
antihypertensive therapy - both kinetic and dynamic - are 
not clearly understood and at present we are unable to 
predict which patients will respond to which drugs. An 
additional problem is that very little is known about dose- 
effect relationships for antihypertensive drugs - 
information which would constitute a basis for optimising 
drug therapy prospectively in individual patients. It has 
been suggested that for a number of antihypertensive drugs 
no predictable concentration-effect relationship exists but 
this probably reflects the negative findings of those 
previous studies which considered the response for groups of 
subjects rather than for individuals.
In a series of single blind studies 46 patients with 
mild to moderate essential hypertension received treatment 
with placebo for 2 weeks followed by nifedipine, or
17
enalapril, or doxazosin, or ketanserin. Each active 
treatment was administered as monotherapy for 4-6 weeks and 
patients attended for a series of 8-hour study days to 
evaluate the effects of placebo, 1st dose and chronic (1-6 
weeks) therapy. At frequent intervals during each study 
day, and at 24 hours after dosing, blood pressure and heart 
rate were recorded and venous blood samples collected for 
measurement of plasma drug concentration. Additional blood 
samples were obtained for plasma renin activity, aldosterone 
and catecholamines. Pressor responsiveness to intravenous 
infusions of the selective alpha-] agonist phenylephrine (PE) 
and the non-adrenergic vasoconstrictor angiotensin II (All) 
was measured on each study day.
The pharmacokinetics and pharmacodynamic effects were 
evaluated after acute and chronic treatment. Drug 
concentration-effect analysis was used to characterise the 
antihypertensive response of each individual patient in 
terms of kinetic as well as dynamnic parameters and to 
describe the temporal discrepancy for the plasma 
concentration-effect relationship (Keq).
In each study there was no simple direct relationship 
between plasma drug concentration and the placebo-corrected 
fall in blood pressure. However, using the integrated 
kinetic-dynamic model drug levels were well correlated with 
reductions in both systolic and diastolic blood pressure in 
individual patients. The kinetic-dynamic relationships for 
nifedipine, doxazosin and ketanserin were most appropriately
18
described by the simpler linear model and responses of 
individual patients were characterised in terms of the fall 
in blood pressure per unit drug concentration. For example, 
responsiveness to nifedipine (m), as the mean of the group, 
was -0.48 following the first dose, -0.45 after 1 week and 
-0.49 mmHg systolic/ng/ml after 6 weeks. There was an 
average reduction of 30% in the responsiveness to doxazosin 
during chronic treatment compared with single dose 
administration: for example, the mean responsiveness for
the group was -2.1 following the first dose and -1.4 mmHg 
systolic/ng/ml after 6 weeks. There was a similar reduction 
in responsiveness to ketanserin from -0.47 to -0.25 mmHg 
systolic/ng/ml after 1 month and additionally there was a 
significant increase in K.n from 0.49 (1st dose) to 1.86
“ M
hours"^ (1 month).
The pharmacokinetics and kinetic-dynamic relationships 
of enalapril were different in several respects compared 
with the other three drugs. A conventional 
pharmacokinetic model did not satisfactorily describe all 
the features of the disposition, particularly the 
accumulation of enalaprilat during chronic therapy. An
alternative approach using a physiologically realistic model 
which assumes saturable binding of the drug to ACE was most 
appropriate for characterising both the kinetics and the 
concentration-effect relationships. In the case of 
enalapril, but with none of the other drugs, the linear 
concentration-effect model was inferior to the full Langmuir
19
(Emax) equation for describing the kinetic-dynamic 
relationships. Accordingly individual patient responses to 
enalapril were quantified by the parameters Em_v and C-50.
lil a  X  “
In terms of blood pressure reduction, the vasodilator 
activities of nifedipine, enalapril and doxazosin were 
broadly similar but the three drugs produced contrasting 
effects on adrenergic and non-adrenergically mediated 
vascular pressor responses. The alpha blocker doxazosin 
produced significant attenuation of the pressor response to 
phenylephrine but had no effect on responses to All. In 
contrast, the two non-adrenergic vasodilators, nifedipine 
and enalapril, affected both PE and All mediated 
vasoconstriction. Nifedipine attenuated the responses to 
All and PE but treatment with enalapril was associated with 
increased responsiveness to both pressor agents. This may 
reflect receptor re-setting in the case of the calcium 
antagonist and receptor up-regulation in the case of the ACE 
inhibitor.
Pharmacokinetic as well as pharmacodynamic variability 
account for interindividual differences in blood pressure 
response. To date, kinetic and dynamic variability have 
been addressed separately because no clear or consistent 
relationship between drug concentration and effect has been 
identified. Having demonstrated an integrated method for 
describing antihypertensive response, it is now feasible to 
investigate factors responsible for the inter and 
intrasubject variability in responsiveness. There was no
20
relationship between patient age and pretreatment plasma 
renin activity and the responsiveness to the drugs studied. 
However, important determinants of response during longterm 
treatment are the height of the starting blood pressure and 
the response to the first dose.
This work has shown that drug concentration-effect 
relationships can be identified in individual hypertensive 
patients. The parameters derived from concentration-effect 
analysis can be used to investigate antihypertensive 
mechanisms and additionally provide not only a useful means 
of evaluating the kinetic and dynamic variability of drugs 
but also a potential basis for optimising longterm 
treatment in individual patients.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1. DRUG TREATMENT OF ESSENTIAL HYPERTENSION
It has been recognised since the early 1940s that 
strokes, cardiac failure, coronary heart disease and 
progressive impairment of renal function occur more 
frequently and at an earlier age in people with above 
average blood pressures. Furthermore, the risk of these 
complications is directly proportional to the level of blood 
pressure, even when measured in quite casual circumstances 
(Robertson, 1983). Hamilton and his colleagues in 1964 were 
among the first to show that antihypertensive drug therapy 
conferred protection against cardiovascular complications in 
patients with pretreatment diastolic blood pressures of 110 
mmHg and above and this was later confirmed by the larger 
Veterans Administration studies of 1967 and 1970. Since 
then there has been a progressive lowering of the presenting 
blood pressure above which antihypertensive drug therapy can 
demonstrate a protective effect (Robertson, 1984) but the value 
of treatment in mild hypertension has been more difficult to 
establish and required studies of large numbers of patients 
(Veterans Administration, 1970; Australian Therapeutic 
Trial, 1980; Hypertension Detection Follow-up Programme,
1982; MRC Trial, 1985).
Antihypertensive therapy is widely prescribed for 
patients with moderate or severe hypertension but the choice 
of a drug and its dosage is often empirical and based on a 
'trial and errorT approach. Furthermore, we know very 
little about factors which determine the response to
23
treatment and attempts to predict the most effective drug or 
an optimum dosage schedule for an individual patient have so 
far been unsuccessful. This may be partly related to the 
apparent lack of a useful dose-response relationship for the 
commonly used drugs: for example, beta adrenoceptor
antagonists and thiazide diuretics are reported to have 
relatively flat dose-response curves (Hansson et al, 1974; 
MacGregor et al, 1983) and the relationship between plasma 
concentration and drug effect for vasodilators is ill- 
defined. In practice, therefore, as the clinical response 
- blood pressure fall - is readily measurable, little 
attempt is made to rationalise therapy prospectively: drug
dose is adjusted retrospectively.
Thus, in contrast to developments in other areas of 
therapeutics, e.g. with anticonvulsant, antiarrhythmic and 
bronchodilator drugs, little attempt has been made to apply 
recent developments in clinical pharmacokinetics to improve 
drug use in hypertension. A direct consequence of this has 
been that misleading and conflicting statements have been 
made about dose schedules and about variations in 
responsiveness related to factors such as age, ethnic 
origin and biochemical indices. For example, it has been 
suggested that the response of hypertensive patients to 
calcium antagonists is not only quantitatively but 
qualitatively different from normotensives (Buhler and 
Hulthen, 1982), implicating abnormalities of smooth muscle 
calcium as a primary pathogenic mechanism in hypertension.
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These claims have been based on incomplete and sometimes 
anecdotal data, with observations being made of responses to 
different doses at different times and with no account taken 
of interindividual and time-related differences in plasma 
drug concentrations.
The fstepped-caref strategy for antihypertensive 
treatment emerged in the early 1970s (Zacest et al, 1972), 
providing the doctor with a sequence of therapeutic 
manoeuvres which would ensure control of the blood pressure 
in most cases of hypertension. The drugs used in the first 
two steps have remained consistent over the years, namely 
beta adrenoceptor antagonists and thiazide diuretics, but at 
best only 50X of patients with mild to moderate hypertension 
are adequately controlled with either drug alone (Moser, 
1978). In the last few years a great deal of information 
has accrued to permit a re-examination of the traditional 
stepped-care approach to hypertension. Several multicentre 
clinical trials, which have taken over a decade to conduct, 
have reported their results and highlighted some important 
limitations of conventional treatments in mild to moderate 
hypertension. One particular message that has emerged from 
several of the major trials, and which forms the underlying 
theme of this project, is that an individualised approach to 
the hypertensive patient should be adopted rather than the 
pursuit of an empirical, pragmatic, therapeutic policy.
The scope for improvement in antihypertensive therapy is 
particularly well illustrated by the data on coronary heart
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disease mortality and by the somewhat surprising results 
concerning the adverse effects relative to benefit of 
conventional beta blocker and diuretic regimens.
Coronary heart disease
In both the Australian (Australian Therapeutic Trial in 
Mild Hypertension, 1980) and British MRC (Medical 
Research Council Trial in Mild to Moderate Hypertension, 
1985) trials two thirds of all vascular complications were 
due to ischaemic heart disease but the MRC trial showed 
clearly that conventional antihypertensive treatment with a 
beta blocker or diuretic does not prevent coronary events. 
Several possible explanations may account for the failure to 
improve coronary heart disease mortality (Reid, 1988). One 
popular suggestion, however, is that beta adrenoceptor 
antagonists and thiazide diuretics may have an unfavourable 
influence on a coronary risk factor which off-sets their 
beneficial effect on blood pressure. Changes in plasma 
lipids have been particularly implicated in this hypothesis 
and considerable attention has been focused on the adverse 
metabolic effects of diuretics and beta blockers (Berglund 
and Andersson, 1981; Bauer et al, 1981; Lant, 1985; 
Weidmann et al, 1985).
A decrease in high density lipoprotein (HDL) 
cholesterol or increase in low density lipoprotein (LDL) 
cholesterol may both augment the risk of coronary heart 
disease (Kannel et al, 1979; Miller, 1982) and a similar
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tendency is suspected for elevated blood levels of 
triglyceride-rich lipoproteins (Carlson and Roessner, 1979; 
Weidmann et al, 1985). Some beta adrenoceptor antagonist 
drugs and almost all diuretics have been shown to adversely 
affect the ratio of LDL/HDL cholesterol (Weidmann et al, 
1985), whereas some of the newer antihypertensive agents
appear to have neutral or even beneficial effects on blood
lipids. Additional concern has also been expressed about 
some of the other metabolic effects of diuretics (Holme et 
al, 1984), in particular hypokalaemia, carbohydrate 
intolerance and uric acid retention, and their possible 
impact during longterm therapy on cardiovascular morbidity 
and mortality (Multiple Risk Factor Intervention Trial,
1 982).
Appropriate clinical trials are awaited to assess 
whether or not some of the newer antihypertensive drugs such
as calcium antagonists and ACE inhibitors will fare better
than conventional treatments in reducing coronary heart 
disease mortality. However, as discussed in later 
sections, there is increasing evidence to suggest that the 
newer drugs may offer some advantages over beta-adrenoceptor 
antagonists and diuretics.
The risk-benefit relationship
The protective effect of lowering the blood pressure in 
severe hypertension has been clearly demonstrated with 
relatively small numbers of patients (Harington et al, 1959;
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Veterans Administration, 1967) but recent trials have shown 
that the value of treatment in mild hypertension is much 
less obvious (Australian Therapeutic Trial in Mild 
Hypertension, 1980; Hypertension Detection Follow-up 
Programme, 1982; MRC Trial, 1985). The Australian and 
British MRC Trials showed that antihypertensive treatment 
in patients with uncomplicated mild hypertension (defined as 
a diastolic blood pressure between 90 - 109 mmHg and 
systolic pressure below 200 mmHg) significantly reduced the 
incidence of all cardiovascular complications, largely by 
preventing strokes, but in absolute terms the benefits were 
small: for example, in the MRC Trial 850 patients had to
be treated for a year in order to prevent one 
cerebrovascular event - which may be non-fatal.
A further disappointing result which has emerged from 
recent studies in mild to moderate hypertension has been the 
failure to restore the mortality of treated hypertensive 
patients to that of the normotensive population (Lindholm et 
al, 1984; Samuelsson et al, 1985; Bulpitt et al, 1986; 
MacMahon et al, 1986). Since, the prognosis in mild 
hypertension is dominated by ischaemic heart disease, this 
may reflect the failure of conventional antihypertensive 
treatments to improve coronary heart disease mortality 
(Reid, 1988).
As well as evaluating the benefits of treatment in mild 
hypertension the British MRC Trial produced interesting 
results about the incidence of adverse effects associated
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with the beta adrenoceptor antagonist propranolol and 
thiazide diuretic bendrofluazide (MRC Report on Adverse 
Reactions, 1981). The cumulative percentage of men 
withdrawn from treatment with bendrofluazide after 5 years 
was 17%, compared with 12.8% of women, and for propranolol 
the cumulative percentage of withdrawals amounted to 15.5% 
of men and 18% of women. The corresponding number of 
withdrawals from the placebo group after 5 years was 
approximately 5% for both sexes. These results, 
particularly for bendrofluazide, were somewhat surprising - 
as reflected by views expressed in a leading article in the 
Lancet as recently as 1982 which stated fin mild 
hypertension ...... those who employ diuretic treatment
first do so mainly because of the rarity of symptoms, side 
effects and low cost* (Lancet Editorial, 1982).
It has become recognised that in order to maximise the 
beneficial effects of longterm treatment in mild 
hypertension adverse effects must be reduced to a minimum 
and this requires careful consideration of drug dose. Thus 
the high incidence of side effects in the MRC study probably 
compromised the apparent benefits of treatment and this may 
have been due to inappropriate (high) doses of propranolol 
and bendrofluazide.
The modern aim of antihypertensive treatment was 
summarised in a recent editorial in the New England Journal 
of Medicine: fthe goal of therapy should be not only to
reduce morbidity and mortality but to do so without adverse
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effects on the functional well-being of our patients’ 
(Chobanian, 1986). To achieve this aim in the future, we 
will require greater understanding of the dose-effect 
relationships for antihypertensive drugs. So far, this has 
been a neglected area of clinical pharmacology but 
information about the inter-relationship between drug 
concentration and effect will form the basis not only for 
optimising drug therapy in individual patients but also for 
investigating factors which might account for the 
intersubject variability in antihypertensive response.
The information gained from the recent major clinical 
trials in mild to moderate hypertension, together with the 
introduction of newer classes of antihypertensive agents, 
has led to a reappraisal of the management of mild to 
moderate hypertension (Prichard and Owens, 1986). To improve 
the prognosis, more attention has been focused on the 
correctable risk factors for ischaemic heart disease, 
particularly cigarette smoking and hypercholesterolaemia, 
and it has become recognised that non-pharmacological means 
of lowering the blood pressure are useful either as an 
adjunct to drug therapy or as the initial method of 
controlling the blood pressure (Andrews et al, 1982).
While beta-adrenoceptor antagonists and thiazide diuretics 
remain the first line treatments, there are now several 
other drugs such as calcium antagonists, alpha-adrenergic 
blockers and angiotensin converting enzyme (ACE) inhibitors 
which represent reasonable alternatives. The apparent
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limitations of ’’conventional treatments” has therefore 
resulted in a more flexible approach in which the choice of 
the first-line drug is tailored to suit individual patient 
requirements (Hansson, 1985).
1.1.1. Calcium antagonists
The calcium antagonists are a heterogeneous group of 
drugs which have in common the property of inhibiting the 
influx of calcium ions into cardiac and vascular smooth 
muscle cells (Braunwald and Epstein, 1982) thus leading to a 
reduction in the contractile force (Stone et al, 1980).
The original classification of calcium antagonist drugs 
described by Fleckenstein (1983) has recently been 
superseded to include four types (Singh, 1986). The Type 1 
agents - the phenylalkylamine derivatives such as verapamil 
and gallopamil, and the benzothiazepine derivatives such as 
diltiazem - besides dilating blood vessels have important 
action on cardiac conduction tissue, prolonging 
atrioventricular conduction and refractoriness, but have 
little effect on atrial or ventricular refractory period.
The Type II drugs - the dihydropyridines (nifedipine, 
nicardipine, nitrendipine, etc.) - in vivo have no 
electrophysiological effects, while they are potent 
peripheral vasodilators. The Type III drugs, the 
piperazines, include cinnarizine and flunarizine which are 
highly selective for vascular smooth muscle relative to 
cardiac muscle. Finally, more complex are the Type IV
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drugs, such as perhexilene, bepridil and lidofluazine, 
which, as well as their inhibitory action on calcium 
channels, block the fast sodium channels to a variable 
degree.
The diversity of molecular structures of calcium 
antagonists is consistent with differing modes and sites of 
action and contrasts with the tight binding of alpha and 
beta adrenergic blockers to specific receptor sites. Thus, 
the principal drug types bind to slightly different sites on 
the cell membrane (Glossman, 1984) and exert effects which 
also are dependent upon slightly different states of 
’’activity" of the calcium channel (Epstein, 1982).
As a class of drugs the calcium antagonists first became 
established for the treatment of angina pectoris (Lynch et 
al, 1980; Scheidt et al, 1982) but over the last few years 
several studies have documented the longterm 
antihypertensive efficacy of verapamil (Lewis et al, 1978; 
Leonetti et al, 1980; Doyle, 1983) and nifedipine (Guazzi 
et al, 1977; McLeay et al, 1983; Hornung et al, 1983). 
Diltiazem also lowers the blood pressure in hypertensive 
patients (Yamakado et al, 1983) as do other newer calcium 
antagonists that have been assessed, e.g. nitrendipine 
(Burris et al, 1982), nicardipine (Littler et al, 1986) and 
tiapamil (Chu and De Gori, 1982).
The lowering of blood pressure is achieved by a 
reduction in peripheral vascular resistance (Olivari et al, 
1979; Opie, 1980) due to selective vasodilation of
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resistance vessels and little or no effect on capacitance 
vessels (Robinson et al, 1980). Differences in their sites 
of action may. partly explain the different pharmacodynamic 
effects of the various calcium antagonist drugs 
(Fleckenstein, 1984). Compared with nifedipine, verapamil 
has a similar but relatively less marked effect on vascular 
smooth muscle (Midtbo et al, 1982) and, unlike nifedipine, 
it has important depressant effects on cardiac conduction 
(Rowland et al, 1979). The fall in blood pressure with 
nifedipine and other dihydropyridines is associated acutely 
with reflex increases in cardiac output (Lederballe- 
Pedersen, 1981) and plasma noradrenaline (Muiesan et al,
1982) but with verapamil cardiac output is unchanged (Opie, 
1980) .
Vasodilator drugs such as hydralazine and minoxidil are 
often associated with counter-regulatory effects involving 
reflex stimulation of the sympathetic and renin-angiotensin 
systems leading to increased cardiac output and fluid 
retention (Dunstan et al, 1972; Zacest et al, 1972) which 
may counteract their antihypertensive activity (Koch-Weser, 
1974). A possible advantage of the calcium antagonists over 
vasodilators such as hydralazine is that while there is 
evidence of reflex activity acutely during chronic treatment 
baroreflex activity attenuates and heart rate returns to 
normal (McLeay et al, 1983; Bruun et al, 1985).
Since the prognosis in mild-moderate hypertension is 
dominated by ischaemic heart disease and conventional
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treatment with a beta blocker or diuretic appears to have 
little effect on coronary mortality, there is considerable 
interest in the effects of the newer antihypertensive drugs 
on coronary risk factors. There have not been any 
secondary prevention studies with calcium antagonists but 
there is some animal evidence suggesting a cardioprotective 
effect in experimental ischaemia (Nayler and Ferrar, 1979). 
In addition, some of the ancillary properties of calcium 
antagonists may have a beneficial effect on ischaemic heart 
disease: for example, calcium antagonists have been shown
to reduce coronary artery spasm (Antman et al, 1980), 
inhibit platelet aggregation (Dale et al, 1983) and have a 
favourable effect on blood lipids (Sasaki and Arakawa,
1987) .
Side effects are not uncommon with calcium antagonists 
and symptoms associated with vasodilation, such as headache 
and flushing, are more common with nifedipine than verapamil 
(Krebs, 1983). The overall incidence of adverse 
effects is approximately 20% and this may be related, at 
least in part, to the dose and drug plasma concentration 
(Sorkin et al, 1985), and some series have shown relatively 
high drop-out rates (14-22%) from nifedipine (Bayley et al, 
1982; Eggertsen and Hansson, 1982). Ankle oedema due to 
increased capillary permeability occurs in 0.6% of patients 
treated with nifedipine and is resistant to diuretics 
(Krebs, 1983). Constipation is quite common with verapamil 
(12-42%) but the infrequent gastrointestinal side effect of
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nifedipine is usually diarrhoea (Sorkin et al, 1985). 
Significant negative inotropic effects may occur in patients 
with compromised cardiac function following verapamil, but 
it is rarely seen with nifedipine (Krebs, 1983). Calcium 
antagonists may therefore be used to treat patients in whom 
beta-adrenoceptor blocking drugs are contraindicated: for
example, nifedipine may be given to patients with poor left 
ventricular function and, in contrast to beta-blockers, 
calcium antagonists do not increase airways resistance or 
exacerbate peripheral vascular disease.
Despite having widely different chemical structures, 
calcium antagonists exhibit common pharmacokinetic 
properties. They all undergo high hepatic extraction which 
is mainly dependent on liver blood flow and therefore their 
bioavailabilities are low, for example 40-5016 for 
nifedipine, despite almost complete absorption following 
oral administration (Echizen and Eichelbaum, 1986). A 
sensitive and reliable assay for measuring nifedipine in 
plasma has only recently become available (McAllister, 1982; 
Waller et al, 1984) and therefore there is still a relative 
paucity of information about the pharmacokinetics of 
nifedipine, particularly in patients with essential 
hypertension (Echizen and Eichelbaum, 1986). In contrast, 
the pharmacokinetics of verapamil have been more clearly 
characterised. Several studies have shown a reduction in 
verapamil clearance during chronic compared with acute 
administration (Freedman et al, 1981; Kates et al, 1981,
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Shand et al, 1981; Wagner et al, 1982) and this is likely 
to reflect drug-induced alterations in hepatic blood flow 
(Meredith et al, 1985a) or enzyme activity (Bach et al,
1 986) .
A feature common to all the calcium antagonists is 
marked intra- and inter-individual variations in drug 
clearance and bioavailability (Echizen and Eichelbaum, 1986). 
In patients with hepatic impairment (e.g. cirrhosis) the 
various pharmacokinetic parameters are grossly altered - 
clearance decreases, elimination half-life is substantially 
prolonged and bioavailability more than doubles (Somogyi et 
al, 1981). Whereas renal disease has no impact on the 
pharmacokinetics of diltiazem and verapamil (Mooy et al, 
1985), the elimination half-life of nifedipine increases in 
relation to the degree of renal impairment due to an increase 
in volume of distribution (Kleinbloesem et al, 1984b). 
Systemic clearance, however, remains unchanged.
1.1.2. Angiotensin converting enzyme inhibitors
Angiotensin converting enzyme (ACE), also known as 
kininase II, is responsible for the enzymatic conversion of 
angiotensin I to the potent vasoconstrictor peptide 
angiotensin II. The ACE inhibitor drugs, captopril and 
enalapril, have recently become established in the treatment 
of hypertension (Brunner et al, 1981; Hodsman et al, 1982; 
Velasco et al, 1985) and cardiac failure (Kjekhus et al,
1983; CONSENSUS trial, 1987). The fall in blood pressure
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is due to arteriolar vasodilation, producing a reduction in 
peripheral vascular resistance (Velasco et al, 1985; Tarazi 
et al, 1980) and is partly related to the activity of the 
renin-angiotensin system (Gavras et al, 1978). Activation 
of the renin-angiotensin-aldosterone system by posture, 
exercise, salt and volume depletion, or treatment with 
diuretics, therefore enhances the antihypertensive effect of 
ACE inhibition (Brunner et al, 1980; Atkinson et al, 1980). 
Although the fall in blood pressure is due primarily to a 
reduction in angiotensin II formation, additional mechanisms 
have been implicated: for example, changes in baroreflex
activity (Mancia et al, 1982) and reduced vascular 
responsiveness to noradrenaline (Fruncilo et al, 1983). It 
has additionally been suggested that these effects may be 
particularly important in explaining the characteristic 
absence of a reflex tachycardia when the blood pressure is 
lowered by ACE inhibitors (Cody et al, 1979; Velasco et al, 
1985) .
Captopril was first used in what now would be 
regarded as large doses (up to 450 mg a day) in the 
treatment of severe or renovascular hypertension, and was 
associated with a high incidence of side effects (e.g. skin 
rash) and a worrying incidence of potentially serious 
adverse effects such as neutropenia and deteriorating renal 
function. With the advent of lower dose regimens, and better 
patient selection, the incidence of adverse effects 
associated with captopril is low and appears to be similar
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to that caused by enalapril (Veterans Administration, 1982a; 
Thind et al, 1983; Edwards and Padfield, 1985). The most 
serious adverse effects are the dramatic decrease in blood 
pressure, accompanied by bradycardia, which may follow the 
initial dose and impaired renal function. First dose 
hypotension occurs most often in patients with congestive 
cardiac failure, particularly in those treated with large 
doses of diuretics (Fagard et al, 1980; Whitworth et al,
1982). ACE inhibitors are contraindicated in the presence 
of bilateral renal artery stenosis, since they lead to a 
rapid deterioration in renal function, and this probably 
reflects the importance of angiotensin II in maintaining 
efferent arteriolar constriction and thus glomerular 
filtration pressure (Johnston, 1984).
Captopril has a relatively short duration of action on 
ACE inhibition and blood pressure but enalapril is longer- 
acting and administered once or twice daily. Following 
oral administration, enalapril undergoes hepatic de- 
esterification to the active diacid metabolite enalaprilat 
which is excreted unchanged via the kidneys (Tocco et al,
1982). Pharmacokinetic studies of enalapril have shown 
that a lower dose should be used in the elderly (Hockings et 
al, 1986; Lees and Reid, 1987), in patients with impaired 
renal function (Johnston, 1984), and in those with 
congestive cardiac failure (Schwartz et al, 1985).
ACE inhibitors appear to be well tolerated and 
effective antihypertensive drugs. They do not interfere
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with the sympathetic control of blood vessels, therefore 
there is no postural hypotension, and they do not cause 
reflex tachycardia. Additional advantages include improved 
renal blood flow and there is evidence to suggest that 
hypertensive left ventricular hypertrophy, which carries a 
poor prognosis (McLenachan et al, 1987), resolves more 
quickly on treatment with ACE inhibitors than with other 
drugs (Dunn et al, 1984).
1.1.3. Alpha^-adrenoceptor antagonists
The most useful antihypertensive alpha-adrenoceptor 
inhibitor drugs are selective for post-junctional alpha«j- 
adrenoceptors (Graham, 1984). Several studies have shown 
that the alpha^-antagonist prazosin and other related 
quinazoline derivatives, such as doxazosin, are effective 
antihypertensive drugs (Stanaszek et al, 1983; Lund- 
Johansen et al, 1986). Not surprisingly the haemodynamic 
effect is greater under those conditions in which the 
maintenance of blood pressure is particularly dependent upon 
increased sympathetic activity, for example on standing, 
after exercise, in a hot environment, after food, or with 
reduced blood volume. The haemodynamic profile of alpha^ 
adrenoceptor inhibitory drugs is such as to reverse the 
pathological haemodynamic changes of hypertensives back 
towards that seen in normotensives (Taylor, 1982). The 
fall in blood pressure is due to a reduction in peripheral 
vascular resistance (Lund-Johansen et al, 1986) and is
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associated acutely with reflex sympathetic activation 
(Elliott et al, 1982).
The principal adverse effect of alpha-adrenergic 
blockers is "first dose" orthostatic hypotension and reflex 
tachycardia. This was a significant problem during the 
early stages of the use of prazosin (Bendall et al, 1975). 
The first dose phenomenon is, in part, dose dependent 
(Rosendorff, 1976) and may be alleviated by using a low 
starting dose given immediately before going to bed. First 
dose hypotension is enhanced by a low sodium diet but a high 
sodium diet may abolish the effect (Stokes et al, 1977).
Following oral administration, prazosin undergoes high 
hepatic extraction and has both a short half-life and a 
relatively short duration of action (Bateman et al, 1979), 
requiring two or three doses daily. In contrast, doxazosin 
has a prolonged terminal elimination half-life (Elliott et 
al, 1987) and the maximum antihypertensive effect is delayed 
until 5-6 hours, even after intravenous administration 
(Elliott et al, 1982). The more gradual onset of action of 
doxazosin may make it less likely to cause the acute 
postural hypotensive effects associated with prazosin, and 
additionally it may be suitable for once daily 
admin istration.
Provided care is taken to minimise or avoid the first- 
dose phenomenon, particularly in susceptible patients, 
alpha-adrenoceptor antagonist drugs are generally well 
tolerated and effective, with no important contraindications
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to treatment. Unlike beta-adrenoceptor antagonists, they 
also may be useful in cardiac failure (Stanaszek et al,
1983) and they do not increase airways resistance (Marlin et 
al, 1982). In addition, alpha-adrenoceptor blocking drugs 
increase peripheral blood flow (Coleman, 1981) and have been 
used successfully for the treatment of Raynaud’s phenomenon 
(Clement, 1978). Although tolerance to the alpha blocking 
effect has been reported in cardiac failure, clinical 
studies in hypertension have shown that blood pressure 
control using a fixed dose of prazosin is sustained during 
longterm therapy (Stanaszek et al, 1983).
An important potential advantage of prazosin and 
related alpha blockers is their effects on blood lipids.
It now seems clear that elevated low density lipoprotein 
(LDL) cholesterol is associated with an increased risk of 
ischaemic heart disease while the HDL cholesterol fraction 
is relatively ’cardioprotective’ (Miller, 1982). In 
contrast to beta-adrenoceptor antagonists and thiazide 
diuretics, which have adverse effects, alpha-adrenoceptor 
blocking drugs produce favourable changes in blood lipids, 
though the effects are small. Prazosin is reported to 
increase the HDL-LDL cholesterol ratio (Kokubu et al, 1982; 
Leren et al, 1982) but longterm clinical studies have not 
been entirely consistent (Lithell et al, 1982).
1.1.4. Antihypertensive combinations
Antihypertensive drugs given as monotherapy are often
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effective in controlling the blood pressure but a large 
proportion of patients require treatment with more than one 
drug. Combined therapy using two or more antihypertensive 
agents offers the potential for pharmacokinetic as well as 
pharmacodynamic drug interactions. The conventional 
stepped care regime advocates the use of a beta-blocker or 
diuretic, or both, in combination with a vasodilator 
(Zacest et al, 1972). Hydralazine is particularly 
effective for third-drug treatment (McAreavey et al, 1984) 
but in recent years preference has switched towards newer 
drugs which have fewer adverse effects, for example the 
calcium antagonists, ACE inhibitors and alpha blockers.
The fall in blood pressure with a vasodilator is often 
associated with increased reflex sympathetic activity to the 
heart (Koch-Weser, 1974) and if this is attenuated, for 
example with a beta adrenoceptor antagonist, the 
antihypertensive effect is increased. Thus, the 
combination of a dihydropyridine calcium antagonist such as 
nifedipine, or an alpha blocker such as prazosin, with a 
beta adrenoceptor antagonist results in an additional fall 
in blood pressure (Elliott et al, 1981; Bayley et al, 1982; 
Eggertsen and Hansson, 1982). In contrast, heart rate is 
unchanged when the blood pressure is lowered by an ACE 
inhibitor and there is no evidence to suggest that a beta 
blocker combined with an ACE inhibitor has useful additive 
antihypertensive efficacy (MacGregor et al, 1982a).
Nifedipine added to a combination of a diuretic plus a
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beta adrenoceptor blocking drug may be effective in patients 
with severe or resistant hypertension (Dean and Kendall,
1983) but there have been conflicting reports about whether 
thiazide diuretics and calcium antagonists form a useful 
combination in the treatment of mild to moderate 
hypertension (Cappuccio et al, 1987; Poulter et al, 1987). 
In contrast, thiazide diuretics and ACE inhibitors form an 
established treatment combination (Atkinson et al, 1980).
The combination of a beta blocker with a calcium 
antagonist drug, typically of the dihydropyridine type, is 
popular and well established for the treatment of both 
hypertension and angina. The therapeutic results of such 
combinations are thought to reflect a summation of the 
pharmacodynamic effects of each drug but there is recent 
evidence to suggest that there may be an additional 
pharmacokinetic interaction leading to a beneficial 
alteration in the plasma concentrations of the beta blocker 
(Elliott et al, 1988a). The oral bioavailabilities of both 
atenolol and particularly propranolol are significantly 
increased when co-administered with nisoldipine (Elliott et 
al, 1988a) and this is thought to reflect, in part, 
alterations in hepatic, splanchnic and renal blood flow 
which are associated acutely with calcium antagonists 
(Feely, 1984; Meredith et al, 1985a and 1985b).
Antihypertensive combinations usually incorporate a 
beta blocker or diuretic, or both, with a vasodilator such 
as a calcium antagonist or an ACE inhibitor• However,
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since there has been concern about the adverse effects of 
beta blockers and diuretics, particularly the metabolic 
effects associated with longterm thiazide diuretic 
administration (Holme et al, 1984), alternative combination 
treatments require consideration.
Recent open studies in severe hypertension have shown 
that the addition of a calcium antagonist to treatment with 
an ACE inhibitor produces a useful synergistic effect with 
good patient tolerance (Mimran and Ribstein, 1985; White et 
al, 1986). These observations have been confirmed in a 
controlled study which was designed to investigate the 
haemodynamic and pharmacokinetic effects of adding the 
dihydropyridine calcium antagonist nicardipine to the 
treatment of patients with mild to moderate hypertension in 
whom blood pressure control was unsatisfactory with 
conventional beta-blocker regimens and in whom only a 
partial response was obtained with the ACE inhibitor 
enalapril alone (Donnelly et al, 1987). Treatment with 
enalapril and nicardipine for two weeks produced significant 
reductions in blood pressure compared with the enalapril- 
placebo combination, on average 30/19 mmHg supine at 2 hours 
after drug administration, and the additional treatments 
were well tolerated. In particular, the introduction of 
nicardipine was not associated with any significant side 
effects and this tends to support previous suggestions that 
at least some of the adverse symptoms which often accompany 
the acute administration of a calcium antagonist, for
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example headache and fluid retention, may be attenuated in 
the presence of an ACE inhibitor to block the renin- 
angiotensin system (Brouwer et al, 1935} Bach et al, 1986). 
There was no evidence of any pharmacokinetic interaction 
between nicardipine and enalapril. The addition of 
nicardipine, after both first dose and repeated doses, had 
no significant effect on the steady-state kinetics of 
enalaprilat or, more importantly, the profile of plasma ACE 
inhibition (Donnelly et al, 1987).
Another new drug combination which has been shown to be 
effective and well tolerated is the combination of a calcium 
antagonist with an alpha blocker. In both normotensive and 
hypertensive subjects the fall in blood pressure with the 
combination of verapamil and prazosin is significantly 
greater than the simple additive effect from each drug 
(Pasanisi et al, 1984; Elliott et al, 1988b). This 
synergistic effect has been explained on the basis of a 
pharmacokinetic interaction whereby the addition of 
verapamil significantly increased the systemic 
bioavailability of prazosin (Elliott et al, 1988b). This 
may reflect alterations in hepatic blood flow (Meredith et 
a1, 1985a) or enzyme activity (Bach et al, 1986) due to the 
calcium antagonist drug. The addition of prazosin did not 
affect the disposition of verapamil.
1.2. VARIABILITY IN THERAPEUTIC RESPONSE
The factors which determine the response to
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antihypertensive treatment are not clearly understood and in 
clinical practice the choice of a drug and its appropriate 
dose is largely empirical. Studies with calcium 
antagonists, for example, have consistently shown large 
interindividual differences not only in blood pressure 
reduction, but also in plasma drug concentrations (Echizen 
and Eichelbaum, 1986) and such variability clearly contributes to 
the large differences between patients in the magnitude of 
therapeutic response. In most previous studies pharmacokinetic 
and pharmacodynamic variability has been addressed separately 
and a clear relationship between plasma concentration and 
effect has not been established. This may reflect the wide 
range of inter-subject variability in both kinetic and 
dynamic parameters when group data are evaluated but there 
is now evidence that for several groups of antihypertensive 
drugs the fall in blood pressure can be related to the drug 
concentration in plasma w ithin an individual.
1.2.1. Pharmacodynamic variability
In the early 1970s biochemical indices, particularly 
plasma renin activity (PRA), were proposed as important 
determinants of antihypertensive drug response (Laragh,
1973). Buhler and colleagues (1981) developed the 
hypothesis that essential hypertension evolved from a state 
of high cardiac output and renin secretion in the early 
stages to a state of high peripheral vascular resistance in 
established hypertension. They further suggested that
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hypertensive patients could be categorised according to PRA 
such that patients with high levels of PRA responded better 
to beta adrenoceptor antagonists (Buhler et al, 1972; 
Hollifield et al, 1976) whereas those with low levels of PRA 
respond better to diuretics (Adlin et al, 1972). This 
simplified approach was not generally accepted and in 
clinical practice it failed to help the clinician in 
choosing between a beta blocker and a diuretic as the most 
appropriate first-line drug (Zanchetti, 1985).
The recent introduction of ACE inhibitors and calcium 
antagonists has revived the debate about the usefulness of 
PRA as a predictive marker of the haemodynamic response. 
There is some evidence that the fall in blood pressure due 
to ACE inhibition is dependent upon renin status (Gavras et 
al, 1978) but the effectiveness of ACE inhibitors in 
hypertension is much greater than would be predicted from 
measurements of PRA alone: for example, patients with low
PRA, and even anephric subjects, have been shown to respond 
adequately to ACE inhibitors (Man inTt Veld et al, 1980). 
Plasma renin activity has also been related to the 
antihypertensive effect of calcium antagonists (Buhler et 
al, 1982) with a strong negative correlation between PRA and 
the fall in blood pressure with verapamil (Figure 1.1.).
Attempts to identify a relationship between blood 
pressure response and other biochemical measurements, such 
as plasma catecholamine levels (Schwietzer et al, 1983), 
urinary aldosterone excretion (Hansson et al, 1974) and
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lymphocyte Na+-K+ concentrations (Costa et al, 1985; 
Zanchetti, 1985; M'Buyamba-Kabangu et al, 1988), 
have met with little consistent, confirmed success.
Demographic studies, however, have yielded more useful 
observations with respect to the variability in drug 
response. It has been shown both in Africa (Seedat and 
Reddy, 1971) and the USA (Veterans Administration Co­
operative Study, 1982b) that blacks respond better to 
thiazide diuretics than to beta-adrenoceptor antagonists and 
that whites respond better than blacks to ACE inhibitors.
Age may also be an important determinant of the 
response to treatment. Buhler and his colleagues (1982) 
have shown that the fall in blood pressure with verapamil is 
greater in the elderly (Figure 1.1.), while others have 
reported an opposite relationship between blood pressure 
reduction and age for the calcium antagonist nitrendipine 
(Ferrara et al, 1985). Both these studies have postulated 
that age is an important factor in determining the 
haemodynamic response to calcium antagonists but neither 
study took account of differences in plasma drug 
concentrations, which may also depend upon age (Section
1.2.2.). Since kinetic as well as dynamic variability 
accounts for interindividual differences in blood pressure 
response, it is possible that the observations of Buhler and 
Ferrara may have been due to age-related differences in 
pharmacokinetics rather than increased responsiveness £e£ se. 
It is therefore inappropriate to consider dynamics in
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isolation when assessing the variability or constancy of the 
antihypertensive response.
One of the conclusions from the MRC Trial ( 1 985) was 
that the fall in blood pressure with propranolol was less in 
cigarette smokers than non-smokers, whereas no such 
difference occurred with bendrofluazide. Similar findings
were also reported in the IPPPSH study with another non- 
selective beta blocker, oxprenolol (IPPPSH Study Group,
1985), but not in the HAPPHY study which used selective 
beta-| antagonists (Wilhelmsen et al, 1987). While this 
may reflect a difference in smokers to the haemodynamic 
effects of beta blockade, it is also possible that a 
pharmacokinetic basis seems more likely since smoking has 
been shown to increase the clearance of propranolol (Dawson 
and Vestal, 1981). This illustrates again the importance 
of considering kinetic as well as dynamic differences when 
assessing the variability in antihypertensive drug response.
It has been suggested from recent studies with calcium 
antagonists that these agents lower blood pressure to a 
greater extent in hypertensive patients than in normotensive 
subjects (MacGregor et al, 1982b) and a relationship has been 
described between the pretreatment or initial blood pressure 
and the magnitude of the fall with treatment (Erne et al,
1983). However, care is necessary with the statistical 
methods used in this type of analysis (Gill et al, 1 985) and 
it is probably more appropriate to seek correlations which 
also take account of interindividual differences in drug
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concentrations and in the extent of the blood pressure fall 
associated with placebo (Sumner et al, 1988a).
1.2.2. Pharmacokinetic variability
The pharmacokinetics of some antihypertensive drugs 
vary with increasing age and therefore dosage adjustment may 
be required in the elderly. Peak plasma levels and the 
area under the concentration-time curve for the alpha-j- 
antagonists prazosin and terazosin are higher in older 
subjects (Rubin et al, 1981; McNeil et al, 1987) and there 
are similar age-related reductions in the clearance of 
nifedipine (Robertson et al, 1988) and enalapril (Hockings 
et al, 1986; Lees and Reid, 1987).
The oral pharmacokinetics of drugs which undergo high 
hepatic extraction, for example the calcium antagonists, are 
mainly dependent on liver blood flow and hepatic enzyme 
activity (Echizen and Eichelbaum, 1986). Changes in these 
parameters are likely to explain the reduction in verapamil 
clearance during chronic administration (Section 1.1.1.) and 
the increased bioavailability of verapamil in patients with 
liver cirrhosis (Somogyi et al, 1981). In addition, the 
acute effect of verapamil on liver and splanchnic blood flow 
probably accounts for its pharmacokinetic interaction with 
prazosin (Elliott et al, 1988b). The pharmacokinetics of 
ACE inhibitors, in contrast to calcium antagonists, are 
dependent more on renal than hepatic function (Hockings et 
al, 1986).
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The intersubject variability in plasma concentrations 
of an antihypertensive drug may therefore reflect several 
factors, including differences in hepato-renal 
function and including the further effects of aging on these 
organs* Some drugs show a change in kinetics during 
chronic compared with acute administration, for example 
verapamil (Freedman et al, 1981) and the serotonin (5HT2) 
antagonist ketanserin (Persson et al, 1987), and some 
antihypertensive drugs may modify the disposition of others, 
as in the case of verapamil and prazosin (Elliott et al, 
1988b).
1.3. DRUG C O N C E N T R A TI O N- E F F E C T  RELATIONSHIPS
Pharmacokinetics describes and characterises the 
change in plasma drug concentration per unit time but 
provides only indirect information about the onset, 
intensity and duration of the effect. For some drugs there 
is a simple direct correlation between the time course of 
plasma drug concentration and the response implying a rapid 
equilibration between drug concentration in the plasma and 
drug concentration at the receptor site. For many drugs, 
however, the relationship is not simple and the time course 
of the effect is displaced to the right of the plasma 
concentration profile i.e. delayed (Figure 1.2.). This 
time lag or phase discrepancy may reflect the formation of 
an active metabolite or the delayed penetration of drug into 
a deep tissue compartment or simply the time taken for the
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drug-receptor interaction to produce an effect.
The relationship between a continuously changing plasma 
drug concentration and the corresponding response is usually 
depicted as a plot of effect against the log of drug 
concentration, when it typically takes the form of a sigmoid 
curve. Following a single dose of a drug, the magnitude 
of the response relates to both the concentration and the 
portion of the concentration-response curve covered. Some 
antihypertensive drugs, particularly beta-blockers and 
thiazide diuretics, have long been thought to have flat 
dose-response curves (Hansson et al, 1974; MacGregor et al,
1 983) but this may simply reflect the use of doses which 
produce concentrations at the top end of the concentration- 
effect curve.
Attempts to identify a relationship for 
antihypertensive drugs between plasma concentration and the 
fall in blood pressure have largely been unsuccessful but 
many previous studies have sought correlations between drug 
concentration and effect data for groups of subjects 
(Lehtonen et al, 1977; Biollaz et al, 1982; Johnston et al, 
1983; de Leeuw et al, 1983; Kleinbloesem et al, 1987a). A 
principal component of this failure is likely to be the wide 
range of intersubject variability in both kinetic and 
dynamic parameters when group data are evaluated but there 
is preliminary information that the concentration-effect 
relationship is potentially more useful when individual 
patients are considered (Kelman et al, 1983; Pasanisi and
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Plasma
concentration ..... Effect
Time
Figure 1.2.
A diagrammatic representation of the temporal discrepancy between 
drug plasma concentration and effect which is characteristic of 
many types of drug. From the concentration-effect analysis 
(Chapter 2.5.) K (hour§) characterises the phase discrepancy.
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Reid, 1983). An individual approach has been used 
successfully to define concentration-effect relationships 
with alpha blockers in normotensive subjects (Meredith et 
al, 1983; Vincent et al, 1983; Elliott et al, 1984) and it 
is now feasible to investigate individual hypertensive 
patients using a wider variety of drugs.
1.4. SCOPE OF THE THESIS
In recent years there has been a tendency to move away 
from a standardised stepped care regimen for treating 
patients with hypertension and to adopt instead a more 
flexible approach in which antihypertensive treatment is 
tailored to the needs of individual patients.
"Individualisation’1 of antihypertensive drug treatment 
ideally involves an initial selection from 4 or 5 
alternative drugs, a rapid assessment that the patient is 
likely to have a satisfactory response and then the choice 
of the optimum dosage. Very little is known about factors 
which determine the outcome of treatment but kinetic as well 
as dynamic variability account for the large interindividual 
differences in therapeutic response. Information about the 
relationship between drug concentration and effect 
constitutes a basis for determining the therapeutic regimen 
and dose requirements needed for optimum treatment of 
individual patients. To date, however, this information 
has been lacking and a clear relationship between plasma 
concentration and the fall in blood pressure has not been
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established in hypertensive patients.
This thesis incorporates a series of studies which 
evaluated in patients with essential hypertension the 
pharmacodynamic effects and pharmacokinetics of some of the 
newer alternative first-line antihypertensive drugs. As well 
as measuring the fall in blood pressure, counter-regulatory 
mechanisms were also examined, including changes in 
baroreflex activity and vascular pressor sensitivity to 
exogenous vasoconstrictor agonists. An integrated 
pharmacokinetic and pharmacodynamic model was used to 
characterise the antihypertensive response for each 
individual patient in terms of blood pressure reduction per 
unit drug concentration and to describe the temporal 
discrepancy for the plasma concentration-effect relationship 
(Holford and Sheiner, 1981). The derived concentration- 
effect parameters were used to investigate the underlying 
antihypertensive mechanisms and reflex responses following 
acute and chronic drug administration.
Chapters 3-7 demonstrate that drug concentration-effeet 
relationships can be identified in individual hypertensive 
patients after acute and chronic dosing and illustrate an 
improved method for incorporating kinetic as well as dynamic 
information in the description of individual patient 
responses. Chapter 8 addresses the intersubject 
variability in "responsiveness" for each drug and identifies 
factors which may be of clinical importance in predicting 
the outcome of different antihypertensive treatments.
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2.1. GENERAL CLINICAL PROTOCOL
Patients with essential hypertension were recruited 
from the Hypertension Clinic at Stobhill Hospital and 
directly from general practices in the area, through the 
helpful co-operation of local General Practitioners. 
Forty-six patients with essential hypertension gave informed 
consent to participate in the principal project, which was 
approved by the Research and Ethical Committee of the 
Greater Glasgow Health Board (Northern District), and were 
entered into one of four studies. Patients were either 
newly diagnosed and previously untreated essential 
hypertensives or patients in whom current antihypertensive 
therapy was ineffective or poorly tolerated. Before 
entering a study all patients underwent full clinical 
screening, including physical examination, routine 
biochemistry, haematology, urinalysis and an 
electrocardiogram to exclude other significant 
cardiovascular disease or evidence of significant end-organ 
damage. Each patient discontinued any previous medication 
and, after a treatment-free run-in period of at least 6 
weeks, was entered into a study if blood pressures on three 
consecutive occasions were within the range 160/90 - 
210/115 mmHg.
The general clinical protocol for each study was 
similar. In a single blind design a matching placebo 
tablet was administered for 2 weeks then treatment with 
nifedipine, or enalapril, or doxazosin, or ketanserin as
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monotherapy for 6 weeks.
Study davs
To evaluate the effects of placebo, first dose and 
chronic (1-6 weeks) treatment each patient attended for a 
series of 8—hour study days in the Clinical Pharmacology 
Research Unit (CPRU). On each occasion, following an 
overnight fast, they attended the CPRU at 8 a.m. Baseline 
blood pressure and heart rate measurements were recorded 
before the insertion of an indwelling cannula into an 
antecubital vein and then placebo or active drug was 
administered orally with 100 mis water. At frequent 
intervals during each study day, and at 24 hours after 
dosing, blood pressure and heart rate were measured supine 
after 10 minutes recumbency and erect after 5 minutes 
standing using a Datascope Accutorr semi-automatic 
sphygmomanometer. Venous blood samples were collected at 
corresponding times for the measurement of plasma drug 
concentrations and additional samples were taken for hormone 
measurements and plasma renin and ACE activity. A standard 
light lunch was provided after 4 hours.
2.2. VASCULAR PRESSOR RESPONSES
Pressor responses to intravenous infusions of the 
selective alpha-j-adrenoceptor agonist phenylephrine (PE) and 
the "non-adrenergic” vasoconstrictor angiotensin II (All) 
(Hypertensin, Ciba) were measured on each study day using a
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similar protocol. The pressor agent in 50 mis of 0.9% NaCl
was administered in incremental doses using a Braun Perfusor 
pump to produce a controlled progressive rise in blood 
pressure, with a target increase of 20 mmHg in mean arterial 
pressure. For safety reasons the infusion was terminated 
if increases in blood pressure above 45 mmHg systolic or 30 
mmHg diastolic blood pressure occurred. Each dose was 
infused for 8 minutes and the mean of the final five 
sequential blood pressure and heart rate measurements 
(recorded at 1 minute intervals between minutes 3-8) was 
calculated for each dose level. Administered doses were 
within the range 2.5-20 ng/kg/min for angiotensin II and 
0.5-9.0 ug/kg/min for phenylephrine.
All data points in each individual patient for the 
pressor responses to phenylephrine and angiotensin II were 
fitted to a quadratic function according to the method 
described by Sumner et al (1982). For each individual 
pressor dose-response curve the derived PD20 value 
represents the dose of agonist required to raise mean 
arterial pressure by 20 mmHg. Agonist dose ratios were 
calculated from the ratio PD2oactive/PD2QPlacebo.
Cardiovascular baroreflex activity
The simultaneous blood pressure and heart rate changes 
during the infusion of phenylephrine were fitted in 
individual patients to a linear function and used as an 
index of cardiovascular baroreflex activity. The derived
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measurements of baroreflex function are expressed as the 
change in heart rate per unit increase in systolic blood 
pressure.
2.3. LABORATORY METHODS
Venoms blood samples for laboratory assay were 
withdrawn: from the indwelling forearm'cannula and collected 
into chilled lithium heparin and EDTA tubes* Plasma was 
separated-by centrifugation at 4°C for 15 minutes at 3000 
rpm and stored at -70°C until assay.
2.3.1 . Plasma aldosterone concentration
Plasma aldosterone concentrations were measured 
according to the radioimmunoassay technique described by 
McKenzie and Clements (1974). This method involves the 
competition between I^^-labelled aldosterone and the 
aldosterone contained within the plasma sample, for a fixed 
number of antibody binding sites. After an incubation 
period, the amount of labelled aldosterone bound to the 
antibody is inversely related to the amount of unlabelled 
aldosterone present in the plasma sample. The quantity of 
antibody-bound ligand is measured by radioactive counting 
using a gamma camera.
The normal range for plasma aldosterone in our 
laboratory is 12-125 pg/ml, and the inter- and intra-assay 
coefficients of variation were 11$ and ?.3$ respectively.
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2.3.2. Plasma renin activity
Renin is secreted from the juxtaglomerular apparatus of 
the renal nephron and is responsible for the enzymatic 
conversion of angiotensinogen to angiotensin I. Plasma 
renin activity was measured by incubating plasma with sheep 
renin substrate (angiotensinogen) and determining the rate 
of formation of angiotensin I (Derkx et al, 1972). The 
enzymatic reaction is stopped after a fixed incubation 
period and angiotensin I levels are measured by 
radioimmunoassay.
The normal range for plasma renin activity in our 
laboratory is 0-12 ngA1/ml/hr, and the inter- and intra­
assay coefficients of variation were 1.0% and 5.5% 
respectively.
2.3.3. Plasma catecholamine concentrations
Plasma concentrations of adrenaline and noradrenaline 
were measured using a radioenzymatic assay which is based 
upon the use of the isolated enzyme catechol-o-methyl 
transferase (COMT) to transfer a radioactive methyl group 
from S-adenosyl-L-methionine (SAM) to an endogenous 
catecholamine acceptor molecule to form a radioactive 
derivative (da Prada and Zurcher, 1976). Plasma is 
incubated with 3H-SAM and COMT and the resulting products, 
^H-normetanephrine and ^H-metanephrine, are isolated by
thin layer chromatography. The radioactivity attributable
/
to each catecholamine is measured by Scintillation counting.
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The inter- and intra-assay coefficients of variation 
were 15% and 13% respectively, and the normal ranges 
are 0.3-7.5 nmol/L (supine) for noradrenaline and 0-1.0 
nmol/L for adrenaline.
2.3.4. Plasma angiotensin converting enzvme activity
Angiotensin converting enzyme (ACE) converts the
decapeptide angiotensin I to the octapeptide angiotensin II 
through cleavage of the carboxy-terminal dipeptide histidyl- 
L-leucine. The assay that was used to determine plasma ACE 
activity is based on an HPLC technique for measuring the 
rate of release of hippuric acid from an artificial 
substrate of angiotensin I (Chiknas, 1979). One unit of 
enzyme generates one nanomole of hippuric acid per minute 
and the normal range in our laboratory for plasma ACE 
activity is 5-32 EU/ml. The inter- and intra-assay 
coefficients of variation were 6% and 2% respectively, with 
a limit of detection of 0.1 EU/ml.
2.4. PHARMACOKINETIC ANALYSIS
Pharmacokinetics seeks to describe the time-course of 
drug concentration in the body and this is usually achieved 
with mathematical models which view the body as a series of 
compartments. The rates of transfer of drug from one 
compartment to another are governed by first-order processes 
defined by equations of the form:
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where X represents the amount of drug in the central and 
peripheral compartments, and K 12 and K2 i are the 
intercompartmental first-order rate constants.
The parameters which characterise a pharmacokinetic 
model are determined by fitting plasma concentration-time 
data to equations which define the model, so that the amount 
of drug in the central compartment mirrors that actually 
measured in the plasma. The central compartment therefore 
corresponds to the plasma but the other compartments 
probably have little physiological significance.
Solutions to equations of the type shown above 
(equation 1) lead to the amount of drug in a given 
compartment, Xn , at any time t being described by the 
summation of a series of exponential terms:
Xn = I > n e -  cyn t  (2 )
where An is the nth coefficient and a n is the exponent of 
the n^h exponential term. An and a n are functions related 
to the first-order intercompartmental rate constants. The 
values of the parameters An and a n can be estimated by 
comparing the measured plasma concentrations with those 
predicted by the model by non-linear least-squares 
regression analysis. The disposition characteristics of 
any particular drug will determine the most appropriate
pharmacokinetic model.
In this project plasma drug concentration-time profiles 
for individual patients on each study day were fitted to a 
hierarchy of pharmacokinetic models using an "in house" 
nonlinear least squares fitting program employing the 
Marquardt algorithm (Bevington, 1969) and in each case the 
most appropriate model was identified by the general linear 
test. Measurements were derived for the area under the 
concentration-time curve (AUC), elimination half life, (A)
Cmax and fcmax*
2.5. CONCENTRATION-EFFECT ANALYSIS
In recent years considerable attention has been devoted 
to refining mathematical models for more accurate 
description of drug disposition in the body and thereby to 
attempt to optimise dosage regimens. However, the time- 
course of drug concentration cannot in itself predict the 
time-course or magnitude of drug effect. Until recently, 
comparatively little attention has been focused on 
mathematical modelling of the inter-relationship between the 
effect of a drug and its concentration in plasma (Whiting 
and Kelman, 1980). This integrated approach to
pharmacodynamics and pharmacokinetics has been variously 
called fconcentration-effect analysis' or 'pharmacodynamic 
modelling *.
One of the most striking features of concentration- 
effect analysis is that the measured effect is not in phase
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with the amount of drug in any of the predetermined 
pharmacokinetic compartments (Whiting and Kelman, 1980). 
Characteristically, there is a variable time-lag between the 
effect of a drug and the concentration in plasma and this is 
thought to reflect an equilibration delay in drug reaching 
the effector site (Figure 1.2.). To take account of this 
phase discrepancy, Sheiner et al (1979) developed a unified 
modelling approach which integrates kinetic and dynamic data 
to characterise the drug concentration-effeet relationship 
in individual subjects. This method involves extending the 
simple pharmacokinetic model to incorporate an additional 
"effect11 compartment which is constrained to be small enough 
so as not to perturb the pharmacokinetic parameters defined 
by the original model (Figure 2.1.). The amount of drug in 
the effect compartment, Xe , is described by the equation:
dX
—  * K 1eX, - KeqXe (3)
dt
where is the amount of drug in the central compartment 
and K«je and Keq are first-order rate constants. Keq 
describes the removal of drug from the effect compartment 
and characterises the temporal discrepancy for the plasma 
concentration-effect relationship, i.e. it defines the phase 
lag shown diagrammatically in Figure 1.2.
The measured effect, in this case l)lood pressure 
reduction, is then described as a function of drug 
concentration, Ce , in the effect compartment:
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E = f(Ce )
This function is likely to be sigmoid in configuration and
therefore defined accurately by the Hill or Langmuir (E )
max
equations:
^max • ^e
E = -z---------    Langmuir (E ) model (5)
ce( 50) + ce max
where E is the measured effect and Ce the drug concentration 
in the effect compartment. However, in clinical studies 
most data points are usually obtained within a relatively 
restricted concentration-response range and therefore a 
linear equation is often more appropriate (Figure 2.2.):
E = mCe + i Linear model (6)
For the linear model the slope of the relationship, m,
represents the "responsiveness" to the drug in terms of
effect (in mmHg) per unit drug concentration in the effect 
compartment, while for the Langmuir model Emax is the 
maximum possible effect and is the concentration
required to produce 50$ of Emax (Holford and Sheiner, 1981).
Using this technique, the pharmacodynamic effects of a 
number of drugs have been correlated with their 
pharmacokinetic properties: for example, the prolongation
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EXTENDED KINETIC MODEL
linear model
E = mCe + I 
m = responsiveness eq
Figure 2.1.
For the concentration-effeet analysis the simple pharmacokinetic 
model, for example with central (C) and peripheral (P) compartments, 
is extended to incorporate an additional "effect” compartment (E).
K is the rate constant which determines the removal of drug from E. 
In most clinical studies the linear model satisfactorily describes the 
relationship between drug effect and drug concentration in E(Ce).
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Sigmoid model
E = f(C e )
max
m'=responsiveness
Linear model 
E = mCe + i
Figure 2.2.
The effect, in this case blood pressure reduction, is related as a 
function of drug concentration in the effect compartment (Ce). This 
relationship is sigmoid in configuration and therefore described by 
the Langmuir equation, but in most clinical studies data points are 
usually obtained over a restricted portion of the curve and thus a 
simpler linear model is often more appropriate. The slope of the 
linear relationship, m, represents the responsiveness in terms of 
effect (in mmHg) per unit drug concentration.
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of the QT interval on the electrocardiogram in response to 
disopyramide (Whiting et al, 1980) or quinidine (Holford et 
al, 1981), the change in the force of muscle contraction 
following d-tubocurarine (Sheiner et al, 1979), and the 
improvement in respiratory function in response to 
theophylline (Whiting et al, 1981). In this project the 
same method has been applied with antihypertensive drugs to 
define concentration-effeet relationships in individual 
patients and thereby characterise antihypertensive responses 
in terms of kinetic as well as dynamic parameters.
Having firstly defined the pharmacokinetic model and 
the appropriate parameters in individual patients the 
pharmacodynamic data was then fitted to both the Emax and 
linear effect models using an "in-house" non-linear least 
squares fitting procedure. The most appropriate model was 
identified on the basis of the general linear test and the 
concentration-effect parameters, m (or Emax) and Keq, 
derived for individual patients on each study day. The 
data sets for nifedipine, doxazosin and ketanserin were 
satisfactorily described using the linear effect model and 
the responsiveness (m) was calculated for individual 
patients in terms of the placebo-subtracted fall in blood 
pressure per unit change in drug concentration. The 
Langmuir model was fitted most appropriately to the kinetic- 
dynamic relationships for enalapril and Emax values (in 
mmHg) were expressed in terms of the placebo-subtracted 
reduction in both systolic and diastolic blood pressure.
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2.6. STATISTICAL ANALYSIS
Blood pressure and heart rate measurements were 
evaluated by repeated measures analysis of variance. The 
derived pharmacokinetic and concentration-effeet parameters, 
and the measurements of plasma renin activity, aldosterone, 
catecholamines and ACE activity, were compared between study 
days by repeated measures analysis of variance.
Linear regression analysis was used to investigate the 
relationship between the concentration-effeet parameter, m 
(or Emax), and factors such as patient age, plasma renin 
activity and starting blood pressure.
For the pressor response analysis the PD20 values> 
which represent the dose of agonist required to raise mean 
arterial pressure by 20 mmHg, were compared by repeated 
measures analysis of variance.
Measurements throughout are expressed as mean + 
standard deviation.
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NIFEDIPINE
CHAPTER 2
ESSENTIAL HYPERTENSION: RESPONSES AND
CONCENTRATION-EFFECT RELATIONSHIPS IN INDIVIDUAL PATIENTS
3.1 . INTRODUCTION
The calcium antagonist drug nifedipine, which is widely 
used in the treatment of angina pectoris and essential 
hypertension, shows large inter-individual differences not 
only in drug disposition and dose requirements but also in 
the magnitude of the antihypertensive response (Bayley et al, 
1982; Kiowski et al, 1983; Kleinbloesem et al, 1984a and 
1984b; Landmark, 1985). Attempts to identify a 
relationship between plasma drug concentration and the fall 
in blood pressure have produced conflicting reports and a 
clear relationship between plasma concentration and blood 
pressure reduction has not been established (Lederballe- 
Pedersen et al, 1979 and 1980; Aoki et al, 1982; Taburet 
et al, 1983). This may reflect the wide range of inter­
subject variability in both kinetic and dynamic parameters 
when group data are evaluated but there is preliminary 
information that the concentration-effeet relationship is 
potentially more applicable when individual patients are 
considered (Pasanisi and Reid, 1983).
This study investigates the pharmacodynamics and 
pharmacokinetics of monotherapy with nifedipine in patients 
with essential hypertension and, by integrated 
pharmacokinetic and pharmacodynamic modelling (Holford and 
Sheiner, 1981), characterises the responses to acute and 
chronic nifedipine in individual patients.
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3.2. PATIENTS AMD METHODS
3.2.1 . General
Fourteen patients (7 male, 7 female) with mild to 
moderate essential hypertension, age range 33-66 years, gave 
consent to participate in this study. Individual patient 
details are shown in Table 3.1.
Following a preliminary assessment period of at least 6 
weeks (without treatment) the average entry blood pressure 
was 181/105 ± 20/8 mmHg supine and 183/107 ± 17/5 mmHg 
erect. Thereafter, in a single blind design, patients 
received placebo for 2 weeks followed by 6 weeks treatment 
with nifedipine 20 mg b.i.d using a delayed release 
formulation tablet (Adalat Retard, BAYER UK Ltd). Each 
patient attended four 8-hour study days in the Clinical 
Pharmacology Research Unit (CPRU) to evaluate the effects of 
placebo, 1st dose nifedipine and then 1 week and 6 weeks of 
nifedipine therapy.
The protocol for study days is described in detail in 
Chapter 2.1. At frequent intervals during each study day, 
and at 24 hours after dosing, supine and erect blood 
pressure and heart rate were measured and venous blood 
samples collected for plasma nifedipine concentrations. 
Additional blood samples were obtained at 1.5 and 6 hours 
for plasma renin activity, aldosterone and catecholamines.
3.2.2. Nifedipine concentrations.
Blood and plasma samples were placed into tubes
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wrapped with aluminium foil to prevent photodegradation of 
nifedipine. Plasma nifedipine concentrations were measured 
using the reverse phase HPLC technique described by Waller 
et al (1984). The extraction procedure was carried out 
under sodium light and the recovery of nifedipine was 
between 7 0 — 8 0. j . Ultra-violet detection was used, and the
inter and intra-assay coefficients of variation for the drug 
assay were 8% and 5% respectively, with a limit of detection 
of 3-5 ng/ml.
3.2.3. Pharmacokinetics and concentration-effect analysis 
Plasma nifedipine concentration-time profiles for 
individual patients on each study day were most 
appropriately described by a one compartment pharmacokinetic 
model with first order input and inverse weighting of the 
drug concentrations. Measurements derived from fitting this 
model to the data were the apparent elimination half-life, 
area under the concentration-time curve (AUC), C;7iax and
fcmax •
For the concentration-effect analysis the standard 
pharmacokinetic model was augmented by an "effect" 
compartment, as described in Chapter 2.5. The effect of 
nifedipine on blood pressure was then related to the drug 
concentration in the effect compartment by means of both the 
linear and non-linear models (Holford and Sheiner, 1981).
In all cases, both acutely and chronically, the data were 
most appropriately described by the linear model on the
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basis of the general linear test. The concentration-effect 
parameters, m and Ke^, were derived for individual patients 
on each study day and the responsiveness (m) to nifedipine 
was calculated in terms of the placebo-subtracted change in 
both erect systolic and diastolic blood pressure per unit 
change in drug concentration.
3.3. RESULTS 
3.3.1. Blood pressure
Nifedipine produced significant reductions (p <0.01) in 
supine and erect blood pressure, as illustrated by the erect 
systolic and diastolic blood pressures (Figure 3.1.). The 
maximum antihypertensive effect of this formulation of 
nifedipine occurred 5-6 hours after drug administration 
(Figure 3.1.): for example at 5 hours after the first dose, 
erect blood pressure had fallen from a baseline of 166/104 + 
12/10 to 1 35/86 ± 16/8, compared with 171/105 ± 16/9 to 
162/97 ± 9/7 mmHg following placebo. The average maximal 
fall in blood pressure following the first dose (baseline- 
and placebo-corrected) was 21/11 ± 11/8 mmHg supine and 
27/13 ± 18/10 mmHg erect.
With continued treatment there was a sustained 
antihypertensive effect (p < 0.01): for example, baseline
measurements of supine blood pressure (recorded 12 hours 
after the last dose) after 1 week and 6 weeks were 
respectively 23/11 and 33/15 mmHg lower than with placebo.
In addition, there were further reductions in blood pressure 
after drug administration, reaching a nadir at 5 hours of
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1 35/80 + 1 3/ 9 supine and 1 29/84 + 1 1/8 mmHg erect after 1 
week and 136/81 + 10/7 supine and 132/82 + 11/10 mmHg erect 
after 6 weeks (Figure 3.1.) .
3.3-2. Heart rate
The acute reduction in blood pressure, particularly 
following the first dose and after 1 week of nifedipine, was 
associated with significant increases in heart rate (Figure
3.2.). Erect heart rate increased from a baseline of 87 + 
13 to 108 + 14 bpm 5 hours after the first dose, compared 
with a corresponding change from 86 + 14 to 94 + 12 bpm 
following placebo. After 1 week of nifedipine, reflex 
tachycardia was considerably reduced but significant 
increases in heart rate were again observed at 4-5 hours 
(Figure 3.2.). Heart rate profiles after 6 weeks were not 
significantly different from placebo.
3.3.3. Hormone measurements
The first dose of nifedipine was associated with a 
significant increase in plasma noradrenaline: for example 
at 1.5 hours, 4.2 ± 2.1 compared with 2.5 ± 1.3 nmol/L 
following placebo (Table 3.2.). After 1 week of nifedipine 
plasma noradrenaline was again increased at 1.5 hours (3.9 ± 
1.7 nmol/L) and there were additional significant increases 
in plasma renin activity and aldosterone (Table 3.2.). 
Measurements after 6 weeks were not significantly different 
from placebo.
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Mean profiles of erect systolic and diastolic blood pressure after 
placebo ( •  ), 1st dose nifedipine ( O  ) and after 1 week ( ♦  ) and 6 
weeks C O )  nifedipine treatment.
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TABLE 3.2.
NIFEDIPINE STUDY. HORMONE MEASUREMENTS at 1,5 AND 6 HOURS 
AFTER DRUG ADMINISTRATION.
MEAN + SD
TIME
(HRS) PLACEBO 1ST DOSE 1 WEEK 6 WEEKS
Plasma renin 
activity 
(ngA1/ml/hr)
1.5 1.5 ± 
1.4
1.8 + 
1.0
2.6* +
1.4
3.3 ± 
4.9
6 1.7 ± 
1.2
1.8 + 
1.1
2.5* + 
2.1
2.9 ± 
3.2
Plasma
aldosterone
(pg/ml)
1.5 76 + 
33
99 ± 
60
110* +
58
106 + 
79
6 75 ± 
44
110 +
60
111* +
57
103 + 
71
Plasma
noradrenaline
(nM/L)
1.5
6
2.5 ± 
1.3
2.8 + 
1.5
4.2** +
2.1
4.2** ±
2.4
3.9* ± 
1.7
3.3 ± 
1.6
3.0 ± 
1.6
3.0 ± 
0.9
* P < 0.03 ** P < 0.006
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3.3.4. Pharmacokinetics
There were large inter-subject differences in plasma 
nifedipine concentrations but the intra—individual mean 
pharmacokinetic parameters were not significantly different 
across the three study days (Tables 3.3. - 3.5.).
Following the first dose, after 1 week and after 6 weeks, the 
mean values for AUC (ng.h.ml”1) were respectively 824 + 327, 
813 ± 282 and 880 + 814; for apparent elimination half-life 
(hrs), 6.0 + 2.8, 10.0 ± 3.1 and 7.5 ± 2.3; for Cmax 
(ng.ml“ ^), 74 + 25, 53 ± 15 and 77 ± 68; for tmax (hrs),
2.5 ± 1.0, 2.0 + 0.7 and 2.0 + 0.6. There was a significant 
correlation between age and the maximum concentration of 
nifedipine achieved following the first dose (Figure 3.3.).
3.3.5. Concentration-effect relationships
In individual patients, as illustrated by patient 9 
(figure 3.4.), there was no simple direct relationship 
between the plasma nifedipine concentration and the fall in 
blood pressure. Using the linear concentration-effect model 
the data for all individuals were satisfactorily fitted and 
the two examples shown in Figures 3.5. and 3.6. illustrate 
above and below average goodness of fit for changes in 
systolic blood pressure. Figure 3*7. illustrates fits for 
diastolic blood pressure in a representative patient. The 
derived m and KAn values and the "goodness” of fit (R) for
“m
the data sets of individual patients are shown in Tables
3.6. and 3.7. Responsiveness to nifedipine in terms of
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TABLE 3.3.
NIFEDIPINE PHARMACOKINETICS AFTER THE FIRST DOSE
PATIENT AUC
(ng.h.ml”1)
1 495 6.4 44 2.2
2 408 1.3 77 2.2
3 404 6.4 19 1.0
4 661 4.6 90 1.6
5 1237 3.7 90 5.4
6 673 7.4 53 2.0
7 1087 6.6 101 2.1
8 757 8.1 59 2.1
9 986 4.4 111 2.4
10 428 1.2 89 2.1
11 1378 11.3 70 3.1
12 1181 7.0 89 3.0
13 906 5.9 81 2.8
14 933 9.4 58 3.1
MEAN 824 6.0 74 2.5
+ + + + +
SD 327 2.8 25 1.0
APPARENT C T
ELIMINATION (ngTml) (hours)
HALF-LIFE 
(hours)
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TABLE 3.4.
NIFEDIPINE PHARMACOKINETICS AFTER TREATMENT FOR 1 WEEK
PATIENT AUC
(ng.h.ml"')
APPARENT
ELIMINATION
HALF-LIFE
(hours)
fn&H) (fes)
1 746 11.2 42 1.7
2 452 8.1 30 3.0
3 524 9.0 36 1.4
4 689 7.3 57 2.1
5 1328 13.0 69 1.9
6 559 9.5 37 1.9
7 885 11.5 49 2.1
8 768 6.9 74 0.8
9 697 6.2 74 0.7
10 713 5.7 65 2.9
11 1150 16.0 46 2.0
12 - - - —
13 1305 13.7 56 3.1
14 751 10.9 47 1.9
MEAN 813 10.0 53 2.0
+ + + + ±
SD 282 3.1 15 0.7
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TABLE l.S.
NIFEDIPINE PHARMACOKINETICS AFTER TREATMENT FOR 6 WEEKS
PATIENT AUC
(ng.h.ml” ')
APPARENT
ELIMINATION
HALF-LIFE
(hours)
(ng?rnK) (fes)
1 839 5.7 96 1.9
2 464 8.9 33 1.6
3 410 5.4 42 1.8
4 636 7.9 54 1.3
5 806 5.0 99 2.6
6 497 8.4 38 1.3
7 550 6.7 46 2.2
8 727 10.0 44 2.3
9 814 4.0 120 1.1
10 461 5.9 52 2.3
11 954 10.6 55 2.1
12 406 11.3 22 2.2
13 1162 9.3 84 2.0
14 3597 6.4 290 3.5
MEAN 880 7.5 77 2.0
+ + + + ±
SD 814 2.3 68 0.6
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Figure 1*1.
Nifedipine study. Correlation between patient age and the maximum 
plasma concentration (Cmax) °f nifedipine after the first dose.
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systolic blood pressure, as the mean of the group, was -0.48 
mmHg/ng/ml following the first dose, -0.45 after 1 week and 
-0.49 after 6 weeks. The corresponding values for changes 
in diastolic blood pressure were -0.25 (first dose), -0.24 
(1 week) and -0.26 mmHg/ng/ml (6 weeks). There were 
significant correlations both acutely and chronically 
between the responsiveness to nifedipine in terms of 
systolic and diastolic blood pressure (Figure 3.8.). In 
addition, for individual patients there were significant 
correlations (p < 0.001) between the responsiveness to the 
first dose of nifedipine and the responsiveness after 1 week 
( r = 0 .8 3) and after 6 weeks treatment (r = 0 .7 8 ), as 
illustrated in Figure 3.9., the slope of both these 
regression lines being not significantly different from 
unity. There were no significant differences in Kc q
between the three study days.
There was a significant positive correlation (p < 0.02) 
between the responsiveness to the first dose of nifedipine 
and the baseline (pretreatment) blood pressure (r = 0.6 ; 
Figure 3.10a.). There was no significant correlation between 
responsiveness and the maximal change in heart rate although 
there was a trend towards an inverse relationship (Figure 
3 .10b.) .
There was no significant relationship between the 
responsiveness to nifedipine and patient age, pretreatment 
plasma renin activity (Figure 3.11.) or plasma 
noradrenaline.
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Figure 3.4.
The relationship between plasma nifedipine concentration and the 
placebo-subtracted fall in erect systolic blood pressure in an 
individual patient after the 1st dose of nifedipine.
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Nifedipine concentration-effect analysis. The observed
( ▲ a  ) and fitted ( ▲ A ) effect of nifedipine on erect
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Nifedipine concentration-effect analysis. The observed
( ▲ — ▲  ) and fitted ( ▲----▲  ) effect of nifedipine on erect
diastolic blood pressure after the 1st dose and after 6 weeks in 
a representative patient (patient 8).
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TABLE 3.6.
NIFEDIPINE CONCENTRATION-EFFECT PARAMETERS. m (mmHg/ng/ml) and K (h 
and the goodness of fit R (AS a fraction of UNITY) eq
FOR CHANGES IN ERECT SYSTOLIC BLOOD PRESSURE
-1
PATIENT
m
1st DOSE 
Keq R m
1 WEEK 
Keq R
6 WEEKS 
m Keq R
1 -0.29 49.6 0.84 -0.24 12.5 0.88 -0.24 0.2 0.67
2 -0.79 2.1 0.92 -0.95 0.9 0.81 -0.87 1.0 0.88
3 -0.63 1.9 0.92 -0.55 0.8 0.74 -0.61 0.9 0.90
4 -0.84 0.8 0.88 -0.58 3.7 0.95 -0.56 0.1 0.83
5 -0.34 12.2 0.92 -0.34 12.5 0.89 -0.37 0.2 0.76
6 -0.39 2.0 0.91 -0.46 46.9 0.85 -0.51 2.4 0.92
7 -0.18 1.1 0.86 -0.25 7.6 0.76 -0.27 0.6 0.84
8 -0.43 1.8 0.90 -0.42 1.3 0.71 -0.46 4.7 0.78
9 -0.43 0.5 0.96 -0.50 0.6 0.83 -0.48 0.3 0.85
10 -0.55 0.6 0.97 -0.39 3.8 0.90 -0.46 0.1 0.87
11 -0.52 0.3 0.93 -0.37 0.9 0.84 -0.36 0.5 0.71
12 -0.57 0.9 0.93 - - - -0.48 0.1 0.56
13 -0.18 9.3 0.62 -0.25 0.8 0.77 -0.39 1.1 0.70
14 -0.67 29.1 0.94 -0.54 1.5 0.91 -0.78 1.1 0.69
Mean + 
SD
-0.48+
0.20
8.0+
14.3
0.89±
0.10
-0.45+
0.19
7.2+ 
12.7
0.83±
0.07
-0.49±
0.17
0.9±
1.2
0.78±
0.10
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TABLE 3.7.
NIFEDIPINE CONCENTRATION-EFFECT PARAMETERS m (mmHg/ng/ml) AND K (h” )^ 
AND THE GOODNESS OF FIT R (AS A FRACTION OF UNITY) 6Q
FOR CHANGES IN ERECT DIASTOLIC BLOOD PRESSURE
PATIENT 1st DOSE 1 WEEK 6 WEEKS
m Keq R m Keq R m Keq R
1 -0.24 4.4 0.94 -0.19 17.7 0.63 -0.18 26.1 0.72
2 -0.51 7.0 0.96 -0.45 3.1 0.89 -0.40 3.8 0.89
3 -0.47 28.2 0.78 -0.34 1.1 0.72 -0.40 1.3 0.88
4 -0.25 5.3 0.79 -0.19 27.1 0.85 -0.22 6.3 0.95
5 -0.10 8.3 0.88 -0.14 49.9 0.62 -0.17 4.8 0.95
6 -0.25 3.9 0.95 -0.19 2.9 0.87 -0.28 1.9 0.85
7 -0.15 1.7 0.97 -0.22 1.1 0.81 -0.25 1.1 0.95
8 -0.24 4.5 0.76 -0.21 1.5 0.90 -0.27 3.9 0.78
9 -0.08 2.3 0.88 -0.28 2.6 0.86 -0.18 1.3 0.96
10 -0.25 0.6 0.88 -0.23 2.7 0.79 -0.16 17.4 0.78
11 -0.35 0.4 0.87 -0.15 1.3 0.78 -0.28 0.6 0.87
12 -0.20 1.1 0.81 - - - -0.34 3.1 0.83
13 -0.18 2.6 0.94 -0.24 1.6 0.83 -0.20 1.9 0.83
14 -0.23 12.9 0.86 -0.35 22.2 0.92 -0.33 5.8 0.82
Mean + 
SD
-0.25+
0.12
5.9±
7.2
0.88+
0.07
+1Zf 
CTi
CVI 
o
 
. 
.
o 
o
 
1 10.4+
14.9
0.80+
0.1
-0.26+
0.08
5.7±
7.2
0.86+
0.07
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Nifedipine study. Correlation between the responsiveness to nifedipine 
(m) after 6 weeks in terms of systolic and diastolic blood pressure.
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3.4. DISCUSSION
Reliable assays for measuring nifedipine in plasma have 
only recently become available and there is still a relative 
paucity of information about the pharmacokinetics of 
nifedipine and, more importantly, about the kinetic-dynamic 
relationships in essential hypertension (Kleinbloesem et al, 
1987a). An interesting feature of the pharmacokinetics of 
other calcium antagonists, particularly verapamil, which 
potentially might complicate the concentration-effect 
relationship, is the observed reduction in drug clearance 
during chronic compared with single dose administration 
(Shand et al, 1981). A similar finding has been observed 
with the dihydropyridine nicardipine (Donnelly et al, 1987) 
and also with nifedipine itself when the kinetics of 
intravenous administration have been determined following 
chronic treatment with oral nifedipine (Kleinbloesem et al, 
1987b). These changes in clearance have been ascribed to 
drug-related alterations in hepatic blood flow (Feely, 1984; 
Meredith et al, 1985b) or enzyme activity (Bach et al, 1986). 
Such a change in pharmacokinetics was not observed in this 
study but the use of a delayed release formulation of 
nifedipine obviously did not permit full characterisation of 
the disposition, particularly the terminal elimination phase
of nifedipine.
It has been reported in healthy, elderly subjects that 
there is an age-related decline in the clearance of
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nifedipine (Robertson et al, 1988; Scott et al, 1988). 
Across the relatively narrow range of middle-aged 
hypertensive subjects in this study there was no obvious 
relationship between age and nifedipine disposition but 
there was a significant correlation between age and first 
dose Cmax, which is consistent with an age-related effect on 
absorption or first pass hepatic extraction. Similarly, it 
has been suggested that there is bimodal distribution within 
a population for the rate of metabolism of nifedipine 
(Kleinbloesem et al, 1984b) but there was no evidence of 
bimodality in this relatively small study.
It has been suggested that there is no predictable 
concentration-effeet relationship for nifedipine but this 
probably reflects the negative findings of those previous 
studies which considered the response for groups of 
patients rather than for individuals (Lederballe-Pedersen et 
al, 1 979 and 1 980; Aoki et al, 1 982; Taburet et al, 1 983). 
This study has shown that nifedipine concentrations are 
correlated with the reductions in both systolic and 
diastolic blood pressure in individual hypertensive patients 
and has extended the preliminary findings of Pasanisi and 
Reid (1983) by defining individual concentration-response 
relationships which are applicable during chronic treatment. 
Additionally, there were significant correlations between 
the parameters derived from the first dose and those after 1 
week and 6 weeks treatment, which suggests that the first 
dose response may be used to forecast the steady state
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effect for an individual patient. Clearly this has 
potential application in therapeutics as a means of quickly 
identifying poor or non-responders and for determining 
individual dose requirements for optimum longterm blood 
pressure control. During the first week of nifedipine 
treatment there was evidence that the fall in blood pressure 
was associated with reflex sympathetic activation but this 
did not perturb the correlation with the response obtained 
at 6 weeks, when baroreflex mechanisms had apparently 
"reset”. Despite these changes in sympathetic activity, 
the responsiveness to nifedipine after six weeks, in 
contrast to that reported for nisoldipine (Waller and 
Ramsay, 1987), showed no significant reduction and this 
study has highlighted the importance of considering kinetic 
as well as dynamic parameters when assessing the constancy 
of the antihypertensive response.
Changes in heart rate with nifedipine have been 
correlated with acute reductions in blood pressure in young 
healthy normotensives (Kleinbloesem et al, 1984a). In this 
study of hypertensive patients there was an opposite trend 
whereby the responsiveness to nifedipine following the first 
dose tended to be greatest in those showing the smallest 
increase in heart rate. A possible explanation is that the 
increase in heart rate is a component of the reflex 
mechanism attempting to counteract the acute 
antihypertensive or vasodilator response to nifedipine, as 
seen in healthy normotensives, but if the compensatory
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increase in heart rate and resultant cardiac output is 
inadequate then the reduction in blood pressure will tend to 
be more pronounced. Since reflex mechanisms are blunted in 
the elderly (Vestal et al, 1979), this may partly explain 
why calcium antagonists have been reported to be more 
effective in the older age group (Erne et al, 1983).
The relationship between pretreatment or initial blood 
pressure and the magnitude of the fall with treatment has 
been described previously (MacGregor et al, 1982b; Erne et 
al, 1983). Care is necessary with the statistical methods 
used in this type of analysis (Gill et al, 1985) and it is 
probably more appropriate to seek correlations which also 
take account of inter-individual differences in drug 
concentrations and in the extent of the blood pressure fall 
associated with placebo (Sumner et al, 1988a). In this 
study, illustrated by the placebo-corrected reduction in 
erect systolic blood pressure, there was a significant 
relationship between the baseline (pre-treatment) blood 
pressure and responsiveness (m) to the first dose of 
nifedipine. It has also been suggested that plasma renin 
activity influences the antihypertensive effect of 
nifedipine (Erne et al, 1983) but in this study there was no 
significant relationship between the pretreatment plasma 
renin activity and the responsiveness to nifedipine.
In conclusion, this study has evaluated the 
pharmacokinetics of nifedipine in essential hypertension and 
characterised the antihypertensive response to nifedipine in
101
individual patients. The derived concentration-effect 
parameters provide not only a useful means of evaluating 
factors which influence the kinetic and dynamic variability 
of nifedipine but also a potential basis for optimising 
longterm treatment in individual patients.
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CHAPTER 4
ENALAPRIL IN ESSENTIAL HYPERTENSION: 
RESPONSES AND CONCENTRATION-EFFECT RELATIONSHIPS 
IN INDIVIDUAL PATIENTS
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4.1. INTRODUCTION
The angiotensin converting enzyme (ACE) inhibitor 
drugs, captopril and enalapril, have become established in 
the treatment of both hypertension (Brunner et al, 1980; 
Hodsman et al, 1982) and cardiac failure (Kjekhus et al, 
1983; CONSENSUS 1987). In contrast to captopril which 
itself is active, enalapril is a prodrug and following oral 
administration undergoes de-esterification (principally in 
the liver) to the active diacid metabolite enalaprilat 
(Tocco et al, 1982). In general, there is a relationship 
between the dose and plasma concentration of an ACE 
inhibitor and its effects on blood pressure and the renin- 
angiotensin system but previous studies, which have examined 
data for groups of subjects, have reported variable 
relationships between drug levels, blood pressure reduction 
and ACE inhibition (Biollaz et al, 1982; Johnston et al, 
1983; de Leeuw et al, 1983; Johnston et al, 1984;
Schwartz et al, 1985). While this is likely to reflect the 
intersubject variability in both kinetic and dynamic 
parameters, there is preliminary evidence that 
concentration-effect relationships for ACE inhibitors are 
potentially more useful when individual subjects are 
considered (Kelman et al, 1983) and this approach has been 
used successfully in single-dose studies in healthy 
volunteers (Witte et al, 1984; Francis et al, 1987).
This study in patients with essential hypertension 
evaluates the pharmacodynamic effects, including
104
inhibition of plasma ACE activity, and the pharmacokinetics 
of enalapril after acute and chronic administration, and 
using an integrated kinetic—dynamic model (Holford and 
Sheiner, 1981) characterises the antihypertensive responses 
and concentration-effeet relationships in individual 
patients.
4.2. PATIENTS AND METHODS
4.2.1 . General
Thirteen patients (6 male and 7 female) with mild to 
moderate essential hypertension, age range 41-66 years, 
participated in this study. Individual patient details are 
shown in Table 4.1. Each patient discontinued all 
medication and at the end of a drug-free run-in period of at 
least 6 weeks the mean entry blood pressures were 181/101 + 
15/8 (supine) and 175/101 + 13/6 mmHg (erect). In a 
single-blind design placebo was then administered for 2 
weeks, followed by enalapril 20 mg once daily for 6 weeks, 
and each patient attended 8-hour study days in the Clinical 
Pharmacology Research Unit (CPRU) to evaluate the effects of 
placebo, 1st dose enalapril and after 1 week and 6 weeks 
treatment.
The clinical protocol is described in detail in Chapter
2.1. At frequent intervals during each study day, and at 
24 hours after dosing, supine and erect blood pressure and 
heart rate were recorded and venous blood samples collected 
for measurement of plasma enalaprilat concentration and ACE
105
activity. Additional blood samples were obtained in 7 
patients at 12 and 32 hours after dosing. Blood was also 
collected at 0, 1.5 and 6 hours on each study day for plasma 
renin activity, aldosterone and catecholamines.
4.2.2. Enalaprilat concentrations
Plasma concentrations of enalaprilat were measured 
using a specific radioimmunoassay technique (Hichens et al, 
1981). Plasma is incubated with antibody and a radioactive 
label (an iodinated precursor of MK-521). The antibody 
bound fraction is precipitated by a second antibody, 
separated by centrifugation and counted using a gamma 
counter. The amount of enalaprilat in the sample is 
inversely proportional to the amount of antibody bound 
label. The inter and intra-assay coefficients of variation 
for the enalaprilat assay were 8.5% and 7% respectively, and 
the limit of detection was 0.4 ng/ml.
4.2.3. Pharmacokinetics and concentration-effect ana lysis 
The pharmacokinetics of.enalapril were evaluted by a
number of different approaches because previous studies 
have described some unusual characteristics of ACE 
inhibitor kinetics. The most appropriate method, as 
assessed by the general linear test was to fit the plasma 
enalaprilat concentration-time profiles for individual 
patients on the three study days simultaneously to a 
unified one compartment pharmacokinetic model with
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saturable protein binding.
For the concentration-effeet analysis the standard 
pharmacokinetic model was augmented by an "effect" 
compartment, as described in Chapter 2.5. The effects 
of enalapril on both systolic and diastolic blood pressure 
were then related to the concentration of enalaprilat in the 
effect compartment by means of both the linear and non­
linear models (Holford and Sheiner, 1981). In each case, 
after acute and chronic dosing, the data were most 
appropriately described by the Langmuir-Eraax model (Chapter 
2.5.) .
The pharmacodynamic data were fitted independently for 
each study day and simultaneously for all three study days 
and the concentration-effeet parameters, Emax> Ce(50) and 
Kpn, were derived for individual patients. ^max was 
calculated in terms of the placebo-subtracted fall in both 
erect systolic and diastolic blood pressure and Ce(50) 
represents the concentration required to produce 50% of Emax 
(chapter 2.5.).
4.2.4. Statistical analysis
The statistical methods are described in general in 
Chapter 2.6. Measurements of plasma ACE activity at 
individual times after dosing were compared between study 
days by repeated measures analysis of variance.
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4.3. RESULTS
4.3.1. Patient tolerance
Enalapril was generally well tolerated and there were 
no significant adverse effects reported. In particular, 
there were no symptomatic 'hypotensive' responses to the 
first dose and there were no significant changes in serum 
urea and creatinine during the study.
4.3.2. Blood pressure
Enalapril was associated with significant reductions in 
both supine and erect blood pressure following the first dose: 
for example, erect blood pressure was reduced from a 
baseline of 171/101 ± 17/10 to 122/80 ±20/13 mmHg at 6 
hours, compared with a change from 178/106 + 21/10 to 155/94 
± 11/7 6 hours after placebo (Figure 4.1.). The maximum 
antihypertensive effect of enalapril occurred at 5-6 hours 
after drug administration (Figure 4.1.) and there was no 
significant orthostatic component: baseline-corrected
reductions in supine and erect blood pressure 6 hours after 
the first dose were 46/27 and 49/21 mmHg respectively.
The antihypertensive effect of enalapril was sustained 
during chronic treatment and there were significant 
reductions in predose blood pressures: for example,
measurements of supine blood pressure recorded 24 hours 
after the last dose were 1 53/93 ± 23/12 after 1 week and 
157/94 ± 18/12 mmHg after 6 weeks, compared with 187/105 ± 
17/10 mmHg following placebo. In addition, there were
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further significant reductions in blood pressure following 
drug administration, reaching a nadir at 6 hours of 123/76 + 
18/9 supine and 1 18/76 + 26/10 erect after 1 week and 122/73 
± 18/10 supine and 122/77 ± 19/13 mmHg erect after 6 weeks 
(Figure 4.1.).
4.3.3. Heart rate
The fall in blood pressure with enalapril, particularly 
after the first dose, was not associated with any significant 
change in heart rate (Figure 4.2.). Average supine and 
erect heart rates over the 8 hours were respectively 71 and 
84 bpm after the first dose; 71 and 85 bpm after 1 week; and 
68 and 83 bpm after 6 weeks; compared with 73 and 84 bpm 
after placebo.
4.3.4. Angiotensin converting enzvme activity
The first dose of enalapril was associated with a prompt 
reduction in plasma ACE activity (Figure 4.3.), significant 
at 1 hour and reaching a nadir at 3-4 hours after drug 
administration: for example, ACE activity was reduced from
a baseline of 39.3 ± 11.9 to 4.1 ± 1.5 EU/ml at 4 hours, 
compared with a corresponding change from 36.8 + 12,6 to 
34.9 + 12.2 EU/ml after placebo (Table 4.2.). Significant 
inhibition of ACE activity was sustained for up to 24 hours 
after the first dose: 22.0 + 8.2 compared with 35.9 ± 12.1
EU/ml 24 hours after placebo. During chronic treatment 
with enalapril predose measurements of plasma ACE activity
110
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Figure 4.1.
Mean profiles of erect systolic and diastolic blood pressure after 
placebo ( ■  ), 1st dose enalapril ( ♦  ) and after 1 week ( □  ) and 
6 weeks ( A  ) enalapril treatment.
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Figure 4.2.
Mean profiles of erect heart rate after placebo ( ■  ), 1st dose 
enalapril (♦  ) and after 1 week ( □  ) and 6 weeks ( ▲  ) enalapril 
treatment.
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(recorded 24 hours after the last dose) were not 
significantly reduced: 33.7 ± 18.9 after 1 week and 32.2 ±
11.1 after 6 weeks, compared with 36.8 + 12.6 EU/ml 
following placebo (Table 4.2. and Figure 4.3.). In 
addition, although there was significant inhibition of 
plasma ACE activity during the 8 hour study day, 
measurements at 24 hours had returned towards placebo 
values: 31.7 ± 18.5 (1 week) and 32.3 ± 16.9 EU/ml (6
weeks), compared with 35.9 ± 12.1 EU/ml at 24 hours after 
placebo (Figure 4.3.).
4.3.5. Hormone measurements
Enalapril produced significant increases in plasma 
renin activity (PRA), particularly during chronic treatment 
and at 6 hours after drug administration (Table 4.3.): for
example, measurements of PRA at 6 hours increased 
progressively from 5.1 (placebo) to 12.4 (first dose), 50.3 
(1 week) and 58.0 ngA1/ml/hr after 6 weeks. In addition, 
there were modest but significant reductions in plasma 
aldosterone concentration after 1 week: for example at 6
hours, 58 pg/ml compared with 102 pg/ml after placebo (Table
4.3.). Measurements of plasma aldosterone after 6 weeks 
were not significantly different compared with placebo. 
Enalapril had no significant effect on plasma noradrenaline 
(Table 4.3.) .
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enalapril treatment.
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TABLE 4.3.
ENALAPRIL STUDY. MEASUREMENTS OF PLASMA RENIN ACTIVITY. ALDOSTERONE AND 
NORADRENALINE AT 0. 1.5 AND 6 HOURS AFTER DRUG ADMINISTRATION.
MEAN + SD
TIME PLACEBO 
(HRS)
1ST DOSE 1 WEEK 6 WEEKS
Plasma renin activity 
(neA1/ml/hr)
0 4.0 ± 3.8 7.4 ± 5.3 23.0 ± 22.2** 20.3 ± 19.5**
1.5 3.6 ± 3.5 6.9 ± 6.9 18.3 ± 14.4* 18.0 ± 17.5*
6 5.1 ± 7.3 12.4 ± 12.1* 50.3 ± 40.1** 58.0 ± 77.2**
Plasma aldosterone 
(PS/ml).
0 116 ± 64 97 ± 32 92 ± 45 131 ± 98
1.5 82 ± 54 69 ± 45 67 ± 41* 85 ± 34
6 102 ± 74 53 ± 31* 58 ± 46* 71 ± 24
Plasma noradrenaline 
(nmol/L)
0 3.8 ± 1.8 3.8 ± 1.7 3.5 ± 1.9 3.7 ± 1.5
1.5 3.2 ±1.5 3.0 ± 1.3 2.7 ± 1.2 2.3 ± 0.9
6 3.8 ±2.2 2.9 ± 1.2 3.0 ± 0.9 2.7 ± 1.1
* p < 0.01 
** p < 0.001
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4.3.6. Pharmacokinetics
The pharmacokinetics of enalapril were evaluated by a 
number of different approaches. The initial approach 
adopted was to fit a hierarchy of conventional kinetic 
compartmental models, governed by first order processes, to 
the enalaprilat concentration data from each study day 
independently. In all subjects on both acute and steady 
state study days a two compartment open model was most 
appropriately fitted to the data and the parameters obtained 
from this approach are shown in Table 4.4. It is apparent 
from Table 4.4. that the kinetics evaluated in this manner 
suggest significant differences in enalaprilat disposition 
between acute and steady state dosing. Although there are 
no significant differences in the apparent elimination half- 
life of enalaprilat in translation from acute to chronic 
therapy, the AUC values at steady state are significantly 
smaller than those after the first dose: for example, 864 + 
378 ng.h.ml'"*' after 6 weeks compared with 1279 ± 452 
following the first dose (Table 4.4.). Additionally, if 
one predicts a steady state trough drug concentration from 
the first dose kinetics the values predicted are in all 
patients greater than the measured values.
These findings are entirely consistent with those of 
Till et al (1984) who suggested that a conventional 
pharmacokinetic approach was inappropriate for ACE 
inhibitors and that such analysis should be based on urinary 
drug excretion data. Francis et al (1987) adopted a
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modelling approach which successfully attributed the kinetic 
characteristics of the ACE inhibitor cilazapril to binding 
of drug to ACE. Accordingly a similar approach was adopted 
in this study, with a pharmacokinetic model which assumes 
saturable protein binding. Using this method it was 
demonstrated, by a number of criteria of goodness of fit, 
that a unified approach fitting this model simultaneously to 
acute and steady state data was superior both to the 
original ’conventional’ approach and to independent fitting 
to each study day. The derived pharmacokinetic parameters 
for free and bound enalaprilat are shown in Table 4.5.
The mean values for free and bound drug respectively were 
1388 + 451 and 147 ± 95 ng.h.ml”  ^ for AUC and 2.7 ± 0.5 and 
16.8 + 9.4 hours for elimination half-life (Table 4.5.).
There was no significant relationship between patient 
age and any of the pharmacokinetic parameters for 
enalaprilat.
4.3.7. Concentration-effect relationships
There was no simple direct relationship between plasma 
enalaprilat concentration and the fall in blood pressure, as 
illustrated for an individual patient (Figure 4.4.).
However, using concentration-effeet analysis, drug levels 
were well correlated with reductions in both systolic and 
diastolic blood pressure in individual patients, and in each 
case the kinetic-dynamic relationships after acute and 
chronic dosing were described most appropriately by the
118
TABLE 4.4
THE PHARMACOKINETIC PARAMETERS FOR ENALAPRILAT DERIVED FROM A CONVENTIONAL 
TWO-COMPARTMENT MODEL BY FITTING THE INDIVIDUAL DATA SETS FOR EACH STUDY 
DAY INDEPENDENTLY
AUC (ng.h.ml*1) ELIMINATION HALF-LIFE (hrs)
PATIENT 1ST DOSE 1 WEEK 6 WEEKS 1ST DOSE 1 WEEK 6 WEEKS
1 815 442 637 3.6 2.7 3.3
2 1182 753 942 3.5 1.6 3.9
3 1003 684 499 4.6 4.3 4.1
4 1288 1051 1201 4.3 3.6 3.5
5 2273 787 1447 5.0 2.9 4.3
6 1293 1267 1499 4.6 3.9 5.0
7 544 - 425 3.9 - 3.6
8 1390 1043 1011 5.0 5.8 5.3
9 1089 634 486 9.9 3.6 3.5
10 1307 1197 814 5.3 3.9 4.1
11 1484 779 331 3.6 4.3 3.9
12 1951 1161 1011 5.0 3.6 3.2
13 1002 1079 929 3.6 3.5 5.1
MEAN + 1279 ± 906 + 864 + 4.8 + 3.6 + 4.1 +
SD 452 260 378 1.7 1.0 0.7
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TABLE 4.5.
THE PHARMACOKINETIC PARAMETERS FOR FREE AND BOUND ENALAPRILAT DERIVED FROM 
A ONE COMPARTMENT MODEL WITH SATURABLE PROTEIN BINDING. THE MOST 
APPROPRIATE FIX WAS OBTAINED USING A UNIFIED APPROACH FITTING THE DATA SETS 
FOR ALL THREE STUDY DAYS SIMULTANEOUSLY
PATIENT
AUC (ng.h.ml”1) 
FREE BOUND
ELIMINATION
FREE
HALF-LIFE (hrs) 
BOUND*
1 1001 84 2.3 -
2 1328 60 2.6 -
3 1025 101 2.8 15.4
4 2506 103 3.3 -
5 1543 161 2.6 -
6 1359 396 2.2 -
7 722 106 3.3 28.9
8 1595 238 3.7 21.7
9 1667 166 2.3 8.3
10 1014 115 2.4 7.3
11 1401 230 2.6 8.0
12 1736 60 2.9 27.7
13 1152 86 2.5 -
MEAN + 1388 + 147 ± 2.7 ± 16.8 ±
SD 451 95 0.5 9.4
* This parameter was characterised only in the 7 patients from 
whom additional blood samples were collected at 12 and 32 
hours after dosing.
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Langmuir-Emax model.
The pharmacodynamic data, i.e. the reductions in 
systolic and diastolic blood pressure, were fitted 
independently for each study day and simultaneously for all 
three study days. The concentration-effect parameters 
derived from these different approaches for changes in 
systolic blood pressure are shown in Tables 4.6. and 4.7. 
and the correlation coefficients are shown in Table 4.8.
On the basis of the goodness of fit, i.e. the R values shown 
in Table 4.8., the unified simultaneous approach was the 
most appropriate in all patients and fits for representative 
subjects are illustrated in Figures 4.5. and 4.6. The 
concentration-effeet parameters for changes in diastolic 
blood pressure derived from simultaneous fits are shown in 
Table 4.9.
Responsiveness to enalapril (Emax), as the mean of the
group, in terms of systolic and diastolic blood pressure was
-46.1 ± 16.5 and -19.7 ± 3.8 mmHg respectively (Tables 4.7.
and 4.9.). There was no significant relationship between
Emov and patient age or pretreatment plasma renin activity m 3 x
(Figure 4.7.). However, there was a significant 
correlation between Emax and the height of the starting 
blood pressure, as illustrated for erect systolic blood 
pressure (Figure 4.8.).
The parameters derived from fitting the data sets for 
each study day independently (Table 4.6.) were examined to 
compare first dose with steady state responses. There was
121
PATIENT 3-FIRST DOSE ENALAPRIL
Placebo-corrected fall in erect 
systolic BP
80-1
60-
40-
20-
T T T▼TT TTr
0 20 40 60 80 100 120 140
Plasma enalaprilat conc. (ng/ml)
Figure 4.4.
The relationship between plasma enalaprilat concentration and the 
placebo-subtracted fall in erect systolic blood pressure in an 
individual patient (patient 3) after the 1st dose of enalapril.
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TABLE 4.7.
THE ENALAPRILAT CONCENTRATION-EFFECT PARAMETERS Emax, Ce50 AND Keq 
FOR CHANGES IN ERECT SYSTOLIC BP DERIVED FROM THE UNIFIED APPROACH 
FITTING THE DATA SETS FOR ALL THREE STUDY DAYS SIMULTANEOUSLY
PATIENT Emax (mmHg) Ce50 (ng/ml) Keq (hours"1)
1 -56 64.9 0.3
2 -49 99.6 0.3
3 -58 43.0 0.6
4 -31 72.1 1.9
5 -69 56.1 0.3
6 -53 100.5 2.2
7 -73 68.2 0.7
8 -35 64.4 0.6
9 -26 66.4 2.1
10 -33 47.8 0.3
11 -24 64.7 0.8
12 -59 82.1 0.3
13 -34 29.4 0.3
MEAN + 
SD
-46.1 + 
16.5
66.1 + 
20.2
0.8 + 
0.7
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TABLE 4.8
THE GOODNESS OF FIT LR1 FOR THE PHARMACODYNAMIC MODELLING OF 
ERECT SYSTOLIC BP USING AN INDEPENDENT APPROACH WITH EACH 
STUDY DAY SEPARATELY AND A UNIFIED APPROACH WITH THE THREE 
STUDY DAYS FITTED SIMULTANEOUSLY
CORRELATION COEFFICIENTS (R)
PATIENT 1ST DOSE 1 WEEK 6 WEEKS UNIFIED FIT
1 0.96 0.82 0.74 0.93
2 0.96 0.74 0.89 0.90
3 0.98 0.98 0.95 0.96
4 0.88 0.91 0.87 0.87
5 0.97 0.91 0.91 0.87
6 0.98 0.96 0.80 0.89
7 0.98 - 0.96 0.97
8 0.93 0.91 0.84 0.85
9 0.92 0.94 0.67 0.90
10 0.86 0.87 0.86 0.84
11 0.93 0.94 0.84 0.92
12 0.93 0.95 0.94 0.92
13 0.98 0.82 0.71 0.86
MEAN + 
SD o 
o
 
i+ 0.89 ± 
0.07
0.84 + 
0.09
0.91 ± 
0.04
125
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Figure 4.5.
Enalaprilat concentration-effect analysis. The observed (----- )
and fitted (----- ) effects of enalaprilat on erect systolic BP in a
representative patient (patient 3) after the 1st dose and after 6 
weeks fitted simultaneously to a unified model; illustrating above 
average goodness of fit. (The data at 1 week is omitted for clarity, 
though represented in the derived parameters).
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PATIENT 13 - UNIFIED FITS
TIME (hours)
0 1  2 3 4 5 6 7 8
■ ■ ■ • »  ■ ■ ■__. i * > i > ■ I
6 WEEKS 
O —  OBSERVED 
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E
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a -20
w -25 
£
5 -30
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UJ -35 
<
-40
Emax- -34 mmHg
-45
Ce50* 29.4 ng/ml
Keq -  0.3 h 1
Figure 4.6.
Enalaprilat concentration-effect analysis. The observed (------)
and fitted (-----■) effects of enalaprilat on erect systolic BP in a
representative patient (patient 13) after the 1st dose and after 6 
weeks fitted simultaneously to a unified model; illustrating below 
average goodness of fit. (The data at 1 week is omitted for clarity, 
though represented in the derived parameters).
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TABLE it.q.
THE ENALAPRILAT CONCENTRATION-EFFECT PARAMETERS Emav, C=50 AND Kmax' q eq
AND GOODNESS OF FIT (R), FOR CHANGES IN ERECT DIASTOLIC BP DERIVED 
FROM THE UNIFIED APPROACH FITTING THE DATA SETS FOR ALL THREE STUDY 
DAYS SIMULTANEOUSLY
PATIENT Emax (mmHg) C05O (ng/ml) K0q (hours"1) R
1 -22 48.0 0.32 0.83
2 -21 41.2 0.37 0.96
3 -12 41.3 0.98 0.82
4 -19 89.1 1.13 0.88
5 -18 58.4 0.28 0.81
6 -22 102.0 2.13 0.87
7 -28 48.3 1.71 0.90
8 -20 72.2 0.87 0.91
9 -18 59.0 0.33 0.83
10 -21 55.6 2.13 0.85
11 -16 78.3 1.91 0.91
12 -22 84.4 1.32 0.83
13 -17 22,7 0.33 0.93
MEAN + -19.7 ± 61.6 + 1.1 ± 0.87 ±
SD 3.8 22.5 0.7 0.05
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Figure 4.7.
Relationships between the responsiveness to enalaprilat (Emax) after 
the 1st dose and patient age and pretreatment plasma reniri activity.
129
210
205
200 —
1 9 5 -
1 9 0 -
185-
R 3 0.69 
P < 0.009
1 8 0 -
O)
I  1 7 5 -
170-
165-
160 -
155-
150-
145-
140-
135-
130
20 28 36 44 52 60 68 76 84
Emax (mmHg) -  Unified model
Figure 4.8.
Correlation between the responsiveness to enalaprilat (Emax^  a^ter 
the 1st dose and the height of the pretreatment systolic' Dlood pressure.
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Figure 4.9.
From the concentration-effect parameters derived from fitting the
enalaprilat data for each study day independently, there was a 
significant correlation between the responsiveness to the 1st dose 
(Emax^  and the responsiveness after 6 weeks.
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a highly significant correlation between the responsiveness 
^max^ the first dose of enalapril and the responsiveness 
obtained after 6 weeks (Figure 4.9.).
4.4. DISCUSSION
In this group of salt replete patients enalapril was 
generally well tolerated and in particular no patient showed 
excessive reductions in blood pressure after the first dose. 
The antihypertensive effect of enalapril was sustained for 
24-hour blood pressure control with a dosage regimen of 20 
mg once daily. After treatment for 6 weeks, predose blood 
pressures recorded 24 hours after the last dose were 
significantly reduced, on average 157/94 supine and 151/92 
mmHg erect, and in 9 patients the blood pressure was less 
than 150/90 mmHg. There was no significant orthostatic 
component to the antihypertensive effect: for example,
baseline-corrected reductions in supine and erect blood 
pressure at 6 hours after the first dose were 46/27 and 
49/21 mmHg respectively. Additionally, in contrast to the 
reflex sympathetic activation which is often seen with other 
vasodilators, the fall in blood pressure with enalapril, 
particularly after the first dose, was not associated with 
any significant change in heart rate or plasma 
noradrenaline. The absence of a reflex tachycardia during 
converting enzyme inhibition has been reported previously 
with enalapril (Millar et al, 1982a; Velasco et al, 1985) 
and with a number of other ACE inhibitors (Cody et al, 1979;
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Richer et al, 1987) but the underlying mechanism has not 
been clearly established. There is evidence that it may 
reflect changes in both the set-point and sensitivity of 
baroreflex mechanisms (Ibsen et al, 1983; Giudicelli et al, 
1985) but these have not been consistent observations 
(Mancia et al, 1982; Warren et al, 1983) and Millar et al 
(1982a) have shown that enalapril has no effect on autonomic 
reflexes. Other studies have led to an alternative 
explanation that ACE inhibitors produce enhancement of 
parasympathetic vagal tone (Millar et al, 1982b; Ajayi et 
al, 1985).
The increase in plasma renin activity (PRA) after
enalapril is thought to be due to the removal of angiotensin
inhibition on renal renin release (Davies et al, 1984). In
this study, it was noted that the increase in PRA during 
chronic treatment with enalapril was higher than that seen 
after the first dose. One possible explanation is that with 
chronic administration there is a further rise in PRA in 
response to decreased plasma renin substrate concentration, 
which occurs during longterm treatment with an ACE inhibitor 
due to withdrawal of angiotensin II-mediated stimulation of 
hepatic angiotensinogen synthesis (Rasmussen et al, 1981). 
The largest increase in PRA occurred at 6 hours after drug 
administration, which coincided with the peak hypotensive 
effect of enalapril, and in previous studies similar 
relationships have been described between maximal blood 
pressure reductions and changes in endocrine parameters
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(Johnston et al, 1983).
During chronic treatment with an ACE inhibitor there is 
a sustained reduction in plasma ACE activity and increased 
plasma renin. In contrast, however, plasma angiotensin II 
and plasma aldosterone levels tend to return towards 
pretreatment values (Johnston et al, 1979; Staessen et al, 
1981; Biollaz et al, 1982) and in this study there was a 
significant reduction in plasma aldosterone concentration 
after 1 week but not after 6 weeks treatment. The 
transient fall in plasma aldosterone is consistent with the 
natriuretic effect associated acutely with ACE inhibitors 
(Millar et al, 1982a; de Leeuw et al, 1983) and also with 
the known effects of ACE inhibitors on renal blood flow 
(de Leeuw et al, 1983; Dunn et al, 1984).
In contrast to the antihypertensive effect during 
chronic treatment with enalapril which was sustained for 24 
hours, the inhibitory effect on plasma ACE activity was 
significantly attenuated during the latter part of a dosage 
interval, with measurements of ACE activity at 24 hours 
returning towards placebo values. This confirms previous 
observations that the fall in blood pressure after 
administration of an ACE inhibitor can be temporally 
dissociated from plasma ACE inhibition (Velletri and Bean, 
1981; Unger et al, 1985). These findings, together with 
the evidence that ACE inhibitors are effective in low or 
normal renin states (Gavras et al, 1981), suggests that the 
antihypertensive response to ACE inhibition cannot be
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explained solely by the suppression of the circulating 
renin-angiotensin system. An alternative explanation for 
the hypotensive effect of ACE inhibitors is inhibition of 
localised tissue ACE (Velletri and Bean, 1981; Cohen and 
Kurz, 1982; Unger et al, 1985) and a number of studies have 
demonstrated local angiotensin II formation in peripheral 
vascular tissue (Mizuno et al, 1988), brain, kidney, adrenal 
and lung (Sakaguchi et al, 1988). It has been shown that 
the degree and time course of ACE inhibition in different 
tissues varies markedly in response to treatment with an ACE 
inhibitor and often bears little relationship to the profile 
of circulating ACE inhibition (Sakaguchi et al, 1988). In 
particular, the duration of inhibition of tissue ACE is much 
longer than that for plasma ACE (Sakaguchi et al, 1988), 
suggesting that in this study sustained tissue, but not 
plasma, ACE inhibition accounts for the 24 hour 
antihypertensive effect.
During the latter part of the dosage interval for 
enalapril there was a tendency after chronic treatment for 
plasma ACE activity to recover more quickly compared with 
the first dose: for example, at 12 and 24 hours
respectively plasma ACE activity was 11.1 and 32.3 EU/ml 
after 6 weeks compared with 8.7 and 22.0 EU/ml after the 
first dose. This is consistent with induction of ACE, 
which has been described both in animals and man after 
chronic administration of an ACE inhibitor (La Rochelle et 
al, 1979; Fyhrquist et al, 1983). The term 'activity1
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refers to circulating uninhibited enzyme only, whereas 
converting enzyme ’concentration1 refers to the total 
concentration of circulating ACE, i.e. the sum of inhibited 
and uninhibited enzyme. Although ACE ’activity’ is 
suppressed during longterm treatment with an ACE inhibitor, 
there is evidence of a gradual increase in converting enzyme 
’concentration’ over a period of several weeks consistent 
with enhanced ACE biosynthesis (Boomsma et al, 1981).
Thus, measurements of plasma ACE activity are of limited 
value in studying the antihypertensive mechanism of ACE 
inhibitors. In contrast, measurements of ACE concentration 
and ACE activity in different tissues are much more 
relevant.
The pharmacokinetics of enalaprilat were consistent 
with the 24 hour blood pressure control and there was no 
significant change in drug disposition during chronic 
compared with acute administration. Because of the 
biotransformation of enalapril to enalaprilat, the tmax for 
enalaprilat was approximately 4-5 hours, which is consistent 
with previous observations (Ulm et al, 1982; Kubo and Cody, 
1985). In this study patients were fasted, but it has been 
shown that food has no effect on the absorption of enalapril 
or the kinetics of enalaprilat (Ferguson et al, 1983).
A number of different pharmacokinetic models were 
fitted to the concentration data. Consistent with the 
observations of Till et al (1984), a conventional 
pharmacokinetic model did not satisfactorily describe all
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the features of the disposition, particularly the 
accumulation of enalaprilat during chronic therapy. The
short elimination half-life derived from the two compartment 
model implied that there was a rapid elimination process and 
suggested that almost no drug accumulation should occur on 
repeated administration, but from the observed trough 
concentration data this was clearly not the case.
Accordingly an alternative approach was evaluated using a 
physiologically realistic model that is based on the 
saturable binding of the drug to converting enzyme (Francis 
et al, 1987). This model was the most appropriate for 
describing the enalaprilat kinetics as well as the kinetic- 
dynamic relationships and essentially the model is identical 
to that for any drug whose clearance is governed by 
Michaelis-Menten kinetics, or for which saturable protein 
binding makes a significant contribution. The theoretical 
basis for such models and the practical implications have 
been investigated extensively (McNamara et al, 1979; Keller 
et al, 1984) but what is unusual about enalaprilat and other 
ACE inhibitors is that the binding protein is an enzyme 
which is intimately associated with the therapeutic 
response.
The short half-life for unbound drug corresponds to 
free, or excess, drug clearance, but the long half-life for 
bound drug, on average 16.8 hours, reflects the high 
affinity of enalaprilat for the enzyme and confirms that 
once daily administration should be adequate to maintain a
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24-hour pharmacological response.
There is evidence that age has an important effect on the 
pharmacokinetics of enalapril, with reduced clearance and 
clearance/bioavailability of enalaprilat in the elderly 
(Hockings et al, 1986; Lees and Reid, 1987), but in this 
relatively small study, across a fairly narrow age range, 
there was no clear relationship between age and the 
disposition of enalaprilat.
Several studies have reported that ACE inhibitors have 
shallow or flat dose-response curves (Davies et al, 1984; 
Nelson et al, 1985) and that an increase in dose of an ACE 
inhibitor, although producing higher drug plasma 
concentrations (Kubo and Cody, 1985), extends the duration 
of action but has no effect on the magnitude of the blood 
pressure response (Gomez et al, 1985). For example, 10 and 
20 mg doses of enalapril were indistinguishable in terms of 
peak reductions in blood pressure but the hypotensive effect 
of the 20 mg dose persisted longer (Webster et al, 1987).
In addition, drug concentration-effect relationships for ACE 
inhibitors have been ill-defined. Although maximal blood 
pressure reductions have been correlated with peak plasma 
concentrations of enalaprilat (Schwartz et al, 1985), no 
direct concentration-effect relationship has been identified 
in individual hypertensive patients. Previous studies with 
enalapril have sought correlations between drug 
concentration and effect data for groups of subjects and the 
relationships obtained, although generally linear, have been
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widely variable (Biollaz et al, 1982; de Leeuw et al, 1983; 
Johnston et al, 1983 and 1984). From single dose studies in 
healthy volunteers it has been suggested that concentration- 
effect relationships can be defined more consistently and 
are potentially more useful when data for individuals, 
rather than for groups of subjects, is considered (Kelman et 
al, 1983; Francis et al, 1987), and this study in 
hypertensive patients has extended these observations by 
defining individual concentration-response relationships 
which are applicable during chronic treatment.
There was no simple direct plasma concentration-effect 
relationship, but using concentration-effect analysis 
enalaprilat levels were well correlated with reductions in 
both systolic and diastolic blood pressure in individual 
patients. In most clinical studies of this type data 
points are usually obtained over a relatively restricted 
concentration-response range and therefore the 
concentration-effect relationship is often best described by 
the simpler linear model (Chapter 2.5.). In this study 
with enalapril, and in a similar study with another ACE 
inhibitor (Francis et al, 1987), the kinetic-dynamic 
relationships were defined most appropriately by the full 
Langmuir (Emax) equation, suggesting that at least some of 
the data points were situated close to the top end of a 
sigmoid-shaped concentration-effect curve. This may partly 
explain why ACE inhibitors have been reported to have flat 
dose-response curves, since previous studies may have used
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doses which produce drug levels at the top end of the E
ffi 3 X
curve •
It has been shown both with captopril (Laragh et al,
1980) and with enalapril (Brunner et al, 1983) that it takes 
several weeks to achieve maximal blood pressure ’response* and 
additionally it has been suggested that the first dose 
response to an ACE inhibitor bears no relationship to the 
response obtained during longterm treatment (Bidiville et 
al, 1988). In this study, which incorporated kinetics as 
well as dynamics in the description of response, there was 
no significant change in the responsiveness to enalapril 
after 6 weeks compared with single dose administration. In 
addition, for individual patients there were significant 
correlations between the responsiveness (Emax) to the first 
dose and the responsiveness after 6 weeks.
It has been shown that the hypotensive response to ACE 
inhibition is partly related to the activity of the renin- 
angiotensin system (Gavras et al, 1978). Thus, conditions 
which lead to an increase in renin release, for example a 
low salt diet or treatment with a diuretic, enhance the 
antihypertensive effect of an ACE inhibitor (Atkinson et al, 
1980). Although extremes of sodium intake undoubtedly 
influence the haemodynamic effects of ACE inhibitors, there 
has been some dispute about the importance of plasma renin 
activity in routine clinical practice as a predictive marker 
of blood pressure response (Cody et al, 1983). There is 
good evidence that ACE inhibitors may be effective in
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patients with low plasma renin activity (Gavras et al, 1931), 
and even in anephric subjects (Man in’t Veld et al, 1980), 
and this study has shown that in a typical group of salt 
replete patients the responsiveness to enalapril cannot be 
usefully predicted by age or measurements of pretreatment 
plasma renin activity. In contrast, there was a 
significant correlation between the responsiveness to 
enalapril and the height of the starting blood pressure.
In summary, this study has shown that enalaprilat 
concentrations are correlated with reductions in both 
systolic and diastolic blood pressure in individual 
hypertensive patients. The kinetic-dynamic relationships 
for enalapril were described most appropriately by the 
Langmuir (Emax) model rather than the simpler linear model. 
The pretreatment blood pressure and the response to the 
first dose were important determinants of response during 
longterm treatment.
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CHAPTER £
CONCENTRATION-EFFECT RELATIONSHIPS AND ALPHA^ ADRENOCEPTOR 
ANTAGONIST EFFECTS OF DOXAZOSIN IN ESSENTIAL HYPERTENSION
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5.1 . INTRODUCTION
The alpha.) adrenoceptor antagonist doxazosin, which is 
a quinazoline derivative related to prazosin, has been shown 
to lower blood pressure in patients with essential 
hypertension (Frick et al, 1986; Baez et al, 1986; Cox et 
al, 1986). In comparison to prazosin, doxazosin has a 
prolonged terminal elimination half-life (Elliott et al, 
1987) and, even after intravenous administration, a more 
gradual onset of antihypertensive effect (Elliott et al, 
1982) and so it may be suitable for once daily dosing 
(Cubeddu et al, 1987; Elliott et al, 1987). The blood 
pressure fall after the first dose of prazosin has been 
shown to be directly correlated with drug concentrations in 
blood (Bateman et al, 1979; Seideman et al, 1981;
La Rochelle et al, 1982) but for doxazosin no comparable 
simple direct relationship exists between plasma 
concentration and the fall in blood pressure (Elliott et al, 
1982; Cubeddu et al, 1987). In normotensive volunteers 
using an integrated kinetic-dynamic modelling technique, the 
acute hypotensive effect of doxazosin has been shown to 
correlate with the concentration of drug in the "effect" 
compartment (Vincent et al, 1983). However, a 
concentration-effect relationship which is applicable during 
chronic treatment in hypertensive patients has not been 
established .
This study in patients with essential hypertension 
evaluates the pharmacodynamics, including alpha.)
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adrenoceptor antagonist activity, and the pharmacokinetics 
of doxazosin after acute and chronic administration and, 
using an integrated kinetic-dynamic model (Holford and 
Sheiner, 1981), characterises the concentration-effect 
relationships and antihypertensive responses in individual 
patients.
5.2. PATIENTS AND METHODS 
5.2.1 . General
Ten patients (4 male, 6 female) with mild to moderate 
essential hypertension, age range 47-70 years, participated 
in this study. Individual patient details are shown in 
Table 5.1. Patients discontinued all medication for at 
least 6 weeks prior to the study and at the end of this 
drug-free run-in period the average entry blood pressure was 
180/103 ± 11/4 supine and 174/102 + 8/5 mmHg erect. In a 
single blind design patients then received placebo for 2 
weeks followed by doxazosin 2 mg once daily for 6 weeks.
Each patient attended four 8-hour study days in the CPRU to 
evaluate the effects of placebo, 1st dose doxazosin and 1 
week and 6 weeks treatment.
The clinical protocol is described in detail in Chapter 
2.1. At frequent intervals during each study day, and at 24 
hours after dosing, supine and erect blood pressure and 
heart rate were measured and venous blood samples collected 
for plasma doxazosin concentrations. Additional blood 
samples were obtained at 1.5 and 6 hours for plasma renin
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activity, aldosterone and catecholamines. Fasting plasma 
triglyceride and total cholesterol levels were measured at 
the start of each study day.
Additional (short) study dav
On the third day of doxazosin treatment patients were 
instructed to take their dose at 8 a.m. and attend the 
Clinical Pharmacology Research Unit 5 hours later. They 
rested supine for one hour and at 6 hours after dosing a 
venous cannula was inserted, blood pressure and heart rate 
recorded and a blood sample collected for doxazosin 
concentration. A pressor infusion of phenylephrine (PE) 
was then administered as described below.
Pressor responsiveness
During each full study day, between 1.5 - 3 hours 
(early) and at 6 hours (late), and at 6 hours after drug 
administration on the short study day, pressor 
responsiveness to the selective alpha-j agonist phenylephrine 
(PE) was measured according to the method described in 
Chapter 2.2. In addition, using a similar method, pressor 
responsiveness to angiotensin II was measured during the 
early period of each full study day.
Early and late pressor infusions were designed to 
roughly coincide with peak plasma doxazosin concentrations 
at 2-3 hours and the maximum antihypertensive effect of 
doxazosin at 5-6 hours after drug administration.
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5.2.2. Doxazosin concentrations
Plasma concentrations of doxazosin were measured using 
the reverse phase HPLC method described by Rubin et al,
1980. An alkaline extraction procedure was used with back- 
extraction into sulphuric acid. The internal standard was 
prazosin and levels were measured by fluorescence detection. 
The inter and intra-assay coefficients of variation for the 
doxazosin assay were 7.5% and 5.8% respectively over the 
concentration range 4-45 ng/ml
5.2.3. Pharmacokinetic and concentration-effect analysis
Plasma doxazosin concentration-time profiles for
individual patients on each study day were most 
appropriately fitted to a single compartment model with 
first order input and inverse weighting of the concentration 
data .
For the concentration-effect analysis the standard 
pharmacokinetic model was augmented by an "effect" 
compartment, as described in Chapter 2.5., and the effect on 
blood pressure was then related to the drug concentration in 
the effect compartment by means of both the linear and non­
linear models (Holford and Sheiner, 1981). In each case, 
after both acute and chronic dosing, the data were most 
appropriately described by the linear model.
The concentration-effect parameters, m and K , were 
derived for individual patients on each study day. The 
responsiveness to doxazosin was calculated in terms of the
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(placebo-subtracted) fall in both erect systolic and 
diastolic blood pressure per unit drug concentration.
5.3. RESULTS
5.3.1 . Patient tolerance
Doxazosin was generally well tolerated but symptomatic 
postural hypotension occurred in 4 patients 5-6 hours after 
the first dose. During chronic treatment no adverse 
effects were reported.
5.3.2. Blood pressure
There were significant reductions in supine and erect 
blood pressure following the first dose of doxazosin (Figure
5.1.): for example, from a baseline of 170/102 + 13/5
supine and 165/102 + 15/8 mmHg erect to 127/77 ± 14/11
supine and 114/69 ± 18/12 mmHg erect at 6 hours, compared
with 175/105 ± 16/7 supine and 173/107 ± 13/6 erect to
147/88 + 7/8 supine and 151/93 ± 11/6 mmHg erect at 6 hours
after placebo. The maximum antihypertensive effect of 
doxazosin occurred 5-6 hours after drug administration 
(Figure 5.1.). Continued treatment with doxazosin 
significantly reduced predose blood pressures: measurements
of supine blood pressure (recorded 24 hours after the last 
dose) were 1 55/94 + 1 3/6 after 1 week and 1 57/95 ± 17/8 
after 6 weeks, compared with 175/105 ± 16/7 mmHg following 
placebo. In addition, blood pressure control was 
particularly good during the 8 hours of each study day, with
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average blood pressures of 137/82 supine and 133/82 erect 
after 1 week, and 140/85 supine and 135/84 mmHg erect after 
6 weeks.
5.3.3. Heart rate
The fall in blood pressure following the first dose of 
doxazosin was associated with a significant increase in 
heart rate, particularly in the erect position 4-5 hours 
after drug administration (Figure 5.2.). Erect heart rate 
increased from a baseline of 79 ± 10 to 92 + 10 bpm 4 hours 
after the first dose, compared with a corresponding change 
from 79 ± 13 to 77 ± 11 bpm following placebo. After 1 
week of treatment with doxazosin the heart rate increase was 
attenuated, although still significant, from a baseline of 
81 ± 9 to 87 ± 11 bpm erect at 4 hours, but after 6 weeks of 
doxazosin the heart rate profiles were not significantly 
different from placebo (Figure 5.2.). Average supine and 
erect heart rates during the 8-hours were respectively 73 
and 85 bpm after 1 week and 70 and 82 bpm after 6 weeks, 
compared to 70 and 79 bpm following placebo.
5.3.4. Hormone measurements and plasma lipids
There were significant increases in plasma
noradrenaline following the first dose of doxazosin (Table
5.2.): for example at 6 hours, 5.1 ± 2.6 compared with 2.8 + 
0.9 nmol/L after placebo. The increase in plasma 
noradrenaline was partially attenuated after 1 week of
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Figure 5.1.
Mean profiles of erect systolic and diastolic blood pressure after 
placebo ( ■  ), 1st dose doxazosin ( ♦  ) and after 1 week
( □  ) and 6 weeks ( ▲ ) doxazosin treatment.
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Mean profiles of erect heart rate after placebo ( ■  ), 1st dose 
doxazosin ( ♦  ) and after 1 week ( □  ), and 6 weeks ( ▲ ) 
doxazosin treatment.
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treatment with doxazosin but significantly higher 
measurements were again observed at 6 hours: 4.4 + 2.0 
nmol/L. Measurements of plasma noradrenaline at 6 weeks 
were not significantly different from placebo (Table 5.2.). 
Doxazosin had no significant effect on plasma renin activity 
or aldosterone (Table 5.2.).
Doxazosin had no significant effect on fasting plasma 
triglyceride and total cholesterol levels. Mean values for 
plasma triglyceride (mmol/L) and total cholesterol (mmol/L) 
were respectively 1.9 ± 0.7 and 7.0 ± 0.4 in the placebo 
phase; 2.2 + 0.9 and 6.6 + 0.4 after the 1st dose; 2.0 +
0.8 and 6.5 ± 0.6 after 1 week; and 1.8 + 0.9 and 6.6 ± 1.0 
after 6 weeks.
5.3.5. Pressor responses
Doxazosin produced significant parallel rightward 
shifts of the phenylephrine pressor dose-response curves, as 
would be expected of this competitive alpha-j adrenoceptor 
antagonist. Pressor dose-response curves for early and 
late PE infusions in a representative patient are shown in 
Figure 5.3. There was a significant increase in the PD20 
values following doxazosin, shown for early and late 
infusions in Tables 5.3. and 5.4. : for example, for 
infusions in the early period the mean PD20 increased from 
1.9 (placebo) to 5.7 (1st dose), 8.7 (1 week) and' 6.2 
ug/kg/min after 6 weeks (Table 5.3.).
On each study day there was no significant difference
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TABLE 5.2.
DOXAZOSIN STUDY. HORMONE MEASUREMENTS AT 1*5 AND 6 HOURS 
AFTER DRUG ADMINISTRATION 
MEAN + SD
TIME
(HRS) PLACEBO 1ST DOSE 1 WEEK 6 WEEKS
Plasma
noradrenaline
(nmol/L)
1.5
6
3.1 ±
2.7
2.8 +
0.9
3.7 ±
2.8
5.1 +**
2.6
4.0 + 
1.6
4.4 +* 
2.0
3.0 ± 
1.9
3.3 ± 
1.6
Plasma 1.5 0.3 + 0.5 ± 0.3 + 0.3 +
adrenaline 0.2 0.3 0.2 0.2
(nmol/L)
6 0.4 + 0.4 + 0.5 ± 0.3 +
0.3 0.5 0.5 0.3
Plasma 1.5 95 ± 94 + 79 ± 71 ±
aldosterone 56 50 38 52
(pg/ml)
6 117 + 117 + 101 + 87 ±
73 28 33 40
Plasma renin 1.5 1.6 + 2.3 ± 2.1 ± 2.4 +
activity 1.0 1.5 1.5 1.4
(ngA1/ml/hr)
6 2.2 ± 2.8 + 2.8 ± 2.2 +
1.6 1.5 3.0 1.9
** p < 0.02 * p < 0.05
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in pressor responsiveness to PE between the early and late 
infusions but there was a trend towards higher dose ratios 
(i.e. greater alpha-j antagonist activity) at 6 hours after 
dosing. The maximum alpha^ antagonist effect of doxazosin 
occurred during the first week of treatment (on both the 
short study day and at one week) and there was a significant 
attenuation of the alpha blockade by 6 weeks: for
example, for infusions in the late period the mean PD2Q was 
significantly reduced (p < 0.02) from 7.2 (1 week) to 5.6 
ug/kg/min (6 weeks).
The relationship between the simultaneous blood 
pressure and heart rate changes during the infusion of PE 
was used as an approximate index of cardiovascular 
baroreflex activity (Chapter 2.2.). Doxazosin had no 
significant effect on this relationship (Table 5.5.).
Doxazosin had no significant effect on pressor 
responsiveness to angiotensin II (Table 5.6.).
5.3.6. Pharmacokinetics
The derived pharmacokinetic parameters AUC, Cmax
and tmov obtained by fitting a one compartment model with m s x
first order input to the data are shown in Tables 5.7. and 
5.8. Analysis of variance revealed a significant increase 
in terminal elimination half-life in translation from acute 
to steady state therapy, with mean values of 12.5 ±
3.3 and 12.3 ± 2.5 hours at 1 and 6 weeks respectively 
compared to 8.8 + 2.3 hours on first dosing (Table 5.7).
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Figure
Pressor dose-response curves for phenylephrine in a representative 
patient during early (Top) and late (Bottom) infusions after placebo (O 
), 1st dose doxazosin ( #  ) and after 1 week ( A ) and 6 weeks ( ▲ ) 
doxazosin treatment. 15 5
TABLE 5.3
THE EFFECT OF DOXAZOSIN ON PRESSOR RESPONSIVENESS TO 
PHENYLEPHRINE (EARLY INFUSION)
PD20 (ug/kg/min)
PATIENT PLACEBO 1ST DOSE 1 WEEK 6 WEEKS
1 2.0 8.0 11.2 10.1
2 1.8 3.3 3.1 4.6
3 3.7 6.5 12.3 7.0
4 2.0 6.6 13.4 11.8
5 2.2 2.7 3.8 3.3
6 2.0 2.5 13.3 9.7
7 1.6 9.9 12.6 7.0
8 1.3 5.0 7.4 3.1
9 1.7 10.3 6.8 4.1
10 0.9 2.7 3.0 1.5
MEAN + 
SD
1.9±
0.7
5.7*±
3.0
8.7**+
4.3
6.2*x+
3.4
Comparison with placebo: * p < 
** p <
0.0005
0.0001
Comparison with 1 week: x p < 0.01
TABLE 5.4.
THE EFFECT OF DOXAZOSIN ON PRESSOR RESPONSIVENESS TO 
PHENYLEPHRINE (LATE INFUSION)
PD20 (ug/kg/min)
SHORT DAY
PATIENT PLACEBO 1ST DOSE (3rd DOSE) 1 WEEK 6 WEEKS
1 - - - - -
2 1.2 5.6 5.4 5.4 5.8
3 2.9 4.9 9.6 4.7 7.0
4 0.9 5.8 13.9 12.7 10.7
5 0.8 2.2 2.4 3.3 3.5
6 1.0 3.3 11.4 3.7 5.0
7 2.2 5.7 14.1 12.8 8.7
8 1.5 3.3 9.6 5.5 5.5
9 0.8 2.4 5.1 10.7 3.1
10 1.0 1.9 3.3 5.9 1.6
MEAN + 
SD
1.4±
0.7
3.9*±
1.6
8.3**±
4.4
7.2**±
3.8
5.6*x±
2.8
Comparison with placebo: * p < 0.0001
** p < 0.00001
Comparison with 1 week and short study day: x p < 0.02
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TABLE
THE EFFECT OF DOXAZOSIN ON THE CHANGE IN HR PER UNIT INCREASE 
IN SYSTOLIC BP DURING PHENYLEPHRINE INFUSION (EARLY PERIOD)
bpm/nmHg
PATIENT PLACEBO 1st DOSE 1 WEEK 6 WEEKS
1 -0.25 -0.40 -0.41 -0.46
2 -0.35 -0.21 -0.62 -0.48
3 -0.60 -0.42 -0.25 -0.30
4 -0.56 -0.48 -0.58 -0.45
5 -0.16 -0.25 -0.30 -0.13
6 -0.40 -0.51 -0.85 -0.42
7 -0.27 -0.49 -1.12 -0.85
8 -0.42 -0.68 -0.78 -0.41
9 -0.33 -0.54 -0.70 -0.29
10 -0.33 -0.22 -0.24 -0.14
MEAN + 
SD
-0.37±
0.13
-0.42+
0.15
-0.58+
0.29
-0.39±
0.20
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TABLE 5.6.
THE EFFECT OF DOXAZOSIN ON PRESSOR RESPONSIVENESS 
TO ANGIOTENSIN II '
PD.2Q (ng/kg/min)
PATIENT PLACEBO 1ST DOSE 1 WEEK 6 WEEKS
1 6.1 6.9 5.5 14.1
2 6.2 3.6 3.7 6.7
3 3.2 3.6 6.6 3.5
4 4.6 7.1 3.9 4.1
5 3.0 4.1 3.3 4.0
6 5.3 2.6 3.3 4.3
7 8.1 4.2 4.3 10.3
8 7.4 7.4 4.1 6.1
9 4.0 3.8 4.3 2.6
10 1.0 3.3 4.2 2.9
MEAN + 4.9+ 4.7± 4.3± 5.9±
SD 2.2 1.8 1.0 3.7
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The apparent increase in half-life with chronic therapy is 
paralleled by a significant increase in AUC (and thereby a 
reduction in oral clearance) from 287.2 + 104.8 ng.h.ml”1 
with acute dosing to 372.6 ± 136.3 and 369.4 + 133.2
_ i
ng.h.ml" at 1 and 6 weeks respectively (Table 5.7.). No
significant changes in maximum concentration (Crnov) or timem q x
to attain Cmax (tmax) were observed (Table 5.8.)
There was no relationship between patient age and the 
pharmacokinetics of doxazosin.
5.3.7. Concentration-effect relationships
In individual patients, there was no simple direct 
relationship between the plasma doxazosin concentration and 
the fall in blood pressure but in each case following both 
acute and steady state treatment the kinetic-dynamic 
relationships were best described by the linear 
model. Using this model, doxazosin concentrations were 
well correlated with changes in both systolic and diastolic 
blood pressure in individual patients and the examples shown 
in Figures 5.4. and 5.5. illustrate above and below average 
goodness of fit for changes in systolic blood pressure. 
Figure 5.6. illustrates the fits for diastolic blood 
pressure in a representative patient after acute and chronic 
dosing. The derived m and Keq values for effects on 
systolic and diastolic blood pressure in individual patients 
are shown in Tables 5.9. and 5.10.
There was a significant reduction (p < 0.03) in the
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TABLE 5.7.
DOXAZOSIN PHARMACOKINETICS. DERIVED PARAMETERS. AUC AND 
ELIMINATION HALF-LIFE
Patient AUC (ng.n.ml-1) t1/2 (h)
1st dose 1 week 6 weeks 1st dose 1 week 6 weeks
1 191 .9 258.3 292.3 7.7 11.3 11 .6
2 136.9 126.5 147.6 6.6 7.1 9.0
3 248.6 327.6 308.0 8.8 10.9 10.0
4 439.8 400.0 613.2 9.5 12.7 15.0
5 309.6 432.2 402.0 12.0 15.5 14.9
6 295.8 487.5 373 .1 6.5 13.1 9.2
7 320.1 427.9 468.5 8.9 11.5 12.6
8 310.1 371 .6 324 .6 11.4 13.9 *15.0
9 449.4 620.0 501 .2 11.2 19.2 14.7
10 169.6 274.0 263.9 5.4 10.2 11.1
MEAN + 
SD
287.2 + 
104.8
372.6*+
136.3
369.4**±
133.2
8.8 ± 
2.3
12. 5**± 
3.3
12.3**±
2.5
Comparison with 1st dose: * 
*«
p < 0.0015 
p < 0.003
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TABLE 5.8.
DOXAZOSIN PHARMACOKINETICS. DERIVED PARAMETERS. C(nax and jmax
Patient ( A ^cmax <ng/<"l) t (hrs)
1st dose 1 week 6 weeks 1st dose 1 week 6 weeks
1 14.7 14.3 15.9 2.1 2.0 1 .9
2 7.5 6.6 8.4 7.5 7.0 4.4
3 15.9 19.6 21 .2 3.1 2.9 0.8
4 27.8 21 .0 26.5 3.0 2.5 2.6
5 16.1 17.9 16.0 2.1 2.3 3.9
6 29.0 22.8 27.3 1.1 3.6 0.7
7 21 .6 23.8 25.5 2.5 1.8 0.4
8 16.1 17.8 14.5 3.1 1 .2 1 .6
9 21 .7 21 .0 21 .1 4.7 2.6 3.2
10 15.9 14.2 13.0 2.9 6.2 4.1
MEAN
SD
18.6 + 
6.5
17.9 ± 
5.1
18.9 ± 
6.4
3.2 ± 
1.8
3.2 ± 
1 .9
2.4 ± 
1 .5
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responsiveness to doxazosin during chronic compared with 
acute administration: for example, the mean responsiveness
in terms of the change in systolic blood pressure was -2.1 
mmHg/ng/ml following the first dose, -1.5 after 1 week and -
1.4 after 6 weeks (Table 5.9). Although, on average, there 
was a 30% fall in the responsiveness during chronic 
treatment, for individual patients there was a significant 
correlation between the responsiveness to the first dose of 
doxazosin and the responsiveness after 1 week (r = 0.65) and 
6 weeks (r = 0.63) treatment (Figure 5.7.). In addition, 
after both acute and chronic dosing there were significant 
correlations (p < 0.002) between the responsiveness (m) 
calculated in terms of change in systolic blood pressure and 
the responsiveness for effects on diastolic blood pressure 
(Figure 5.8.). There was no significant change in KeC} 
between the three study days.
There was a trend towards a relationship between the 
responsiveness to doxazosin after the first dose and the 
degree of peripheral alpha^ adrenoceptor antagonism (Figure 
5.9) but this did not achieve statistical significance (p < 
0.055). There was a significant correlation (p < 0.03) 
between the responsiveness to the first dose of doxazosin 
and the height of the baseline (pretreatment) blood pressure 
as illustrated for erect systolic blood pressure in Figure 
5.10. In addition there was a significant negative 
correlation (p < 0.017) between the responsiveness ~o 
doxazosin acutely and the placebo-corrected maximal change
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Figure S.4.
Doxazosin concentration-effect analysis. The observed
( A— ▲  ) and fitted ( a  A ) effect of doxazosin
systolic blood pressure after the 1st dose and 3fter 6 
representative patient (patient 6), illustrating above 
goodness of fit.
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TABLE 5.9.
DOXAZOSIN CONCENTRATION-EFFECT RELATIONSHIPS. THE DERIVED 
PARAMETERS, m (mmHg/ng/ml) AND Keq(h"1), AND THE GOODNESS OF FIT 
(R) AS A FRACTION OF UNITY FOR CHANGES IN ERECT SYSTOLIC BP.
PATIENT m
1ST DOSE 
Keq R
1
m
WEEK
Keq R
6
m
WEEKS
Keq R
1 -3.2 0.4 0.93 -1.1 0.6 0.80 -1.0 0.8 0.75
2 -3.2 8.5 0.96 -4.3 0.3 0.87 -3.1 0.2 0.90
3 -2.3 1.6 0.95 -1.8 0.4 0.94 -1.9 0.7 0.81
4 -1.1 4.2 0.95 -0.6 2.3 0.87 -0.6 2.3 0.92
5 -3.2 3.9 0.90 -1.7 2.4 0.79 -1.7 6.0 0.82
6 -2.0 1 .0 0.96 -2.0 1.1 0.84 -1.5 0.6 0.84
7 -1.3 1.1 0.96 -0.7 0.5 0.90 -0.7 0.5 0.92
8 -1.3 4.5 0.93 -0.7 0.8 0.88 -0.6 1.8 0.81
9 -2.1 2.1 0.98 -1 .2 0.7 0.96 -0.9 1.0 0.91
10 -1 .4 2.4 0.96 -1.1 4.7 0.86 -1.6 2.2 0.94
MEAN
SD
-2.1 ±
0.8
3.0 ± 
2.4
0.95 ± 
0.02
-1.5*±
1.1
1.4 
1 .4
0.87
0.05
- 1.4»±
0.8
1.6 
1 .7
0.86 ± 
0.06
Comparison with m (1st dose): * p < 0.03.
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TABLE 5.10.
DOXAZOSIN CONCENTRATION-EFFECT RELATIONSHIPS. THE DERIVED PARAMETERS, 
m (mmHg/ng/ml) AND Keq(h"1), AND THE GOODNESS OF FIT (R) AS A FRACTION 
OF UNITY FOR CHANGES IN ERECT DIASTOLIC BP.
PATIENT m
1ST DOSE
Kaneq R m
1 WEEK 
Keq R
6
m
WEEKS
Keq R
1 -2.2 0.3 0.89 -0.6 0.8 0.97 -0.7 1 .0 0.91
2 • -2.2 3.1 0.98 -1 .0 0.7 0.74 -1.9 0.2 0.92
3 -1 .2 3.3 0.95 -1.1 0.4 0.95 -1.6 0.4 0.91
4 -0.9 0.6 0.96 -0.5 1 .2 0.94 -0.4 3.8 0.81
5 -1 .6 8.3 0.96 -0.6 19.7 0.92 -0.8 4.1 0.88
6 -1.2 1.3 0.93 -0.6 0.7 0.89 -0.7 1 .0 0 .98
7 -0.9 0.6 0.90 -0.7 1.8 0.94 -0.6 1 .0 0.92
8 -1.1 1.8 0.98 -0.8 0.9 0.83 -0.8 1 .0 0.97
9 -1.9 1 .0 0.90 -0.6 0.6 0.85 -0.5 1 .2 0.77
10 -1.1 2.6 0.90 -0.7 7.3 0.91 -1 .2 1 .0 0.96
MEAN
SD
-1.4 ±
0.5
2.3 ±
2.4
0.93 ± 
0.03
- 0.7*±
0.2
3.4
6.1
0.89
0.07
-0.9*±
0.5
1 .5 
1.3
0.90 ± 
0.07
Comparison with m (1st dose): * p < 0.02.
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CORRELATION BETWEEN THE RESPONSIVENESS 
TO THE FIRST DOSE OF DOXAZOSIN AND 
THE RESPONSIVENESS AFTER 6 WEEKS
-responsiveness 6 weeks
(mmHg/ng/ml)
3.3-t
2.9- 
2.5- 
2.1- 
1.7-
1.3- 
0 .9 - 
0 .5 -
i 1------1------1------r - — i------ 1 i
1.0 1.4 1.8 2.2 2.6 3.0 3.4 3.8
-responsiveness 1st dose (mmHg/ng/ml)
Figure 5.7.
Correlation between the responsiveness (m) to the 1st dose of 
doxazosin and the responsiveness after 6 weeks.
r = 0.63 
F < 0.05
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Correlations between the responsiveness to doxazosin in terms o 
systolic versus diastolic blood pressure after the 1st dose and 
after c weeks.
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RESPONSIVENESS VERSUS PE DOSE RATIO 
FIRST DOSE DOXAZOSIN
PE Dose Ratio 
(late period)
5.0 — i
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3.0 H
2.0 H
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Figure 5.Q.
r = 0.66 
P < 0.055 (NS)
r
1.0
“I I I I I I I
1.4 1.8 2.2 2.6 3.0 3.4 3.8
Responsiveness (mmHg/ng/ml)
Relationship between the responsiveness to the 1st dose of 
doxazosin and the degree of peripheral alpha blockade (i.e. the
phenylephrine dose ratio). Not significant.
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RESPONSIVENESS VERSUS 
STARTING BLOOD PRESSURE
Erect Systolic BP 
(mmHg)
200-1
188
176 —I
164 H
152 H
140 J
r = 0.69
P < 0.027
I I I I I I I
1.0 1.4 1.8 2.2 2.6 3.0 3.4
Responsiveness (mmHg/ng/ml)
Figure 5.10.
Correlation between the responsiveness to the 1st dose of doxazosin 
and the pretreatment (baseline) systolic blood pressure.
3.8
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RESPONSIVENESS VERSUS THE MAXIMAL 
(PLACEBO SUBTRACTED) CHANGE IN HR 
A Erect HR (bpm)
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Responsiveness (mmHg/ng/ml)
Figure 5.11.
Negative correlation between the responsiveness to the 1st dose 
of doxazosin and the maximal (placebo and baseline-subtracted) 
change in erect heart rate.
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in heart rate (Figure 5.11.). There was no relationship 
between the responsiveness to doxazosin and patient age 
(Figure 5.12.), but there was a significant positive 
correlation between responsiveness and the pretreatment 
plasma renin activity (i.e. on placebo) - Figure 5.12.
DISCUSSION
It has been well established that doxazosin lowers 
blood pressure (Baez et al, 1986; Frick et al, 1986; 
Shionoiri et al, 1987) and this study has confirmed that 
the antihypertensive effect during longterm treatment is 
sustained for 24-hours with a dosage regimen of 2 mg once 
daily. After 6 weeks treatment predose blood pressures 
(recorded 24 hours after the last dose) were significantly 
reduced: 157/95 (supine) compared with 175/105 mmHg
following placebo and blood pressure control was 
particularly good during the 8 hours of the study day, on 
average 140/85 supine and 135/84 erect.
For the purposes of this study the dose of doxazosin 
was fixed at 2 mg. This is larger than the starting dose 
of 0.5 mg recommended for routine clinical use and, although 
doxazosin was generally well tolerated throughout the study, 
the gradual onset of antihypertensive effect did not avert 
symptoms of first-dose orthostatic hypotension in 4 patients 
at 5-6 hours after drug administration. Adverse effects 
after the first dose of an alpha1 antagonist are partly dose 
dependent (Rosendorff, 1976) and in routine clinical
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practice the lower starting dose of 0.5 mg doxazosin appears 
to be better tolerated (Cox et al, 1986).
The pharmacokinetic profile of doxazosin is compatible 
with a single daily dosage regimen (Elliott et al, 1987) 
and in this study the relatively long half-life of 12 hours 
is consistent with the 2H hour blood pressure control.
There was a significant increase in the elimination half 
life and AUC of doxazosin during chronic compared with acute 
administration. Similar reductions in drug clearance 
during chronic doxazosin treatment have been described by 
others (Shionoiri et al, 1987) and also were reported in a 
study that sampled drug levels for up to 72 hours after 
dosing (Cubeddu et al, 1987). The explanation for this 
apparent reduction in clearance is uncertain. In part it 
may reflect the schedule of sampling times and achieved 
plasma concentrations after the first dose but additionally 
it may reflect saturation of hepatic metabolic enzyme 
activity since doxazosin is extensively metabolised in the 
liver (Kaye et al, 1986). There is some evidence with 
prazosin which undergoes metabolism by the same 
demethylation pathway that age and the presumptive decline 
in hepatic function leads to a significant change in drug 
disposition (Rubin et al, 1981). This has not been a 
consistent finding (McNeil et al, 1987) and in this 
relatively small study there was no relationship between age 
and the pharmacokinetics of doxazosin.
The pharmacodynamic profile of doxazosin, in contrast
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to that of prazosin (Seideman et al, 1981), is clearly out 
of phase with plasma drug levels and therefore no simple 
direct relationship exists between plasma concentration and 
the fall in blood pressure (Elliott et al, 1982; Cubeddu et
al, 1987). With prazosin, consistent concentration-effeet
relationships have been identified after acute intravenous 
dosing (Bateman et al, 1979; Seideman et al, 19 81;
La Rochelle et al, '1982) but studies of oral dosing, 
particularly where group data have been analysed, have been 
less successful (MacCarthy et al, 1980; Grahnen et al, 
1981). With doxazosin, Vincent et al (1983) defined 
concentration-effeet relationships in individual subjects 
for both blood pressure reduction and alpha antagonism and 
this study has extended these observations to chronic oral 
treatment in hypertensive patients. In addition, by 
integrating kinetic and dynamic information the 
responsiveness of individual patients was characterised in 
terms of the fall in both systolic and diastolic blood
pressure per unit drug concentration.
There was a significant reduction (of approximately 
30^) in the responsiveness (m) to doxazosin during chronic 
compared with acute administration and this was accompanied 
by an attenuation in the alpha^ adrenoceptor antagonist 
activity after 6 weeks. Tolerance to the alpha-blocking 
effect of prazosin has been well documented in cardiac 
failure (Desch et al, 1979) and there is evidence that 
adaptive changes in alpha adrenoceptor-mediated responses
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occur within a few days (von Bahr et al, 1982) but the 
nature of the underlying changes in alpha^ adrenoceptor 
function have not been clearly established (Lefkowitz, 1978; 
Hamilton and Reid, 1981; von Bahr et al, 1982). It has 
been suggested that ’’tolerance” reflects desensitisation of 
alpha^ receptors and that this may be enhanced by acute 
rises in catecholamine levels (von Bahr et al, 1982). In 
this study kinetic differences did not invalidate pressor 
response comparisons and alpha blockade was maximal during 
the first week, particularly on the short study day and 
after 7 days when reflex sympathetic responses were abating. 
The attenuation in alpha^ antagonist activity after 6 weeks 
may reflect up-regulation of alpha-j adrenoceptor function 
during longterm doxazosin treatment as a result of increased 
receptor density (Lefkowitz, 1978) or changes in post­
receptor mechanisms (Hamilton and Reid, 1981).
Despite the reduction during chronic treatment in 
antihypertensive responsiveness to doxazosin and the changes 
in the extent of alpha blockade, there were significant 
correlations between the responsiveness to the first dose 
and that after 1 week and 6 weeks treatment. This has 
potential clinical application in that the response to the 
first dose, for an individual patient, may be used to 
forecast the response during longterm treatment and thereby 
allow prompt identification of poor or non-responders.
Very little is known about factors which determine the 
response to treatment with an alpha blocker (Stokes et al,
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1980; MacCarthy et al, 1980) but kinetic as well as dynamic 
parameters are important. The fall in blood pressure is 
related to antagonism of alpha^ adrenoceptors in the 
peripheral vasculature but, acutely, reflex increases in 
heart rate tend to counteract the fall in blood pressure and 
if the heart rate response is attenuated, for example with a 
beta-adrenoceptor antagonist, the acute hypotensive effect 
of prazosin is enhanced (Elliott et al, 1981). In this 
study there was a significant negative correlation between 
the responsiveness to the first dose of doxazosin and the 
maximal reflex increase in heart rate. Although it has 
been reported that alpha^ antagonists produce greater 
haemodynamic effects in the elderly (Stokes, 1984) this is 
not a confirmed observation and it takes no account of 
possible age-related differences in pharmacokinetics (Rubin 
et al, 1981; McNeil et al, 1987). In this study, albeit 
across a relatively narrow age range, there was no 
relationship between age and the fall in blood pressure per 
unit drug concentration. There is some evidence that the 
antihypertensive effect of prazosin is inversely related to 
plasma renin activity (Bolli et al, 1981), but in this study 
there was an opposite relationship whereby responsiveness to 
doxazosin was directly proportional to the pretreatment PRA. 
The explanation for this is not entirely clear but 
activation of the renin-angiotensin-aldosterone system may 
indirectly reflect enhanced sympathetic nervous activity and 
increased alpha adrenoceptor mediated vasoconstriction, and
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such haemodynamic changes in hypertension are reported to be 
particularly responsive to treatment with alpha adrenergic 
inhibitory drugs (Taylor, 1982).
Starting blood pressure may be a more important 
determinant of the magnitude of the response to treatment 
with an alpha blocker (Sumner et al, 1988a) and in this study 
there was a significant correlation between the 
responsiveness to doxazosin acutely and the pretreatment 
systolic pressure.
In conclusion, the pharmacokinetic and pharmacodynamic 
profiles of doxazosin are consistent with 24 hour blood 
pressure control using a single daily dosage regimen. 
Concentration-effeet relationships have been identified in 
individual patients for both systolic and diastolic blood 
pressure after acute and chronic treatment. The 
responsiveness to doxazosin is related to its alpha^ 
adrenoceptor antagonist activity and both these parameters 
are significantly attenuated during continued treatment. 
However, the attenuation in responsiveness probably occurs 
early and is not progressive during chronic therapy. Thus, 
the predictability of the longterm response to doxazosin 
(albeit 70% magnitude) from the response to the first dose 
appears to be independent of treatment duration.
The responsiveness to the first dose is dependent upon the 
pretreatment blood pressure and the degree of reflex 
sympathetic activation, particularly the heart rate 
increase, while plasma renin activity may be an additional
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contributory factor. The inter-relationship between these 
variables and the responsiveness to doxazosin is considered 
in further detail in Chapter 8.
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CHAPTER 6
VASCULAR PRESSOR RESPONSES IN TREATED AND UNTREATED 
ESSENTIAL HYPERTENSION
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6.1. INTRODUCTION
In essential hypertension structural (Folkow, 1978) and 
functional (Robinson et al, 1982; Buhler and Bolli, 1985) 
changes in vascular smooth muscle are associated with an 
increase in total peripheral resistance (Lund-Johansen,
1986) and enhanced vascular reactivity (Folkow, 1982;
Buhler and Bolli, 1985). There is evidence to suggest that 
the increased vascular reactivity reflects an increased 
responsiveness to both adrenergic (Amann et al, 1981; Buhler 
et al, 1981) and non-adrenergic (Robinson et al, 1980) 
calcium-dependent vasoconstrictor mechanisms. Accordingly, 
it has been suggested that, independent of vasodilatation 
per seT reduction of peripheral vascular reactivity is an 
important mechanism for antihypertensive drugs (Imai et al, 
1982a; Elliott et al, 1985; Pasanisi et al, 1985).
Reduction of peripheral vascular resistance underlies 
the antihypertensive activity of calcium antagonists 
(Robinson et al, 1980), angiotensin converting enzyme 
(ACE) inhibitors (Velasco et al, 1 985) and alpha-j- 
adrenoceptor antagonists (Lund-Johansen et al, 1986) but 
differences in their effects on adrenergic and non- 
adrenergic vascular responses and on neuro-humoral 
mechanisms, including cardiovascular baroreflex responses, 
have not been clearly established.
This study in patients with essential hypertension 
examines the effects of the calcium antagonist nifedipine, 
the ACE inhibitor enalapril and the alpha«j antagonist
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doxazosin on vascular pressor responses to the "adrenergic" 
agonist phenylephrine and the "non-adrenergic" 
vasoconstrictor angiotensin II .
6.2. METHODS
6.2.1. General
Thirty-seven patients with essential hypertension 
(17M, 20F), age range 33-70 years, participated in one of 
the three studies described in Chapters 3-5. Each patient 
discontinued any previous medication prior to entering the 
study and at the end of a 6 week drug-free run-in period the 
mean supine blood pressure was 181/104 + 14/6 mmHg. In a 
series of single blind studies matching placebo tablets were 
then administered for 2 weeks, followed by nifedipine retard 
20 mg bid (n = 14; 52 + 9 years), or enalapril 20 mg od (n = 1 3; 
55 ± 8 years), or doxazosin 2 mg od (n = 10; 59 ± 7 years). 
Each active treatment was administered as monotherapy for 6 
weeks and patients attended for a sequence of 4 study days 
to evaluate the effects of placebo, first dose of active 
drug and after 1 and 6 weeks drug treatment. At frequent 
intervals during each study day blood pressure and heart 
rate were measured and venous blood samples collected for 
plasma drug concentrations (Chapter 2.1.). Additional 
blood samples were taken at 1.5 hours after drug 
administration for plasma renin activity, aldosterone, 
catecholamines and ACE activity.
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6.2.2. Peripheral vascular pressor responsiveness.
On each study day, between 1.5-3 hours after drug 
administration, pressor responses to intravenous infusions 
of the selective alpha-j-adrenoceptor agonist phenylephrine 
(PE) and the non-adrenergic vasoconstrictor angiotensin II 
(All) were measured using the protocol described in 
Chapter 2.2.
All data points in each individual patient for the 
pressor responses to phenylephrine and angiotensin II were 
fitted to a quadratic function according to the method of 
Sumner et al (1982). The simultaneous blood pressure and 
heart rate changes during the infusion of PE were fitted in 
individual patients to a linear function and used as an 
index of cardiovascular baroreflex activity, expressed as 
the change in heart rate per unit increase in systolic blood 
pressure.
6.2.3. Sta tistical analysis
From each individual pressor dose-response curve the 
PD20 value was derived: this represents the dose of agonist
required to raise mean arterial pressure by 20 mmHg. The 
logarithmic transformations of the PD20 values were compared 
within studies over the period of treatment using repeated 
measures analysis of variance. As a quantitative index of 
the extent of the pressor antagonist effect of each 
treatment dose ratios were calculated from the ratio PD20 
active drug/PD2Q placebo and comparison between studies was
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again by analysis of variance. The relationship between 
age and changes in pressor sensitivity was investigated by 
linear regression analysis. The derived measurements of 
baroreflex function expressed as the change in heart rate 
per unit increase in systolic blood pressure, were compared 
between studies by repeated measures analysis of variance.
6.3. RESULTS 
6.3.1 . Blood Pressure
Nifedipine, enalapril and doxazosin produced 
significant reductions in blood pressure and at the doses 
used appeared overall to have comparable antihypertensive 
activity. Similar blood pressure-time profiles were 
obtained in the three studies with the maximum 
antihypertensive effects occurring 5-6 hours after drug 
administration (Figure 6.1.). In particular, blood 
pressures on equivalent study days, immediately before the 
start of the pressor infusions, were not significantly 
different: for example, supine blood pressure at 1.5 hours
after the first dose of nifedipine was 153/93 ± 16/8; after 
enalapril, 151/90 + 24/10 and after doxazosin 148/90 + 19/3 
mmHg. Similarly, blood pressures at 1.5 hours on the 
corresponding placebo days were not significantly different: 
17 5/104 + 17/6, 171/99 ± 18/9 and l66/99± 13/9 mmHg 
respectively.
During chronic treatment’there were comparable 
reductions in baseline (pre-dose) blood pressures in each
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study: for example, predose supine blood pressures after 6
weeks were 152/93 ± 15/7 (nifedipine), 157/94 + 18/12
(enalapril) and 157/95 ± 17/8 mmHg (doxazosin).
6.3.2. Heart rate
There was no significant change in heart rate following 
the first dose of enalapril but the first doses of both 
nifedipine and doxazosin produced significant increases in 
supine and erect heart rate. For nifedipine, erect heart 
rate increased from a baseline of 87 ± 13 to a maximum of 
108 + 14 bpm 5 hours after the first dose, compared with a 
change from 86 + 14 to 94 + 12 bpm following placebo 
(Figure 3.2.). The corresponding maximal changes in 
heart rate for doxazosin were 79 ± 10 to 100 + 11 bpm at 5 
hours, compared with 79 ± 13 to 84 + 12 bpm after placebo 
(Figure 5.2.). During longterm treatment none of the 
active drugs produced heart rate profiles which were 
significantly different from placebo.
6.3.3. Pressor responsiveness
Nifedipine significantly attenuated the pressor 
responses to both All and PE (Tables 6.1. and 6.2.) with 
non-parallel rightward shifts of the respective dose- 
response curves, as illustrated for a representative 
patient in Figure 6.2. The mean ^or resPonses to
All (ng/kg/min) increased progressively from 8.2 (placebo) 
to 9.9 (1st dose), 13.9 (1 week) and 17.4 (6 weeks). The
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Figure 6.1.
Mean profiles of systolic and diastolic blood pressure for each 
study after placebo ( ■  ), 1st dose active drug ( ♦  ) and after 
1 week ( □  ) and 6 weeks ( A  ) drug treatment.
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increase in PD2Q after 6 weeks nifedipine was 
significantly greater than that following the first dose 
(Table 6.1.) . The attenuating effect of nifedipine on 
pressor responsiveness to PE was of similar magnitude but 
was unaffected by treatment duration (Table 6.2.): 1.9
(placebo), 2.8 (1st dose), 3.2 (1 week) and 2.9 ug/kg/min (6 
weeks).
In contrast, there were non-parallel shifts of the 
dose-response curves to the left following enalapril, 
indicative of enhanced responsiveness to both All and PE 
(Figure 6.3.). There were significant reductions in PD20 
values for All and PE pressor responses (Tables 6.3. and
6.4.): for example, from 9.7 (placebo) to 6.7 ng/kg/min (6
weeks) for All (Table 6.3.) and from 2.1 (placebo) to 1.5 
ug/kg/min (6 weeks) for PE (Table 6.4.)..
The selective alpha antagonist doxazosin had no effect 
on pressor responses to All (Table 5.6.) but was associated 
with significant parallel rightward shifts of the pressor 
dose-response curves to PE (Figure 5.3.). The mean PD20 
increased from 1.9 (placebo) to 5.7 (1st dose), 8.7 (1 week) 
and 6.2 ug/kg/min after 6 weeks (Table 5.3.). There was a 
significant reduction in alpha blockade after 6 weeks 
doxazosin compared with that after 1 week.
For both All and PE there was no relationship between 
age and pressor responsiveness (PD20) before active 
treatment i.e. on placebo. Similarly, there was no 
relationship between age and the pressor responses during
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TABLE 6.1.
EFFECT OF NIFEDIPINE ON PRESSOR RESPONSIVENESS TO ANGIOTENSIN II
PD2q VALUES (ng/ks/min)
PATIENT PLACEBO 1ST DOSE 1 WEEK 6 WEEKS
1 5.3 11.4 28.0 43.8
2 7.0 7.0 16.6 11.1
3 5.8 13.6 10.8 5.0
4 6.1 6.8 13.7 11.6
5 4.7 4.4 3.3 6.7
6 4.7 3.6 7.3 6.7
7 30.2 24.1 13.5 20.9
8 16.6 12.8 16.7 17.5
9 3.5 6.1 7.5 5.7
10 3.9 6.3 7.1 12.9
11 6.5 18.0 26.0 28.6
12 6.9 3.5 - 3.6
13 9.8 11.0 17.9 33.1
14 4.1 10.1 12.7 36.6
Mean ± SD 8.2 + 
7.1
9.9 ± 
5.9
13.9* ± 
7.2
17.‘t**x ± 
13.2
* p < 0.05 ** p < 0.01 x comparison with 1st dose p < 0.02.
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TABLE 6.2.
EFFECT OF NIFEDIPINE ON PRESSOR RESPONSIVENESS TO PHENYLEPHRINE
PD20 VALUES (ug/kg/min)
PATIENT PLACEBO 1ST DOSE 1 WEEK 6 WEEKS
1 1.3 1.0 2.9 2.5
2 0.8 1.2 2.8 2.0
3 0.7 1.0 1.8 1.4
4 0.7 1.0 2.0 2.4
5 2.1 1.9 2.0 1.2
6 1.6 1.8 2.6 3.3
7 1.7 2.8 2.6 2.6
8 3.8 5.0 5.1 3.9
9 1.4 4.5 2.6 3.0
10 0.9 2.3 2.6 1.7
11 4.9 6.9 7.0 5.3
12 1.9 1.0 - 4.1
13 1.9 4.2 4.6 2.4
14 2.5 3.9 2.7 4.8
Mean + SD 1.9 ± 2.8* + 3*2 +
 ^ *
2.9 ±
1.2 1.9 1.5 1.2
* p < 0.05 ** P < 0.01
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Pressor dose-response curves for angiotensin II (Top) and 
phenylephrine (Bottom) in a representative patient following 
placebo (Q ), 1st dose nifedipine ( #  ) and after 1 week 
( A  ) and 6 weeks ( A ) nifedipine treatment.
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TABLE 6.3.
EFFECT OF ENALAPRIL ON PRESSOR RESPONSIVENESS TO ANGIOTENSIN II
PDgg VALUES (ng/kg/min)
PATIENT PLACEBO 1ST DOSE 1 WEEK 6 WEEKS
1 13.3 4.5 10.8 6.9
2 22.8 13.2 9.5 15.3
3 4.8 8.9 3.7 6.3
4 3.1 3.8 1.9 6.0
5 4.3 2.5 2.8 3.3
6 11.7 7.5 3.6 7.2
7 8.9 7.4 - 4.9
8 5.0 4.4 4.3 6.3
9 2.9 3.1 2.3 2.5
10 18.8 13.1 11.1 14.4
11 4.1 3.2 3.4 2.3
12 18.5 11.1 6.2 6.8
13 8.1 8.2 7.1 4.7
Mean + SD 9.7 ± 
6.8
7.0 + 
3.8
c c*5.5 ± 
3.2
£ rr*6.7 ± 
4.0
*  p < 0.05 * *  P < 0.01.
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TABLE 6.4.
EFFECT OF ENALAPRIL ON PRESSOR RESPONSIVENESS TO PHENYLEPHRINE 
PD20 VALUES (ug/kg/min)
PATIENT PLACEBO 1ST DOSE 1 WEEK 6 WEEKS
1 2.1 1.8 1.7 1.8
2 2.9 1.3 2.2 1.8
3 2.0 1.5 1.7 1.3
4 1.6 0.6 0.9 1.2
5 2.8 1.1 1.6 2.2
6 4.5 3.3 4.2 2.0
7 0.9 0.9 - 0.8
8 1.2 1.6 1.8 2.8
9 1.3 1.0 1.3 1.0
10 2.3 2.6 3.9 1.5
11 0.9 0.5 0.5 0.5
12 1.8 1.9 1.3 1.2
13 3.3 1.4 1.6 1.5
Mean + SD 2.1 + 1 c*1.5 ± 1.8* + 1 c*1.5 ±
1.0 0.8 1.1 0.6
* p < 0.05 ** P < 0.01
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Figure 6^3..
Pressor dose-response curves for angiotensin II (Top) and 
phenylephrine (Bottom) in a representative patient following 
placebo ( O  ), 1st dose enalapril ( #  ) and after 1 week 
( A  ) and 6 weeks ( ▲ ) enalapril treatment.
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Figure 6.4.
The attenuation in pressor sensitivity by nifedipine related to 
age. Correlations between patient age and angiotensin II and 
phenylephrine dose ratios after the 1st dose of nifedipine.
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treatment with enalapril and doxazosin but there was a 
significant differential age effect on the responses to 
both All and PE during treatment with nifedipine. There 
was a significantly greater attenuation of the pressor 
responsiveness to All in younger patients (Figure 6.4.) but 
a significantly greater attenuation of PE responsiveness in
older patients (Figure 6.4.).
Cardiovascular baroreflex activity
In contrast to enalapril and doxazosin which had no 
effect (Table 6.5.), nifedipine significantly reduced the 
change in heart rate per unit increase in blood pressure
from -0.62 (placebo) to -0.38 (1st dose), -0.35 (1 week) and
-0.31 bpm/mmHg (6 weeks), as illustrated for the group in 
Figure 6.5.
6.3.4. Plasma renin activity f aldosterone. catecholamines
and ACE activity
The first doses of both nifedipine and doxazosin were 
associated with significant increases in plasma 
noradrenaline (Tables 3.2. and 5.2.). Enalapril produced 
greater than 80$ inhibition of plasma ACE activity 1.5 hours 
after drug administration (Figure 4.3.) and additionally 
there were significant increases in plasma renin activity 
(Table 4.3.) from 3.6 (placebo) to 6.9 (1st dose), 18.3 (1 
week) and 18.0 ng Al/ml/hr (6 weeks).
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TABLE 6.5.
THE CHANGE IN HEART RATE PER UNIT INCREASE IN SYSTOLIC BLOOD PRESSURE 
DURING PHENYLEPHRINE INFUSION
MEAN + S.D. (bpm/mmHg)
PLACEBO 1st DOSE 1 WEEK 6
Nifedipine -0.62+0.33 -0.38+0.36** -0.35 ± 0.12** 0.31
Enalapril -0.49 ± 0.38 -0.40 + 0.25 -0.48 + 0.29 0.50
Doxazosin -0.37 ± 0.13 -0.42 + 0.15 -0.58 ± 0.29 0.39
** p < 0.01
■ ■-1. 
IL
WEEKS
+ 0.41** 
± 0.37 
+ 0.20
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Figure 6.5.
Nifedipine study. The mean relationship between changes in blood 
pressure and heart rate during phenylephrine infusion for all 
patients, following placebo ( •  ), 1st dose nifedipine ( A  ) and 
after 1 week ( O  ) and 6 weeks ( ▲  ) nifedipine treatment.
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4. DISCUSSION
Haemodynamic responses to vasoactive agents have been 
widely used to test various aspects of cardiovascular 
function and the responses to antihypertensive drugs 
(Beretta-Piccoli et al, 1982; Imai et al, 1982b; Van 
Brummelen et al, 1986). However, there has been 
considerable variation in the methodology, not only 
concerning the techniques for the administration of 
agonists but also in the analysis of the dose-response 
data (Sumner and Elliott, 1987). Thus it has proved 
difficult to make comparative assessments of drug effects 
which are independent of other factors such as age and 
starting blood pressure. In this study, a standardised 
approach for measuring and analysing the responses to 
vasoconstrictor agents was employed (Sumner et al, 1987; 
Sumner and Elliott, 1987), and an assessment of baroreflex 
responses was also incorporated (Smythe et al, 1969).
In terms of blood pressure reduction the "vasodilator” 
activity of the three drugs was comparable but the effects 
on vascular pressor responsiveness were significantly 
different. Consistent with its mechanism of action, 
doxazosin produced significant alpha antagonism but no 
antagonism of angiotensin II-mediated vasoconstriction but 
the different effects of the two "non-adrenergic 
vasodilators", nifedipine and enalapril, are of particular 
interest. For nifedipine, there was interference with both 
"adrenergic" and "non-adrenergic" pressor responsiveness.
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This has been reported previously with other dihydropyridine 
calcium antagonists and also with verapamil (Beretta-Piccoli 
et al, 1 932; Elliott et al, 1 985; Pasanisi et al, 1 985). 
Additionally, however, there was a progressive increase in 
the extent of the attenuation of the angiotensin response 
during the 6 weeks of this study. In contrast, there was no 
attenuation of the pressor responsiveness to either 
angiotensin II or phenylephrine during treatment with 
enalapril but instead there was increased responsiveness to 
both pressor agents. Previous studies have produced an 
inconclusive picture concerning the effects of ACE 
inhibitors on pressor responses. Increased responsiveness 
to angiotensin II has been reported (Imai et al, 1982b; 
Koletsky et al, 1984) although not in all studies (Fruncilo 
et al, 1983; Kondowe et al, 1987a), whereas increased 
adrenergic responsiveness has not been reported before. 
Similar previous studies of adrenergic responsiveness (to 
noradrenaline) have described either unchanged or reduced 
responsiveness after ACE inhibitors (Imai et al, 1982b; 
Fruncilo et al, 1983; Vierhapper et al, 1986; Kondowe et al, 
1987b). However, these previous studies have used the 
non-selective alpha agonist noradrenaline whose vasopressor 
effect is mediated predominantly by alph^-adrenoceptors 
(Timmermans and van Zwieten, 1981) whereas this study used 
phenylephrine which is selective for alpha-j-adrenoceptors.
The vasoconstrictor action of angiotensin II is 
mediated not only via stimulation of specific receptors on
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vascular smooth muscle (Lin and Godfriend, 1970) but also 
by facilitation of noradrenergic transmission from 
sympathetic nerves by presynaptic All receptors (Zimmerman 
et al, 1984). It is therefore possible that removal of 
angiotensin II after ACE inhibition leads to up-regulation 
not only of post-junctional angiotensin II receptors but 
also of post-junctional adrenergic receptors, the latter as 
a consequence of reduced neurotransmission.
Alternatively, it may be a reflection of altered post­
receptor mechanisms since both angiotensin II receptors and 
alpha-j-adrenoceptors activate second messenger pathways 
involving phosphoinositol hydrolysis (Nahorski, 1985).
Although the antihypertensive effect of ACE inhibitors 
is essentially due to a reduction in angiotensin II 
formation (Gavras et al, 1978), the specific mechanism and 
site of action have not been clearly established.
Additional factors, including altered baroreflex function, 
have been implicated and there is evidence that baroreflex 
mechanisms are altered by captopril (Mancia et al, 1982; 
Imai et al, 1982b; Clementini et al, 1986). Such an 
alteration to baroreflex-mediated counter-regulatory 
mechanisms might have contributed to the observed increased 
pressor responsiveness (Koch-Weser, 1974) but there was no 
corresponding evidence of altered cardiovascular baroreflex 
activity in this study. However, the blood pressure-heart 
rate correlation with phenylephrine is clearly a relatively 
crude index of cardiac baroreflex response and additionally
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there may be differential effects produced by a pressor 
agent, as opposed to a depressor agent.
Doxazosin had no effect on baroreflex function but with 
nifedipine there was a significant attenuation of the heart 
rate response suggesting "re-setting" of baroreflex 
mechanisms. This has been suggested previously for calcium 
antagonists (Bolli et al, 1985) and changes in both the set- 
point and sensitivity of baroreceptors have been reported 
during chronic treatment with nifedipine (McLeay et al,
1983) .
An additional difference between nifedipine and the 
other two drugs was a differential effect on "adrenergic" and 
"non-adrenergic" responsiveness according to age. In the 
elderly interference with "adrenergic" pressor responsiveness 
was more pronounced whereas in the young "non-adrenergic" 
responsiveness was altered to a greater extent by 
nifedipine. This may simply reflect an age-dependent 
difference in the activity of baroreflex mechanisms and the 
possible baroreflex effect of nifedipine, since bradycardia 
is an important component of the response to phenylephrine 
and this was less in the older subjects. There are 
alternative explanations in terms of age-related differences 
in sympathetic activity, plasma renin activity and starting 
blood pressure. There is some evidence that the renin- 
angiotensin system is activated particularly in the early 
phase of hypertension ie. in younger hypertensives (Buhler 
et al, 1981; Buhler and Bolli, 1985), whereas in elderly
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hypertensives alpha adrenoceptor mediated vasoconstriction 
may assume greater importance (Buhler and Bolli, 1985)
There has been recent discussion about the influence 
which starting blood pressure has on the magnitude of the 
subsequent fall with treatment (MacGregor et al, 1982b;
Erne et al, 1983). It might be suggested that the 
magnitude of the response to a pressor agent may similarly 
be dependent on the starting blood pressure. In terms of 
arterial haemodynamics vascular resistance is directly 
related to vessel diameter (Westerhof and Huisman, 1987) 
and it has been shown in vitro that an increase in the 
cross-sectional area of resistance arterioles (i.e. 
relatively reduced blood pressure) is associated with a 
decrease in the pressor response to vasoconstrictor 
stimuli (Folkow, 1975). In this study there was no 
relationship between the starting (pre-infusion) blood 
pressure (and heart rate) and PI>20> either before or after 
antihypertensive treatment.
In conclusion, a standardised method has been used to 
examine the comparative effects of three vasodilator drugs 
on vascular pressor responses. For comparable reductions 
in blood pressure, doxazosin only affected the adrenergic 
mechanism whereas nifedipine and enalapril affected both 
"adrenergic" and "non-adrenergic" vascular responses. The 
contrasting results for nifedipine and enalapril may reflect 
baroreflex resetting in the case of the calcium antagonist 
and receptor up-regulation in the case of the ACE inhibitor.
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CHAPTER Z
ACUTE AMD CHROMIC KETANSERIN IN ESSENTIAL HYPERTENSION: 
ANTIHYPERTENSIVE MECHANISMS AND KINETIC-DYNAMIC RELATIONSHIPS
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7.1. INTRODUCTION
Ketanserin is a selective serotonin (5HT2) antagonist 
(Van Neuten et al, 1981; Leyson et al, 1981) which, either 
as monotherapy or in combination with a beta-adrenoceptor 
antagonist (De Cree et al, 1981a; Hedner and Persson, 1935; 
Hedner et al, 1935), has been shown to lower blood pressure 
in patients with essential hypertension. There is evidence 
that the antihypertensive effect of ketanserin is associated 
with a reduction in peripheral vascular resistance (Fagard 
et al, 1984) but the principal underlying mechanism remains 
to be established. Although serotonin is implicated in 
cardiovascular regulation, both peripherally and centrally, 
its actions are complex and variable (Page and McCubbin, 
1953) and the blood pressure responses to other serotonin 
antagonists have been inconsistent (Vanhoutte and Van 
Neuten, 1983; Vanhoutte, 1985; Hosie et al, 1987).
Because ketanserin has also been shown to have alpha-j 
adrenoceptor antagonist activity (Van Neuten et al, 1981) it 
has been proposed that alpha blockade underlies the 
antihypertensive effect in man (Reimann and Frolich, 1983).
A number of other mechanisms have also been suggested: for
example, an inhibitory effect in the CNS (Mylecharane et al, 
1985), including arterial baroreflex resetting (Smits et al, 
1987); interference with the renin-angiotensin-aldosterone 
system (Williams et al, 1984; Mantero et al, 1985; Rocco 
et al, 1986); and impairment of the vasoconstrictor 
response to angiotensin II (Neuten et al, 1982).
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Although the principal metabolite of ketanserin, 
ketanserinol, is reported to have negligible affinity for 
arterial 5HT2 receptors (Frenken and Xaumann, 1984), a 
contribution to the clinical pharmacological effects of 
ketanserin cannot be excluded. Furthermore, there is 
evidence to suggest that ketanserinol, during continued 
administration, may influence the disposition of the 
parent drug (Van Peer et al, 1986).
Clinical studies, using a dosage regimen of 
40 mg b.i.d., have shown large interindividual differences 
not only in blood pressure reduction (Hedner et al, 1985; 
Kane et al, 1986; Waller et al, 1987) but also in plasma 
ketanserin concentrations (Heykants et al, 1986). In 
addition, it has been suggested that the dose-response curve 
for the antihypertensive effect of ketanserin is relatively 
flat', whereas the response curve for side effects and drop­
out frequency is much steeper (Amery et al, 1985).
Although maximal blood pressure reductions have been 
correlated with peak plasma levels of ketanserin (Persson et 
al, 1987), no direct relationship between ketanserin 
concentration and the fall in blood pressure has been 
described when group data are evaluated (Hedner et al, 1986; 
Cameron et al, 19 8 7 ). While this may reflect the dynamic 
and kinetic variability between subjects, recent evidence 
for other cardiovascular drugs suggests that the 
concentration-effect relationship is potentially more useful 
when individual patients are considered.
207
This study in patients with essential hypertension 
investigates some of the possible mechanisms underlying the 
antihypertensive effect of ketanserin, including adrenergic 
and non-adrenergic pressor mechanisms, and evaluates the 
kinetic-dynamic relationships of ketanserin in individual 
patients, following single and multiple dosing, and some of 
the factors which might contribute to the intersubject 
variability in antihypertensive response.
7.2. M ETHODS
7.2.1. General
Mine patients with essential hypertension gave 
consent to participate in this study and individual patient 
details are shown in Table 7.1. Five males and four 
females, age range 45-61 years, discontinued any previous 
medication at least 6 weeks prior to entering the study and 
at the end of this drug-free run-in period the mean entry 
blood pressures were 174/102 + 12/7 (supine) and 172/102 + 
12/6 mmHg (erect). Two weeks treatment with placebo, 
followed by ketanserin 40 mg b.i.d. for 4 weeks was 
administered in a single blind design and the patients 
completed three 8-hour study days in the Clinical 
Pharmacology Research Unit to evaluate the effects of 
placebo, first dose ketanserin and steady state (1 month) 
ketanserin (Figure 7.1.).
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Figure 7.1.
Ketanserin study design. Six of the 9 patients continued 
ketanserin therapy for a further 2 weeks and attended a Mth study 
day when prazosin was co-administered with ketanserin.
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Super im posed treatm ent w ith the alpha ^ antagonist prazosin.
Six patients (Nos. 1, 2, 4, 5, 5 and 9), randomly 
selected, continued ketanserin therapy for a further two 
weeks and completed a 4th study day when prazosin 1 mg was 
co-administered with ketanserin (Figure 7.1.).
7.2.2. Study days
The basic protocol for study days is described in 
detail in Chapter 2.1. At frequent intervals during each 
study day, and at 24 hours after dosing, supine and erect 
blood pressure and heart rate were measured and venous blood 
samples collected for the measurement of plasma drug and 
metabolite (ketanserinol) concentrations. Additional blood 
samples were taken at 1.5 and 5 hours for plasma renin 
activity, aldosterone and catecholamines. Urine was 
collected for the 24 hours of each study day.
On each visit to the CPRU patients completed a 
questionnaire relating to adverse effects and the intensity 
of specific symptoms was indicated on a self-rating scale.
Pressor responsiveness
During two periods, 1.5-3 hours (early) and 5-6 hours 
(late), pressor responses to intravenous infusions of 
phenylephrine (PE) and angiotensin II (AID were measured 
using the protocol described in Chapter 2.2. The 
relationship between the simultaneous blood pressure and 
heart rate changes during the infusion of phenylephrine was
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used as an index of cardiovascular baroreflex activity 
(Chapter 2.2.) .
ECG recording
On each study day, at 1 and 5 hours, an ECG recording 
from standard chest leads was fed directly to an ’in-house' 
computer program for the measurement of heart rate and OT 
interval.
7.2.3. Laboratory m ethods
Plasma concentrations of ketanserin and the metabolite 
ketanserinol were measured by reverse phase HPLC with 
fluorescence detection (Okonkwo et al, 1983). An alkaline 
extraction procedure was used with back-extraction into 
sulphuric acid. The extraction efficiency was 80$ for 
ketanserin and 60$ for ketanserinol. The inter and intra­
assay coefficients of variation were 12$ and 10$ 
respectively, and the limits of detection were 2 ng/ml for 
ketanserin and 0.5 ng/ml for ketanserinol.
The concentration-time data for ketanserin were most 
appropriately fitted to a two-compartment pharmacokinetic 
model. Plasma concentrations of prazosin (Yee et al, 1979) 
were fitted to a single compartment model.
7.2.4. Concentration-effect analysis
The pharmacokinetic and pharmacodynamic data for 
ketanserin were sequentially fitted to the linear 
concentration-effect model described in Chapter 2.5. and the 
parameters m and Kpn derived for individual patients
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following the first dose and after 1 month ketanserin. The 
responsiveness to ketanserin (m) was calculated in terms of 
the placebo-subtracted change in erect systolic blood 
pressure per unit change in drug concentration. The first 
order rate constant of the effect model, K , describes the 
removal of drug from the effect compartment and 
characterises the temporal discrepancy for the plasma 
concentration-effect relationship.
7.2.5. Statistical Analysis
Pressor dose-response relationships for PE and All were 
fitted to a quadratic function and the derived P^20 vs,lues 
(dose of agonist required to raise mean arterial pressure by 
20 mmHg) were compared by repeated measures analysis of 
variance. QT intervals were corrected for heart rate (QTC) 
using Bazett’s rule (Bazett, 1920) and compared between 
treatments by Student’s paired t test.
7.3. R E S U L T S
7.3.1. General
Ketanserin 40 mg b.i.d. was generally well tolerated 
and no significant adverse effects were reported.
7.3.2. Blood Pressure
The first dose of ketanserin was associated with a 
significant reduction in blood pressure, both supine and 
erect, after 1 hour (p < 0.01): for supine blood pressure
213
from 178/103 ± 17/11 at baseline to 1 M /  8 7 ± 13/8 mmHg 
following ketanserin, compared with 182/ 107 + 13/9 to 
168/101 + 14/11 mmHg following placebo (Figure 7.2.). A 
similar prompt reduction was observed for erect blood 
pressure but there was no significant orthostatic component 
and there was no associated symptomatic postural 
hypotension. For 6 hours after the first dose supine and 
erect blood pressures were significantly lower than with 
placebo (p < 0.01), on average 23/14 mmHg supine and 27/13 
mmHg erect, but at 24 hours measurements were not 
significantly different. After 1 month of treatment with 
ketanserin, the overall antihypertensive effect was 
comparable to that following the first dose (Figure 7 .2.) 
with blood pressures averaging 141/85 supine and 139/87 
erect over the 8-hour period. The addition of 1 mg 
prazosin to ketanserin treatment in six patients was 
associated with a further significant fall in blood pressure 
(Figure 7.3.), for example 11/3 mmHg (supine) and 9/4 mmHg 
(erect) on average at 1 hour after dosing.
7.3.3. Heart Rate
There were small but significant increases in heart 
rate (p < 0 .0 5 ) at 1 - 2 hours after the first dose of 
ketanserin compared with placebo (Figure 7.4.). In contrast, 
average heart rates during the 8 hours were lower after 1 
month’s treatment (64.6 + 3 bpm supine) compared with the 
first dose (69.2 ± 5 bpm) and placebo (71.2 ± 4) administrations
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7.3.4. Pressor Responsiveness
Ketanserin produced significant (p < 0.05) rightward, 
parallel shifts of the phenylephrine dose-response curves as 
illustrated for a representative patient in Figure 7.5. The 
mean PP>20 values for PE infusions during both periods were 
significantly increased by both active treatments: from 1.4 
(placebo) to 2.7 following the first dose and 2.4 ug/kg/m in 
after 1 month of ketanserin in the early period (Table 7.2.) 
and, correspondingly, 1.6 (placebo), 2.2 (1st dose) and 2.3 
ug/kg/min (1 month) in the late period (Table 7.3.). On 
individual study days the differences in pressor 
responsiveness to PE between the early and late infusions 
were not significantly different and similarly the responses 
associated with acute and chronic ketanserin were not 
significantly different. The addition of prazosin was 
associated with further rightward shifts of the PE pressor- 
response curves, and this is shown for a representative 
subject in Figure 7.5. The increase in mean P ^ q  (n = 6) 
attributable to prazosin (Tables 7.2. and 7.3.) was 
significantly greater for the PE infusions at the early 
period, from 2.4 to 7.1 ug/kg/min, compared to 2.3 to 4.6 at 
the late period. Ketanserin had no effect on the pressor
responses to the infusion of All (Table 7.4.).
Ketanserin had no significant effect on the 
relationship between the simultaneous blood pressure and 
heart rate changes during the infusion of phenylephrine 
(Table 7.5.).
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Pressor dose-response curves for phenylephrine in a 
representative patient after placebo ( ♦  ), 1st dose ketanserin 
( ▲  ), 1 month ketanserin ( A  ) and after the addition of 
prazosin ( O  ).
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TABLE 7.2.
KETANSERIN STUDY. PRESSOR RESPONSES TO PHENYLEPHRINE. 
EARLY PERIOD.
PD20 (ug/kg/min)
KETANSERIN ADDED
PATIENT PLACEBO 1ST DOSE 1 MONTH PRAZOSIN
1 1.3 0.9 1.7 6.3
2 1.6 2.0 1.0 5.8
3 1.1 1.9 1.6 -
4 0.8 1.3 1.5 5.6
5 2.0 3.2 3.2 6.8
6 1.9 4.2 3.9 9.8
7 1.6 3.4 3.1 -
8 1.3 2.9 2.9 -
9 1.3 4.3 2.3 3.5
MEAN + 1.4 + 2.7* + 2.4* + 7.1** ±
SD 0.4 1.2 1.0 1.7
* p < 0.03
## p < 0.00001
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TABLE 7.?.
KETANSERIN STUDY. PRESSOR RESPONSES TO PHENYLEPHRINE. 
LATE PERIOD.
PDqq (ug/kg/min)
KETANSERIN ADDED
PATIENT PLACEBO 1ST DOSE 1 MONTH PRAZOSIN
1 1.1 1.2 1.3 6.4
2 2.1 2.7 1.9 4.9
3 1.4 2.0 1.3 -
4 1.0 1.2 2.8 2.5
5 1.7 3.1 3.1 4.0
6 1.6 2.4 3.5 5.9
7 1.5 2.5 1.9 -
8 2.0 2.0 2.7 -
9 2.1 3.1 2.1 4.1
MEAN + 1.6 + 2.2* + 2.3* ± 4.6** +
SD 0.4 0.7 0.8 1.4
* p < 0.03
** p < 0.0001
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TABLE 7.4.
KETANSERIN STUDY. PRESSOR RESPONSES TO ANGIOTENSIN II 
MEAN PDng ± SD (ng/kg/min)
KETANSERIN ADDED
PLACEBO 1ST DOSE 1 MONTH PRAZOSIN
Early 5.3 ± 4.8 ± 5.7 ± 5.6 ±
(1.5-3 hrs) 1.8 1.8 2.3 3.0
Late 4.5 ± 6.2 + 5.0 + 5.8 +
(5-6 hrs) 1.8 2.1 1.6 3.4
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TABLE 7.5.
CHANGE IN HR PER UNIT INCREASE IN SYSTOLIC BLOOD PRESSURE 
DURING PHENYLEPHRINE INFUSION. MEAN + SD
A hr/ A bp KETANERSIN ADDED
bpm/mmHg PLACEBO 1ST DOSE 1 MONTH PRAZOSIN
Early -0.41 ± -0.35 ± -0.28 + -0.35 ±
(1.5-3 hrs) 0.18 0.24 0.21 0.21
Late -0.43 ± -0.33 ± -0.33 ± -0.40 ±
(5-6 hours) 0.22 0.13 0.16 0.12
H'p't
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7.3.5. OT intervals
After one month’s treatment QTq was significantly 
increased (p<0.05) at 1 hour following drug administration 
(334 + 32 msecs) compared with placebo (302 + 31). 
Measurements at 5 hours, however, were not significantly 
different: 329 ± 27 (1 month) and 327 ± 33 (placebo).
7.3.6. Pharmacokinetics
The AUC and elimination half-life for both ketanserin 
and ketanserinol were significantly increased at steady 
state compared with the first dose (Table 7.6.): for
ketanserin, the elimination half-life (hours) and AUC 
(ng.h.ml” *1) were respectively 4.3 ± 2.2 and 437 ± 163 (1st 
dose), and 13.4 + 6.2 and 830 + 323 ( 1 month). There was 
a proportionately greater increase in ketanserinol AUC which 
accounted for a reduction in the AUC Drug/AUC metabolite 
ratio at steady state. Peak plasma concentrations of 
ketanserin and ketanserinol were achieved within 1.5 hours 
(Figure 7.6.). The addition of prazosin had no effect on the 
steady state kinetics of ketanserin or ketanserinol: for
ketanserin the elimination half-life was 13.5 ± 1.8 hours 
and AUC 830 ± 221 ng.h.ml"1 (Table 7.6.). There was no 
significant change in Cmax or the time to attain Cmax (tmax) 
- Table 7.7.
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TABLE 7.6.
PHARMACOKINETICS OF KETANSERIN. DERIVED PARAMETERS AUC AND 
ELIMINATION HALF-LIFE.
AUC ELIMINATION
PATIENT (ng.h.ml”1) HALF-LIFE (hours)
1st DOSE 1 MONTH
ADDED
PRAZOSIN 1st DOSE 1 MONTH
ADDED
PRAZOSIN
1 565 1255 835 3.9 8.8 11.7
2 496 1114 567 6.9 8.1 13.0
3 467 576 - 8.6 10.7 -
4 730 709 835 2.4 20.6 16.8
5 515 1076 1234 2.8 11.9 12.5
6 289 1089 730 5.3 25.6 14.2
7 202 252 - 3.9 6.6 -
8 311 696 - 2.5 16.0 -
9 357 708 780 2.9 12.5 12.6
MEAN + 
SD
437.4 ± 
163.0
830*
323
+ 830* + 
221
4.3 ± 
2.2
13.4* ± 
6.2
13.5* ± 
1.8
Comparison with 1st dose: * p < 0.005
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TABLE 7.7.
PHARMACOKINETICS OF KETANSERIN. DERIVED PARAMETERS T_...
AND C -max.
- %ax
PATIENT (A) Cmax (ng.h.ml-1) Tmax (hours)
ADDED u ADDED
1st DOSE 1 MONTH PRAZOSIN 1st DOSE 1 MONTH PRAZOSIN
1 184 182 111 0.9 1.3 0.8
2 116 164 103 0.7 0.6 0.8
3 43 107 - 1.0 2.2 -
4 278 144 162 0.9 0.6 0.5
5 164 158 299 0.5 0.9 0.5
6 91 130 85 0.7 1.5 1.9
7 47 38 - 0.8 1.5 -
8 72 46 - 1.6 2.4 -
9 101 98 107 1.4 0.9 1.5
MEAN + 122 + 119 + 144 + 0.9 ± 1.3 ± 1.0 +
SD 76 51 80 0.3 0.6 0.5
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Figure 7.6.
Mean plasma ketanserin concentration-time profiles for 8 hours 
after the 1st dose ( H  ) and after 1 month ketanserin (| )•
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7.3.7. Concentration-effect relationships
When mean data for the group 'were evaluated there was 
no obvious concentration-effect relationship (Figure 7.7.). 
Similarly for individual patients, as illustrated for 
patient 7 (Figure 7.3.), there was no simple direct 
relationship between plasma ketanserin concentration and the 
fall in blood pressure. However, using the effect model, 
ketanserin concentrations were well correlated with the 
reduction in blood pressure in individual patients and fits 
for representative subjects are shown in Figures 7.9. and 
7.10. The concentration-effect parameters, m and K , and 
the goodness of fit (R) for each patient are shown in Table 
7.8. The responsiveness to ketanserin, as the mean of the 
group, was -0.47 following the first dose and -0.25 
mmHg/ng/ml after 1 month. This reduction in responsiveness 
during chronic compared with single dose administration was 
significant (p < 0.02). In addition, there was a 
significant increase (p < 0.01) in Kecj from 0.49 (1st dose) 
to 1.86 h“  ^ (1 month).
There was no correlation between the responsiveness to 
ketanserin and patient age, or plasma renin activity, or the 
degree of peripheral alpha blockade (Figure 7.11). There 
was a trend towards a relationship between the 
responsiveness and the pretreatment blood pressure (Figure 
7.12.) but this did not achieve statistical significance (p 
< 0.07).
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A conventional group approach to concentration-effect analysis 
for ketanserin. The mean plasma ketanserin concentration is 
plotted against the mean (placebo-subtracted) reduction in erect 
systolic BP at different times after drug administration 
following the 1st dose (O ) and after 1 month ketanserin ( •  ).
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Figure Z18.
The relationship between plasma ketanserin concentration and the 
placebo-subtracted fall in erect systolic BP in an individual 
patient after the 1st dose of ketanserin.
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Ketanserin concentration-effect analysis. The observed
( A — ▲  ) and fitted ( ▲ ----▲  ) effect of ketanserin on erect
systolic blood pressure after the 1st dose (Top) and after 1 
month (Bottom) in a representative patient, illustrating above
average goodness of fit.
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a - - - 4 Fitted 
m « -0.36 mmHg ng'ml
-25-
-30 J
systolic BP (mmHg)
Time (hrs)
-20 -
-25-
-30-
4''
a a Observed 
A -  -  -  4 Fitted 
m « -0.26 mmHg/ng/ml 
Keq -  0.49
-35-
4.
-40 J
systolic BP (mmHg)
Figure 7.10.
Ketanserin concentration-effect analysis. The observed
( ▲ — ▲  ) and fitted ( A ----A  ) effect of ketanserin on erect
systolic blood pressure after the 1st dose (Top) and after 1 
month (Bottom) in a representative patient (patient 3), 
illustrating below average goodness of fit.
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TABLE 7.3.
CONCENTRATION-EFFECT PARAMETERS m (mmHg/ng/ml) AND K_n 
(h=i). AND THE GOODNESS OF FIT R (AS A FRACTION 
OF UNITY) FOR CHANGES IN ERECT SYSTOLIC BLOOD PRESSURE.
FIRST DOSE ONE MONTH
PATIENT m Keq R m K R
1 -0.26 0.66 0.87 -0.12 3.60 0.89
2 -0.58 0.49 0.74 -0.12 0.90 0.88
3 -0.36 0.33 0.75 -0.26 0.49 0.82
4 -0.23 0.24 0.79 -0.29 0.40 0.78
5 -0.41 0.46 0.89 -0.19 2.30 0.82
6 -0.72 0.31 0.59 -0.30 0.45 0.75
7 -0.96 0.45 0.83 -0.43 2.75 0.86
8 -0.29 1.01 0.69 -0.25 5.40 0.86
9 -0.44 0.43 0.79 -0.30 0.41 0.87
Mean
+
SD
-0.47
+
0.24
0.49
+
0.23
0.77
+
0.09
-0.25*
+
0.10
1.86x
+
1.80
0.84
+
0.05
ComDarison with 1st dose: * p < 0.02
x p < 0.01
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First Dose Ketanserin
PE dose ratio
3.3-1
2.9- 
2.5- 
2.1- 
1.7-
1.3- 
0.9- 
0.5-
I 1---1---1---1---1---1---1---1
0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
responsiveness (mmHg/ng/ml)
Figure 7.11.
The relationship between responsiveness to ketanserin (1st dose) 
and the degree of peripheral alpha^ adrenoceptor antagonism (i.e. 
the phenylephrine dose ratio).
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First Dose Ketanserin
Baseline BP (mmHg)
180 -m
170 H
160 -i
150 H
140 H
130-J
r = 0.6 
P < 0.07
I I I T I I I I I
0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
responsiveness (mmHg/ng/ml)
FigQre 7.12.
The relationship between responsiveness to the 1st dose of 
ketanserin and the pretreatment systolic blood pressure. Not 
significant - r = 0*.6, p < 0.07.
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TABLE Ltl*.
KETANSERIN STUDY. PLASMA RENIN ACTIVITY. ALDOSTERONE 
AND NORADRENALINE CAT 1.5 HRS). AMD 24-HOUR URINARY VOLUME 
AND SODIUM EXCRETION. MEAN + SD.
KETANSERIN
PLACEBO 1ST DOSE 1 MONTH
Plasma renin 1.0+ 1.9 ± 1.7 ±
activity 0.5 1.7 1.6
(ngA1/ml/hr)
Plasma 83 ± 79 + 67 ±
aldosterone 29 26 23
(pg/ml)
Plasma 2.4 ^  2.7 i 3.2 +
noradrenaline 1.3 1.4 1.6
(nM/L)
Urine Vol 1843 ± 1848 ± 1739 ±
(ml) 732 621 636
Urinary Na+ 184 + 176 ± 174 +
(mmol) 43 71 66
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7.3.8. Hormone m easurem ents and urinary electrolyte 
excretion
Measurements of plasma renin activity, aldosterone and 
catecholamines, and 24-hour urinary volume and electrolyte 
excretion were not significantly different after ketanserin 
compared with placebo (Table 7.9.).
7.4. DISCUSSION
This study has addressed some of the ill-defined areas 
relating to the clinical pharmacology and pharmacokinetics 
of ketanserin.
Ketanserin has previously been shown to lower blood 
pressure (De Cree et al, 1981a; Hedner et al, 1985) and this 
study tends to confirm that the antihypertensive effect is 
sustained for 24-hour blood pressure control with a dosage 
regimen of 40 mg twice daily. While we are unable to 
assess the magnitude of the chronic antihypertensive 
response to ketanserin, it is worth noting that the patients 
in this study were previously in regular attendance at our 
hypertension clinic, and additionally they completed a 
preliminary six week run-in period before the formal placebo 
assessment. It therefore seems likely that placebo effects 
were small. On the third study day predosing blood 
pressures recorded 12 hours after the last dose of ketanserin 
were less than 150/95 in six out of nine patients, and good 
blood pressure control was achieved during 8 hours of a 12- 
hour dosage interval with average blood pressures in 7
'i
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patients less than 145/90 supine and 140/90 erect.
The principal mechanism underlying the antihypertensive 
effect of ketanserin remains uncertain but a number of 
features of this study suggest that peripheral alpha 
adrenoceptor antagonism was not the sole mechanism involved. 
In contrast to the classical alpha^-antagonist drug 
prazosin, the effects of ketanserin on supine and erect 
blood pressure were comparable and the first dose was not 
associated with postural hypotension, marked tachycardia or 
increased catecholamines. Furthermore, whereas heart rate 
is usually unchanged during longterm prazosin therapy (Lund- 
Johansen, 1974), in this and other studies heart rate 
was significantly reduced with ketanserin (Fagard et al, 
1984; Persson et al, 1983). A previous study, which 
demonstrated weak alpha blocking activity in normotensive 
subjects, found no reduction in blood pressure (Zabludowski 
et al, 1985) and the evidence of only modest alpha 
antagonist activity in this study also suggests that this 
mechanism is unlikely to account entirely for the 
antihypertensive effect. There is some dispute about the 
extent of the reduction in peripheral vascular resistance 
associated with the antihypertensive effect of ketanserin 
(Fagard et al, 1984; Omvik and Lund-Johansen, 1983) and in 
this study ketanserin had no effect on the pressor 
responses to angiotensin II.
There is good evidence that serotonergic neurones in 
the CMS are involved in the maintenance of vascular tone and
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therefore a central mode of action has been proposed (Kuhn 
et al, 1980) particularly in relation to baroreflex function 
(Smits et al, 1987). In this study the relationship 
between the simultaneous blood pressure and heart rate 
changes during the infusion of phenylephrine was used as an 
approximate index of cardiovascular baroreflex activity and 
ketanserin had no effect on this relationship. However, 
the reduction in responsiveness (m) to ketanserin during 
chronic treatment may reflect "resetting" of baroreceptor 
mechanisms. In addition, the reduction in heart rate 
observed during chronic therapy may be evidence of a drug- 
related central effect, perhaps producing an enhancement of 
vagal tone.
Ketanserin is reported to cause prolongation of the OT 
interval (Cameron et al, 1 986; Stott et al, 1 985) and this 
may have clinical implications with respect to the 
development of ventricular arrhythmias (Soffer et al, 1982). 
Our results confirm that QT prolongation occurs during 
chronic therapy, particularly at 1 hour after dosing when 
combined drug and metabolite concentrations were highest.
Some aspects of the pharmacokinetics of ketanserin 
remain to be clearly established. In this study the AUC 
and the elimination half-life were significantly increased 
at steady state compared with single dose administration by 
approximately 2 and 3-fold respectively. Similar 3-fold 
changes in elimination half-life have been reported by 
others (Hedner et al, 1986; Persson et al, 1987) and
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additionally there is some evidence of drug accumulation in 
a study of elderly subjects (Kurowski, 1985). These 
changes may reflect alterations in hepatic extraction but, 
more recently, it has been suggested that reformation of 
ketanserin from ketanserinol is a determining factor for the 
elimination half-life of ketanserin (Van Peer et al, 1986).
The haemodynamic effects and pharmacokinetics of 
ketanserin have been widely reported independently 
(De Cree et al, 1981a; Hedner and Persson, 1985; Kurowski, 
1985) but to date little attention has been paid to the 
kinetic-dynamic relationships in essential hypertension. 
Previous studies have sought correlations between ketanserin 
concentration and effect data for groups of subjects (Hedner 
et al, 1986; Cameron et al, 1987; Persson et al, 1987) and 
a clear relationship between plasma concentration and the 
fall in blood pressure has not been identified. In this 
study no obvious direct relationship was identified when a 
group approach was employed but further analysis showed that 
ketanserin concentrations were well correlated with the fall 
in blood pressure when individual patients were considered.
There has been some dispute about the usefulness of 
ketanserin in the clinical management of hypertension 
(Hedner et al, 1 985; Waller et al, 1 987; Jennings and Opie, 
1987). There is evidence that adequate blood pressure 
control is only achieved in a small proportion of patients 
(V/aal-Manning et al, 1 985) and it has been suggested that 
ketanserin is particularly effective in the older age group
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(Hedner et al, 1985) and in patients with higher 
pretreatment blood pressures (De Cree et al, 1981b).
However, interindividual differences in the therapeutic 
effect of ketanserin reflect kinetic as well as dynamic 
variability and many previous studies have failed to take 
account of differences in plasma ketanserin concentrations 
when assessing the variability in antihypertensive response 
(De Cree et al, 1981b; Hedner et al, 1 985; V/aal-Manning 
et al, 1985; Waller et al, 1987; Jennings and Opie, 1987). 
In this study responses to acute and chronic ketanserin were 
characterised for individual patients in terms of blood 
pressure reduction per unit change in drug concentration 
and, albeit across a relatively narrow age range, there was 
no relationship between age and the responsiveness (m) to 
ketanserin.
Concentrat ion-effect analysis has provided additional 
information about the mechanism of action of ketanserin.
An acute hypotensive effect has been reported (De Cree et 
al, 1981b) and in this study the responsiveness to the first 
dose of ketanserin (in mmHg per unit drug concentration) was 
significantly greater than that after 4 weeks treatment. 
There was no relationship between the responsiveness to 
ketanserin and the degree of alpha blockade, which adds 
further evidence that the antihypertensive effect of 
ketanserin is not directly dependent upon its weak 
peripheral alpha-j antagonist activity (Stokes et al, 1 986).
The significance of an increase in the K0q derived from
' i
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the concentration-effect analysis during chronic ketanserin
treatment is not entirely clear. It reflects a change
(i.e. shortening) of the temporal discrepancy between the
plasma concentration and effect profiles and such a change
in Keq has not been observed in studies of other
antihypertensive drugs. While the increase in Kpn ise cj
unlikely to be solely due to the change in kinetics of 
ketanserin, it may reflect a change in receptor sensitivity 
or, alternatively, it may reflect a change in the 
predominant antihypertensive mechanism of ketanserin during 
chronic compared with acute administration.
In conclusion, although ketanserin has a useful 
antihypertensive effect the principal underlying mechanism 
remains uncertain but is unlikely to involve peripheral 
alpha blockade, perturbation of the renin-angiotensin- 
aldosterone system or altered baroreflex sensitivity.
There may be a change in the predominant antihypertensive 
mechanism of ketanserin during chronic compared with acute 
administration. Ketanserin concentrations are correlated 
with the fall in blood pressure in individual hypertensive 
patients and the derived concentration-effect parameters are 
potentially useful for investigating the intersubject 
variability in antihypertensive response and the mechanism 
of action of ketanserin.
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CHAPTER 8
THE CLINICAL PREDICTION OF ANTIHYPERTENSIVE 
DRUG RESPONSE
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8.1. INTRODUCTION
A wider choice of antihypertensive drugs is now 
available and some of the newer agents such as calcium 
antagonists, ACE inhibitors and alpha^ adrenoceptor 
antagonists represent reasonable alternatives to a diuretic 
or beta blocker as first-line treatments in essential 
hypertension. An individualised approach to treatment is a 
laudable goal but, since the factors which determine the 
response to antihypertensive therapy are not clearly 
understood, at present we are unable to identify which 
patients will respond to which drugs. In practice, 
therefore, the choice of a drug and its appropriate dose is 
largely empirical and clinical decisions are usually based 
on ’trial and error'. Attempts to identify demographic, 
racial and biochemical factors which influence drug response 
have produced conflicting and often misleading statements, 
for example about variations in responsiveness related to 
age or ethnic origin ( Breckenridge , 1 987) and overall the 
results have been disappointing both theoretically and 
practically. For instance, two widely quoted studies have 
drawn opposite conclusions about the relationship between 
age and the fall in blood pressure with a calcium antagonist 
(Buhler et al, 1982; Ferrara et al, 1985).
A significant problem with such studies, and a problem 
which is often underestimated, is that the ’response’ to an 
antihypertensive drug is difficult to define because it is 
not a discrete finite end-point. Even the effect - fall in
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blood pressure - is not easy to assess although blood 
pressure may be readily measurable, but a qualitative or 
quantitative assessment of drug response also requires 
consideration of several other factors: for example, drug
dose and variations in plasma drug concentration and blood 
pressure in relation to the dosage interval. Thus 
pharmacokinetic as well as pharmacodynamic factors account 
for the inter and intra-subject variability in blood 
pressure response. More recently, as illustrated in the 
earlier chapters, it has been possible to define 
concentration-effect relationships for several groups of 
drugs and to thereby describe the antihypertensive responses 
of individual patients in terms of both kinetic and dynamic 
parameters.
Having established a method which integrates kinetic 
and dynamic information, having characterised the responses 
to acute and chronic treatment in individual hypertensive 
patients and thereby having an index which is comparable and 
reproducible, it is now feasible to start to address the 
more difficult task of identifying factors which may account 
for the inter and intra-subject variability in 
responsiveness. This study investigates the relationship 
between responsiveness to the calcium antagonists, 
nifedipine and verapamil, the ACE inhibitor enalapril, the 
5HT2-antagonist ketanserin and the alpha blockers prazosin 
and doxazosin, and various haemodynamic, demographic, 
biochemical and neuro-endocrine parameters.
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8.2. PATIENTS AND METHODS
8.2.1. General
’The description and prediction of antihypertensive 
response' has been the subject of several clinical research 
studies. In addition to the four principal drug studies 
presented here, acute and chronic responses to verapamil 
(Meredith et al, 1987) and prazosin (Elliott et al, 1988c)
have also been examined. For the purposes of this chapter,
the combined data for all six drugs will be considered.
In a series of single-blind studies a total of 69 
patients with mild to moderate essential hypertension 
received treatment with placebo for 2 weeks then nifedipine 
retard 20 mg bid (n = 14), or verapamil 120 mg bid (n = 14), or
enalapril 20 mg o.d (n=13), or ketanserin 40 mg bid (n=9), or
prazosin 1 mg bid (n = 9), or doxazosin 2 mg o.d (n = 10). Each
drug was administered as monotherapy for 4-6 weeks and 
patients attended for a sequence of 8-hour sttidy days in the 
Clinical Pharmacology Research Unit to evaluate the effects 
of placebo, first dose and chronic (1-6 weeks) treatment.
The clinical protocol is described in detail in Chapter 2.1.
and the same method was used in all six studies.
8.2.2. The description of antihvpertensive response
Using concentration-effect analysis (Chapter 2.5.),
which integrates both kinetic and dynamic measurements, the
responses of individual patients on each study day
were characterised by the parameters m (in mmHg/ng/ml) or
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Emax m m Hg). The responsiveness (m) of individual
patients to verapamil and prazosin is shown in Tables 8.1. 
and 8.2. In the studies of nifedipine, enalapril and 
doxazosin (Chapters 3-5) responses were described in terms 
of the placebo-subtracted fall in both systolic and 
diastolic blood pressure.
8.2.3. Statistical analysis
In each individual study a number of haemodynamic, 
demographic, biochemical and neuro-endocrine parameters 
which may influence the inter and intra-subject variability 
in responsiveness were identified:
(i) Haemodvnamic variables
- starting (pretreatment) blood pressure
- response to the first dose
- reflex increases in heart rate and plasma 
catecholamines
(ii) Demographic variables
- age
- sex
- cigarette smoking
(iii) Biochemical variables
- plasma renin activity
- plasma noradrenaline
- serum cholesterol
(iv) Neuro-endocrine variables
- vascular pressor responsiveness to
TABLE 8.1.
THE RESPONSIVENESS Cm) TO PRAZOSIN 1 mg bid AFTER THE
1ST DOSE AND AFTER 1 WEEK AND 4 WEEKS TREATMENT
mmHg fall in systolic blood pressure/ng/ml
PATIENT 1ST DOSE 1 WEEK 4 WEEKS
1 -17.0 -15.0 -12.8
2 - 8.9 - 7.8 - 7.0
3 -19.9 -15.2 -17.3
4 -21.1 -14.5 -11.2
5 -13.6 - 9.1 - 7.8
6 -18.2 - 8.6 -10.9
7 - 3.8 - 2.4 - 2.2
8 - 4.8 - 2.3 - 3.2
9 . - 7.0 - 4.1 - 4.0
MEAN + 
SD
-11.5 +
6.7
- 8.7* ±
5.2
- 8.5* ±
5.0
Comparison with 1st dose * p < 0.02.
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TABLE 8.2.
m  RESPONSIVENESS Cm) TO VERAPAMIL 120 mg bid 
AFTER 1 1 S T  DOSE AND AFTER 4 WEEKS TREATMENT
mmHg fall in erect systolic blood pressure/ng/ml
PATIENT 1ST DOSE 4 WEEKS
1 -0.05 -0.07
2 -0.06 -0.05
3 -0.08 -0.05
4 -0.09 -0.08
5 -0.10 -0.07
6 -0.11 -.0.12
7 -0.11 -0.10
.8 -0.13 -0.12
S -0.15 -0.15
10 -0.16 -0.15
11 -0.16 -0.15
12 —0*18 -0.14
13 —0.21 —0.26
14 -0.27 i o TO
.MEAN + -0.13 +
SD 0.06 0 M
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phenylephrine and angiotensin II.
The relationship between these variables and 
responsiveness was investigated at two levels.
Firstly, for individual drugs by simple linear regression 
analysis of the form:
y = AX + Z
where X is the independent variable being examined, e.g. 
starting blood pressure or age, and y is the responsiveness 
to the drug represented by m or Emax in terms of systolic 
blood pressure. Then, stepwise multiple linear regression 
analysis was performed for each drug to investigate the 
relative contributions of 4 variables - starting blood 
pressure, age, pretreatment plasma renin activity and (where 
appropriate) the reflex heart rate response - in accounting 
for the intersubject variability in drug responsiveness to 
the first dose.
The approach of multiple regression analysis involved 
fitting a hierarchy of linear models to the distribution of 
values for responsiveness. Thus, responsiveness is the 
dependent variable and the 4 independent variables are 
modelled separately and then in all combinations with each 
other to find the best fit. The value obtained for each 
model represents the percentage variability in 
responsiveness which can be accounted for by the independent
i
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variables incorporated in the model. One, 2, 3 and in­
variable models were fitted to the data:
y = AX« + Z (1)
y = AX -j + BX2 + Z (2)
y = AX1 + BX2 + CX3 + Z (3)
y = AX -j + BX 2 + CX 3 + DXjj + Z (4)
where y is the responsiveness; X^, X2, X3 and X^ are the 
independent variables, i.e. starting blood pressure, age, 
pretreatment plasma renin activity and heart rate increase; 
and A, B, C and D are the coefficients.
To evaluate differences between nifedipine, enalapril 
and doxazosin in their relative effects on systolic and 
diastolic blood pressure, the ratios of m or 
Emax(systolic)/(diastolic) f°r individual patients were 
compared between treatments by unpaired t test with 
appropriate correction for multiple comparisons.
8.3. RESULTS
8.3.1 . Starting blood pressure
For each of the individual drugs and for all treatments 
as a whole there was a significant positive correlation 
between the responsiveness to the first dose and the
251
baseline (pretreatment) blood pressure. This relationship 
was more evident with systolic than diastolic blood pressure 
and was particularly significant for the calcium antagonists, 
nifedipine (Figure 3.10.) and verapamil (Figure 8.1.), with 
regression coefficients of 0.60 and 0.80 respectively.
8.3.2. The first dose response
In each of the individual studies except ketanserin, 
there was a significant correlation between the 
responsiveness to the first dose and the responsiveness 
after 1-6 weeks treatment. With the ACE inhibitor 
enalapril and with the calcium antagonists, nifedipine and 
verapamil, there was no significant reduction in 
responsiveness during chronic compared with acute 
administration: for example, responsiveness to verapamil as
the mean of the group was -0.13 mmHg/ng/ml after the first 
dose and -0.12 after 4 weeks (Figure 8.2.). In contrast, 
however, with both prazosin and doxazosin and with the 
serotonin antagonist ketanserin, there was a significant 
reduction in responsiveness in- translation from acute to 
steady state therapy: for example, the mean responsiveness
to doxazosin was -2.1 mmHg/ng/ml after the first dose and - 
1.5 and -1.4 after 1 and 6 weeks respectively (Table 5.9). 
Although, on average, there was a 20-30$ fall in 
responsiveness during chronic treatment, for individual 
patients there was a significant correlation between the 
responsiveness to the first dose and the responsiveness
VERAPAMIL
First DoseSystolic BP 
(mmHg)
230-. 
2 2 0 -  
210 -  
2 0 0 -  
190- 
180- 
170- 
160- 
150- 
140-
I "I I I I I I ' ’I 
0 0.04 0.08 0.12 0.16 0.20 0.24 0.28
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Figure 8J..
Correlation between the responsiveness to verapamil (1st dose) and the 
height of the pretreatment systolic blood pressure (n=14).
r = 0.80 
(P < 0.001)
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ACUTE AND CHRONIC RESPONSE TO VERAPAMII
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Figure 8.2.
Correlation between the responsiveness to the 1st dose of 
verapamil and the responsiveness after 4 weeks verapamil 
treatment (n=14), and the line of identity (----- ); r = 0.90.
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after 6 weeks, as illustrated for doxazosin in Figure 5.7.
In the case of ketanserin there was no relationship between 
responsiveness acutely and the responsiveness after 4 weeks.
8.3.3. Counter-regulatorv effects
The fall in blood pressure after the first doses of 
nifedipine, prazosin and doxazosin, but not verapamil or 
enalapril, was associated with a significant reflex increase 
in heart rate (Figures 3.2. and 5.2.) and plasma 
noradrenaline. Tachycardia was particularly marked with 
the alpha blockers and there was a significant negative 
correlation between the responsiveness to the first dose of 
doxazosin and the maximal (placebo-corrected) change in 
heart rate (Figure 5.11). A similar inverse relationship 
was observed with nifedipine (Figure 3.10.) although it did 
not achieve statistical significance. There was no 
relationship between patient age and the reflex rise in 
heart rate as illustrated for nifedipine (Figure 8.3.).
8.3.4. Demographic factors
There was no significant relationship between age and 
responsiveness either for individual drugs or collectively 
in the 69 patients. In particular, neither the 
responsiveness to the calcium antagonists, nifedipine 
(Figure 3.11) and verapamil (Figure 8.4.), nor the 
responsiveness to enalapril (Figure 4.7.) was significantly 
related to patient age.
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A HR versus Age
A HR (1st dose)
32 36 40 44 48 52 56 60 64 68
age (years)
figure 8.8.
Nifedipine study. Relationship between patient age and the 
maximal (placebo and baseline subtracted) change in erect heart 
rate following the 1st dose of nifedipine.
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Figure 8.4.
The relationship between responsiveness to verapamil (1st dose) 
and patient age (n=14).
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The number of cigarette smokers in our group of 
patients (26%) was too small to allow any formal statistical 
analysis. However, in the nifedipine study there were 5 
smokers and 9 non-smokers (Table 3.1.). Interestingly, the 
responsiveness to nifedipine among smokers was greater than 
non-smokers, both acutely and chronically, and was well 
above the average for the group: for example, the mean
responsiveness after the first dose and after 6 weeks among 
smokers was -0.56 ± 0.17 and -0.62 + 0.20 mmHg/ng/ml 
respectively, compared with corresponding values of -0.43 ± 
0.21 and -0.42 + 0.11 for the non-smokers and -0.48 ± 0.20 
and -0.49 ± 0.17 mmHg/ng/ml for the group as a whole.
There was no clear sex difference in the responsiveness 
to treatment: for example, the responsiveness to doxazosin
in males and females respectively was -2.3 ± 1.1 and -2.0 + 
0.7 after the first dose and -1.6 + 1.1 and -1.2 + 0.6 
mmHg/ng/ml after 6 weeks.
8.3.5. Biochemical indices
Doxazosin was the only drug for which there was a 
significant relationship between responsiveness and 
pretreatment plasma renin activity (Figure 5.12.). Such a 
relationship was not observed with prazosin and additionally 
neither the responsiveness to the calcium antagonists 
(Figure 3.11.) nor the responsiveness to enalapril (Figure
4.7.) was directly related to plasma renin activity.
There was no significant relationship between drug
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responsiveness and plasma levels of noradrenaline and 
similarly no relationship between responsiveness and serum 
cholesterol.
8.3*6. Vascular pressor responsiveness
There was no significant relationship between vascular 
pressor sensitivity (PD20) before active treatment (i.e. on 
placebo) and the subsequent responsiveness to 
antihypertensive therapy. However, consistent with the 
mechanism of action of doxazosin, there was a trend towards 
a relationship between responsiveness and the degree of 
peripheral alpha-j adrenoceptor blockade (Figure 5.9.). In 
contrast, the responsiveness to ketanserin appeared to be 
independent of its weak alpha^ antagonist activity (Figure 
7.11.). There was no significant relationship between the 
responsiveness to nifedipine and the attenuation in pressor 
sensitivity to angiotensin II and phenylephrine.
8.3.7. Multiple linear regression analysis
For each of the drugs, the responsiveness to the first 
dose was modelled with 4 independent variables - starting 
blood pressure, pretreatment plasma renin activity, age and 
the maximal (placebo-subtracted) reflex increase in heart 
rate - using stepwise least squares linear regression 
analysis. The values obtained from fitting a hierarchy 
of linear models to the data represent the percentage 
variability in responsiveness which can be accounted for by
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the variable, or variables, incorporated in the model.
The results are summarised in Table 8.3, showing the
p
R values for each of the 1-variable analyses and 
identifying for the different drugs which independent 
variable, or combination of variables, was most appropriate 
for predicting the intersubject differences in 
responsiveness.
Thus, for enalapril, starting blood pressure was 
singularly the best predictor of responsiveness to the first 
dose, accounting for 48% of the variability in E_avt while
111 Cl X  1
age and plasma renin activity accounted for only 8% and 
10.4% respectively (Table 8.3.). The 1-variable model with 
starting blood pressure was the most appropriate fit to the 
data and incorporating additional variables in more complex 
models did not significantly improve the correlation. The 
1-variable model for enalapril was defined by the equation:
Emax = -0.62 (starting BP) +61.3 : R2 = 48%
Similarly, for both prazosin and verapamil, starting 
blood pressure alone was the best predictor of response, 
accounting for 64% and 65% of the variabilities respectively 
(Table 8.3.). In both cases, age and plasma renin 
activity accounted for less than 10%, and more complex 
models, for example with 2 or 3 variables, were inferior to 
the 1-variable models with starting blood pressure which 
were defined by the equations:
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m (prazosin) = -0.3 (starting BP) + 38.8 : R2 = 64%
m (verapamil) = -0.0025 (starting BP) + 0.3 : R2 = 65%
For nifedipine, 1-variable analyses showed that 
starting blood pressure accounted for 37.1% of the 
variability in responsiveness; the reflex increase in heart 
rate accounted for 25%; and age accounted for only 0.9% 
(Table 8.3.). However, the most appropriate model to 
describe the variability in responsiveness to nifedipine was 
a 3-variable model incorporating starting blood pressure, 
age and the heart rate increase. This model accounted for 
87.3% and was defined by the equation:
m (nifedipine) = -0.02 (BP) - 0.02 (Age) + 0.01 (HR) - 1.8
Starting blood pressure, plasma renin activity and the 
reflex heart rate response were all important determinants 
of the responsiveness to the first dose of doxazosin. When 
fitted separately these variables accounted for 43%, 59.4% 
and 52% of the variability in responsiveness respectively.
In contrast, age could explain only 0.6% of the variability 
(Table 8.3.). The most appropriate model for doxazosin was 
a 3-variable model incorporating plasma renin activity, 
starting blood pressure and the reflex heart rate response 
(R2 = 85%), and this was defined by the equation:
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TABLE 8.3.
MULTIPLE LINEAR REGRESSION ANALYSIS USING FOUR INDEPENDENT
VARIABLES: STARTING BP. PLASMA RENIN ACTIVITY (PRA). AGE
AND REFLEX HR INCREASE. R- REPRESENTS THE PERCENTAGE OF THE 
VARIABILITY IN RESPONSIVENESS TO THE FIRST DOSE WHICH CAN BE 
ACCOUNTED FOR BY THE VARIABLES IN THE MODEL
R2 FOR 1-VARIABLE MODELS BEST MODEL (R2)
AGE BP PRA A  HR
Doxazosin 0.6%
Nifedipine 0.9%
Enalapril 8%
Prazosin 10.3% 
Verapamil 7%
43% 59.4% 52%
37.1% 4% 25.5%
48% 10.4%
64% 5.3%
65% 9%
3-variable: PRA + BP 
+ A  HR (85%)
3-variable: PRA + BP 
+ A  HR (87.3%)
1-variable: BP (48%)
1-variable: BP (64%)
1-variable: BP (65%)
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TABLE 8.4.
THE COMPARATIVE EFFECTS OF THREE TREATMENTS ON SYSTOLIC 
VERSUS DIASTOLIC BP EXPRESSED AS THE RATIO RESPONSIVENESS im 
or ELa J  SYSTOLIC/DIASTOLIC BP. MEAN ± SD AFTER ACUTE AND 
CHROKTC ADMINISTRATION.
FIRST DOSE 6 WEEKS
2.23 ± 1.92+
1.20 0.56
1.47 ± 1.51 ±
0.30 0.43
2.39* ± 
1.0
* Erngx values derived from fitting the data sets for 
all 3 study days simultaneously (see Chapter 4.3.5.).
Nifedipine:
Doxazosin:
Enalapril:
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m (doxazosin) = -0.4 (PRA) - 0.02 (BP) + 0.03 (HR) + 0.9
8.3.8. Differential effects on systolic and diastolic blood 
pressure
Responsiveness to nifedipine, enalapril and doxazosin 
was characterised in terms of the fall in both systolic and 
diastolic blood pressure (Chapters 3-5). In each study 
there were significant correlations between the 
responsiveness (m or Emax) in terms of systolic and 
diastolic blood pressure. The mean ratios of 
systolic/diastolic response are shown in Table 8.4. and 
there was no significant difference between treatments in 
their relative effects on systolic versus diastolic blood 
pressure.
DISCUSSION
Many studies during the last fifteen years have 
investigated the inter and intra subject variability in 
response to different antihypertensive drugs and produced a 
number of conflicting and often misleading statements, for 
example about variations in responsiveness related to age 
(Buhler et al, 1982; Ferrara et al, 1985; Ram, 1987; 
Bidiville et al, 1988; M'Buyamba-Kabangu et al, 1988), 
ethnic origin (Seedat and Reddy, 1971) and biochemical 
parameters such as plasma renin activity (Buhler et al, 
1982; Cody et al, 1983; Bidiville et al, 1988). Much of
the confusion that has arisen is a direct result of the
<,
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inconsistent and often unsatisfactory methods used for 
describing antihypertensive response: for example, in most
previous studies response has been quantified on the basis 
of pharmacodynamics alone - usually single measurements of 
blood pressure recorded on one or two separate occasions - 
and no account has been taken of interindividual or time 
related differences in plasma drug concentration. A good 
example of this is the widely quoted study by Buhler and 
colleagues (1982) which over the last few years has formed 
the basis of an over-stated and probably misconceived 
argument that calcium antagonists are significantly more 
effective in the elderly. Buhler investigated a group of 
patients receiving different doses of verapamil and showed 
that the fall in blood pressure was directly proportional to 
age (Figure 1.1.) but the study took no account of placebo 
effects, starting blood pressure or, more importantly, 
plasma verapamil concentrations which may have been higher 
in the elderly. Since kinetic as well as dynamic 
variability accounts for interindividual differences in 
blood pressure rsponse, it is possible that the observations 
of Buhler may have been due to age-related differences in 
pharmacokinetics rather than increased responsiveness pen 
se. Similar criticism may be extended to the study by 
Ferrara et al (1985) which purported to show an opposite 
relationship between age and the antihypertensive response 
to nitrendipine.
Another example which illustrates the need for
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integrated pharmacokinetic-pharmacodynamic analysis concerns 
the relationship between smoking and antihypertensive drug 
response. One of the conclusions from the MRC Trial (1985) 
was that the fall in blood pressure with propranolol was 
less in cigarette smokers than non-smokers, whereas no such 
difference occurred with bendrofluazide. Similar findings 
were also reported in the IPPPSH study with the non- 
selective beta blocker oxprenolol (IPPPSH study group,
1985). While this may reflect a difference in smokers to 
the haemodynamic effects of beta blockade, it is also 
possible that a pharmacokinetic basis seems more likely 
since smoking has been shown to increase the clearance of 
propranolol (Dawson and Vestal, 1981). Thus, the fall in 
blood pressure per unit drug concentration may have been 
similar in smokers compared with non-smokers.
The present study has highlighted the importance of 
considering pharmacokinetic as well as pharmacodynamic 
variability when investigating interindividual differences 
in blood pressure response. The measurements of 
responsiveness derived from the concentration-effeet 
analysis incorporate both kinetic and dynamic data for 
individual patients and additionally take account of placebo 
effects and variations in blood pressure and drug 
concentration during the dosage interval. A number of 
haemodynamic, demographic and biochemical markers were 
examined in relation to the responsiveness to different 
drugs and by far the most important determinants of
' t
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antihypertensive response during longterm treatment were the 
height of the pretreatment blood pressure and the response 
to the first dose.
The relationship between starting blood pressure and 
the magnitude of the fall with treatment has been described 
previously with calcium antagonists (MacGregor et al, 1982b; 
Erne et al, 1983). However, there are statistical problems 
in correlating two dependent variables (Gill et al, 1985),
i.e. BP and A  BP, and it is probably more appropriate to 
seek correlations which also take account of interindividual 
differences in drug concentrations and in the extent of the 
blood pressure fall associated with placebo (Sumner et al, 
1988a). In this study there were significant positive 
correlations not only with the calcium antagonists but also 
with the other four drugs between responsiveness and the 
baseline (pretreatment) blood pressure. The relationship 
was seen most clearly with systolic blood pressure and 
this probably reflects the wider range of systolic 
blood pressures observed. The slope of the correlation was 
greatest for nifedipine and verapamil and this may partly 
explain why calcium antagonists are reported to be 
particularly effective in severe or resistant hypertension 
(Bayley et al, 1982; Dean and Kendall, 1983).
It has been suggested that the acute fall in blood 
pressure with a given antihypertensive drug is not a good 
predictor of the response obtained during longterm therapy 
(Bidiville et al, 1988). In this study, however, which
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considered kinetics as well as dynamics in individual 
patients, there were significant correlations between the 
responsiveness to the first dose and the responsiveness 
after 4-6 weeks, which suggests that the first dose response 
may be used to forecast the steady state effect for an 
individual patient. Additionally, with the exception of 
ketanserin, this relationship applied irrespective of 
treatment and was independent of any reduction in 
responsiveness in translation from acute to chronic therapy. 
Clearly this has potential application in clinical practice 
as a means of quickly identifying poor or non-responders and 
for determining individual dose requirements for optimum 
longterm blood pressure control. During the first week of 
treatment with nifedipine and with the alpha blockers, 
prazosin and doxazosin, there was evidence that the fall in 
blood, pressure was associated with reflex sympathetic 
activation but it is noteworthy that this did not perturb 
the correlations with the responses obtained at 6 weeks, 
when baroreflex mechanisms had apparently "reset".
Since the early 1970s when Laragh (1973) proposed a 
volume-vasoconstrictor hypothesis to account for some of the 
pathophysiological abnormalities in hypertension, there has 
been considerable interest in the effects of age and plasma 
renin activity on the response to antihypertensive drugs. 
Initial optimism about the potential value of renin 
profiling was quickly removed when it soon became clear that 
in clinical practice plasma renin activity alone could not
v i
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predict the response to a beta blocker or diuretic (Hansson 
et al, 1974; Zanchetti, 1985). More recently, the 
haemodynamic effects of some of the newer antihypertensive 
agents such as calcium antagonists (Buhler et al, 1982; 
M'Buyamba-Kabangu et al, 1988), ACE inhibitors (Gavras et 
al, 1 978; Case et al, 1981; Cody et al, 1 983) and alpha 
blockers (Bolli et al, 1981) have been shown to be partly 
related to the activity of the renin-angiotensin system and 
there has been revived interest in the role of plasma renin 
as a predictive marker of drug response (Cody et al, 1983). 
While extremes of sodium intake may influence the 
haemodynamic effects of these drugs, this study has shown 
that in a typical group of hypertensive patients on a normal 
diet calcium antagonists, ACE inhibitors and alpha blockers 
are generally far more effective than can be usefully 
predicted by age or measurements of plasma renin activity.
The multiple linear regression analysis showed that for 
all drugs age and plasma renin activity each accounted for 
less than 10% of the variability in responsiveness to the 
first dose. The exception to this was the somewhat 
surprising relationship between PRA and responsiveness to 
doxazosin but, since no such relationship was seen with 
prazosin, the significance of this result should be 
interpreted cautiously. The most important observation 
from the multivariant analysis was that for each of the 
drugs, including doxazosin, starting blood pressure alone 
could explain over 50% of the variability in responsiveness
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to the first dose. Furthermore, the only additional 
variable which produced a clinically significant improvement 
in the correlation between starting blood pressure and 
responsiveness was the reflex increase in heart rate 
associated with nifedipine and doxazosin.
There is some evidence with the dihydropyridine calcium 
antagonist nicardipine that the antihypertensive effect is 
dependent on baseline sympathetic nervous activity (Ryman et 
al, 1987). In this study, and in another study with 
nifedipine and verapamil (Schwietzer et al, 1983), there was 
no relationship between responsiveness and plasma levels of 
noradrenaline but the limitations of this method as an 
index of sympathetic activity are well recognised. In 
addition, it has been shown that impairment of the pressor 
response to noradrenaline is not a prerequisite for the 
antihypertensive action of calcium antagonists (Schwietzer 
et al, 1983) and in this study there was no relationship 
between responsiveness to nifedipine (m) and the attenuation 
in pressor sensitivity to angiotensin II and phenylephrine.
Although not specifically measured in this study, 
intracellular electrolyte concentrations have also been 
proposed as important biochemical determinants of 
antihypertensive response (Breckenridge, 1987). Lymphocyte 
Na+ and K4" levels have been directly correlated with the 
antihypertensive effects of captopril (Costa et al, 1985) 
and nifedipine (M ’Buyamba-Kabangu, 1988) but it demands
great extrapolation to conceive of this becoming a useful
<,
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step in selecting antihypertensive drugs.
Because of the apparent failure of antihypertensive 
therapy to improve coronary heart disease mortality, it has 
become important that we gain greater understanding of the 
inter-relationship between hypertension and other coronary 
risk factors (Reid, 1988). The number of patients in the 
present study was too small to gain any useful insight into 
the effects of cigarette smoking and cholesterol on 
responsiveness to different antihypertensive drugs but 
similar studies with selected patient groups are warranted 
in the future.
The relative importance of systolic and diastolic blood 
pressures in predicting risk and likely benefit from 
treatment remains controversial (Fisher, 1985; Ramsay 
and Waller, 1986). Although systolic and diastolic blood 
pressures are closely correlated (r=0.80), there is 
considerable discord in the relationship: for example, 20%
of men aged MO-59 years with systolic blood pressures 
greater than 180 mmHg have a diastolic blood pressure less 
than 90 mmHg and similarly about 20% of men with diastolic 
blood pressures greater than 100 mmHg have a systolic blood 
pressure of less than 160 mmHg (Shaper et al, 1987). In 
this study the responsiveness to nifedipine, enalapril and 
doxazosin was characterised in terms of the fall in both 
systolic and diastolic blood pressure and there was no 
significant difference between treatments in their relative 
effects on the two parameters. In particular, there was no
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evidence to support previous suggestions that the ACE 
inhibitor enalapril is particularly effective in lowering 
systolic more than diastolic blood pressure (O'Connor et al, 
1984; Beevers et al, 1 984).
In summary, an integrated method for describing 
antihypertensive response, which incorporates both 
pharmacokinetic and pharmacodynamic information, forms a 
useful basis for investigating factors which determine inter 
and intra-subject differences in blood pressure response.
A number of haemodynamic, demographic and biochemical 
parameters have been examined in relation to the 
responsiveness to calcium antagonists, alpha blockers, the 
ACE inhibitor enalapril and the serotonin antagonist 
ketanserin. The most important determinants of response 
during longterm treatment are the height of the pretreatment 
blood pressure and the response to the first dose. This 
has important and encouraging implications for developing an 
individualised approach to antihypertensive treatment.
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DISCUSSION
The scope for improvement in antihypertensive therapy 
has been highlighted by some of the recent major trials in 
mild to moderate hypertension, which have exposed important 
limitations of pragmatic Tstepped-caref policies and 
advocated instead a more flexible individualised approach to 
treatment. However, in contrast to developments in other 
areas of therapeutics, for example with anticonvulsant, 
antiarrhythmic and bronchodilator drugs, little attempt has 
been made to apply developments in clinical pharmacokinetics 
to improve drug selection and dosage in hypertension. An 
understanding of dose-response and concentration-effect 
relationships and of factors which determine the response to 
antihypertensive drugs constitutes a basis for optimising 
drug therapy prospectively in individual patients but so far 
such information has been scarce and ill-defined.
It has been suggested that for a number of 
antihypertensive drugs no predictable concentration-effeet 
relationship exists but this probably reflects the negative 
findings of those previous studies which considered the 
response for groups of patients rather than for individuals. 
This series of studies has shown that drug concentrations 
are correlated with the reductions in blood pressure in 
individual hypertensive patients and has extended some 
preliminary observations (Pasanisi and Reid, 1983; Kelman 
et al, 1983) by defining individual concentration-response 
relationships which are applicable during chronic treatment.
' \
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The linear concentration-effeet model was better than 
the Langmuir (Emax) model for describing the kinetic-dynamic 
relationships of nifedipine, doxazosin and ketanserin and 
the same was found with verapamil (Meredith et al, 1987) and 
prazosin (Elliott et al, 1988c). In contrast, the 
individual data sets for enalapril were fitted most 
appropriately by the Emax relationship and this has been 
reported previously with other ACE inhibitors (Kelman et al, 
1983; Francis et al, 1987). The significance of this 
observation is not entirely clear but it may reflect the 
non-linear kinetics of ACE inhibitors and their binding 
properties to plasma and tissue ACE. Additionally, it may 
partly explain why ACE inhibitors have been reported to have 
flat dose-response curves (Davies et al, 1984), since 
previous studies may have used doses which produce drug 
levels at the top end of the concentration-effeet curve.
Both effect models provide an integrated method for 
quantifying the antihypertensive response of an individual 
in terms of kinetic as well as dynamic parameters and for 
characterising the temporal discrepancy for the plasma 
concentration-effect relationship (Keq). Clearly there are 
potentially numerous applications of this approach both in 
research and in clinical practice. The study of ketanserin 
illustrates the use of concentration-effeet analysis in 
clinical investigations of antihypertensive mechanisms. 
Responsiveness to the first dose of ketanserin was 
significantly greater than that after 4 weeks and there was
275
no relationship between responsiveness and the degree of 
peripheral alpha blockade. Additionally, in contrast to 
the other drugs, there was no relationship between acute and 
chronic responsiveness and there was a significant change in 
the parameter Keq in translation from acute to steady state 
therapy. The increase in Kg reflects an alteration to the 
temporal relationship between the profiles of plasma 
concentration and blood pressure reduction and it is my 
suggestion that this change in Keq, together with the lack 
of a direct relationship between the acute and chronic 
responses, reflects a change in the relative contributions 
of different components of the antihypertensive mechanism of 
ketanserin. Thus, peripheral alpha^ antagonism may make a 
relatively greater contribution after the first dose whereas 
a centrally-mediated effect may predominate during longterm 
treatment.
The studies presented in this thesis have illustrated 
the feasibility of using concentration-effeet analysis to 
examine various aspects of the clinical pharmacology of 
antihypertensive drugs. This work forms the basis for a 
number of further investigations, which are already planned, 
to test the application of this approach in clinical practice 
and to refine pharmacokinetic techniques for improving drug 
use in hypertension. Having identified concentration- 
effect relationships for a number of vasodilator drugs, it 
would be appropriate to investigate conventional drugs like 
beta blockers and diuretics using a similar approach. A
' I
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preliminary study with the beta blocker flusoxolol has shown
that in normotensive subjects the concentration-effect
relationship is defined most appropriately by an Emav modelm s x
(Sumner et al, 1988b). This would be consistent with the 
conventional wisdom that beta blockers have flat dose- 
response curves but would again suggest that previous 
studies have used doses which produce drug levels at the top 
end of the Emax curve. In contrast, beta blockers with 
additional vasodilator properties, for example medroxalol 
and labetalol, appear to have concentration-effeet 
relationships which are described more appropriately by a 
linear model (Elliott et al, 1984).
So far we have only characterised responses to drug 
treatment as monotherapy but a large proportion of patients 
require treatment with more than one drug. A study to 
investigate concentration-effeet relationships with 
combination treatments is therefore warranted and may 
provide additional information about drug interactions. As 
an introduction to this step, we have established the 
efficacy and patient acceptability of two relatively novel 
combinations: the combination of a calcium antagonist with
an ACE inhibitor (Donnelly et al, 1987) and the combination 
of a calcium antagonist with an alpha blocker (Elliott et 
al, 1988b). Using concentration-effeet analysis, it may be 
possible to identify favourable drug interactions: for
example, to compare the effects of an alpha blocker and an 
ACE inhibitor on the responsiveness to additional treatment
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with a calcium antagonist.
Large studies are required to further investigate 
factors responsible for interindividual differences in blood 
pressure response. However, in this project, with a 
relatively small number of patients, it has been possible to 
identify two important determinants of response during 
longterm treatment, the height of the starting blood 
pressure and the response to the first dose. Additionally, 
it has been shown that in a typical group of salt replete 
hypertensive patients on a normal diet calcium antagonists 
and ACE inhibitors are far more effective than can be 
usefully predicted by age or measurements of plasma renin 
activity.
An individualised approach to treatment is a laudable 
goal. Ideally this would involve an initial selection, from 
4 or 5 alternative first-line drugs, based on clinical and 
demographic information about the individual; a rapid 
assessment, ideally following the first dose, that the 
patient is likely to have a satisfactory response; and then 
the selection of the optimum dosage for longterm treatment. 
The present study has raised the possibility that the 
response during longterm treatment for an individual patient 
may be forecast on the basis of the response to the first 
dose. Clearly this would be useful in clinical practice as 
a means of quickly identifying poor or non-responders and 
for determining individual dose requirements for optimum 
blood pressure control. However, the relationships between
K:i
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acute and chronic response were identified retrospectively 
and further work is planned to attempt to predict and 
thereby optimise the longterm response prospectively from 
single dose experiments.
If concentration-effect analysis is to find a place in 
routine clinical practice it must become possible to 
characterise individual patient responses using much fewer 
measurements of blood pressure and drug plasma 
concentration. In the present studies we have measured the 
full kinetic and dynamic profiles over 24 hours but with 
retrospective analysis it may be feasible to derive reliable 
estimates of the concentration-effect parameters using one 
or two important data points, for example peak or trough 
concentrations and the associated blood pressure effects.
An alternative approach may be to use population 
pharmacokinetic analysis, which takes one or two 
measurements per individual from a large group of subjects 
and derives population estimates of pharmacokinetic 
parameters (Whiting et al, 1986). Additionally, this 
technique can incorporate data on efficacy and toxicity, 
allowing the development of a more rigorous approach to the 
concept of the Ttherapeutic range1.
In conclusion, this project has identified drug 
concentration-effect relationships in individual 
hypertensive patients using recently developed methods of 
clinical pharmacokinetic analysis. The derived 
concentration-effect parameters are potentially useful not
'i
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only for identifying factors responsible for intersubject 
variability in response but also for optimising drug therapy 
in individual patients.
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